Study List:

Study 1:
  NCT Number:                   NCT04947111
  Title:                        Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Diagnostic Test: Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
  Outcome Measures:             Percentage of participants with Dengue IgG antibodies|Ratio of neutralizing antibodies against DENV1, DENV2, DENV3 and/or DENV4|Percentage of participants with monotypic and multitypic response
  Sponsor/Collaborators:        Mexican Society of Public Health|Merck Sharp & Dohme LLC
  Gender:                       All
  Age:                          5 Years to 35 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   1960
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    1
  Start Date:                   April 30, 2022
  Primary Completion Date:      July 30, 2022
  Completion Date:              September 30, 2022
  First Posted:                 July 1, 2021
  Results First Posted:         
  Last Update Posted:           March 4, 2022
  Locations:                    Mexican Society of Public Health, Mexico city, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04947111

Study 2:
  NCT Number:                   NCT03612609
  Title:                        Pilot Study to Detect DENGUE Virus in Sperm
  Acronym:                      DENGSPERM
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: blood, urine and semen sample
  Outcome Measures:             dengue virus genomic RNA in patient sperm
  Sponsor/Collaborators:        University Hospital, Toulouse
  Gender:                       Male
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   10
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    RC31/18/0133|2018-A01195-50
  Start Date:                   February 6, 2019
  Primary Completion Date:      August 7, 2019
  Completion Date:              August 7, 2019
  First Posted:                 August 2, 2018
  Results First Posted:         
  Last Update Posted:           August 22, 2019
  Locations:                    Hôpital Saint-Pierre, Saint-Pierre, Réunion
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03612609

Study 3:
  NCT Number:                   NCT05321264
  Title:                        Educational Intervention to Promote Control Behaviors and Prevention of Dengue
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Behavioral: Educational nursing intervention
  Outcome Measures:             Risk control|Participation in health care decisions
  Sponsor/Collaborators:        Universidad de Antioquia
  Gender:                       All
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   116
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    2021-29
  Start Date:                   November 2022
  Primary Completion Date:      April 2023
  Completion Date:              June 2023
  First Posted:                 April 11, 2022
  Results First Posted:         
  Last Update Posted:           April 11, 2022
  Locations:                    Yolima Judith Llorente Perez, Medellín, Antioquia, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05321264

Study 4:
  NCT Number:                   NCT04298138
  Title:                        Dengue 3 Human Infection Model (DENV-3)
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
  Outcome Measures:             Number of Abnormal Laboratory Measurements|Intensity of Abnormal Laboratory Measurements|Duration of Abnormal Laboratory Measurements|Occurrence of Solicited Injection Site Symptoms|Intensity of Solicited Injection Site Symptoms|Duration of Solicited Injection Site Symptoms|Occurrence of Unsolicited Injection Site Symptoms|Intensity of Unsolicited Injection Site Symptoms|Duration of Unsolicited Injection Site Symptoms|Occurrence of Solicited Systemic Symptoms|Intensity of Solicited Systemic Symptoms|Duration of Solicited Systemic Symptoms|Occurence of Unsolicited Systemic Symptoms|Intensity of Unsolicited Systemic Symptoms|Duration of Unsolicited Systemic Symptoms|Number of Serious Adverse Events|Incubation period before onset of fever|Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)|Occurence of fever|Occurrence of Headache|Grade of Headache|Occurrence of Myalgia|Grade of Myalgia|Occurrence of Rash|Grade of Rash|Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Occurrence of Leukopenia|Grade of Leukopenia|Occurrence of Thrombocytopenia|Grade of Thrombocytopenia
  Sponsor/Collaborators:        State University of New York - Upstate Medical University|Walter Reed Army Institute of Research (WRAIR)|U.S. Army Medical Research and Development Command
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   9
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    2019-01-UMU
  Start Date:                   June 29, 2020
  Primary Completion Date:      December 14, 2021
  Completion Date:              December 14, 2021
  First Posted:                 March 6, 2020
  Results First Posted:         
  Last Update Posted:           June 13, 2022
  Locations:                    State University of New York, Upstate Medical University (SUNY-UMU), Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04298138

Study 5:
  NCT Number:                   NCT05307484
  Title:                        Effects of a Serious Game on Knowledge, Attitude and Practice in Vector Control and Dengue Prevention Among Adults in Primary Care
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Other: Serious game|Other: Dengue prevention website
  Outcome Measures:             Change of knowledge, attitude and practice (KAP) assessment score on dengue fever prevention|Change of interest to vaccinate against Dengue|System Usability Scale (SUS) score of serious game
  Sponsor/Collaborators:        SingHealth Polyclinics
  Gender:                       All
  Age:                          21 Years to 60 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   400
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    2020/3091
  Start Date:                   March 3, 2021
  Primary Completion Date:      September 17, 2021
  Completion Date:              September 17, 2021
  First Posted:                 April 1, 2022
  Results First Posted:         
  Last Update Posted:           April 1, 2022
  Locations:                    SingHealth Polyclinics - Sengkang, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05307484

Study 6:
  NCT Number:                   NCT04935801
  Title:                        A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: LD vehicle-GNP|Biological: LD PepGNP-Dengue|Biological: HD vehicle-GNP|Biological: HD PepGNP-Dengue
  Outcome Measures:             Safety: Solicited local & Systemic AEs|Safety: Unsolicited AEs|Safety: SAEs|Safety: Adverse Events of Special Interest (AESI)|Safety: Haemoglobin blood levels measurement|Safety: Alkaline Phosphate Blood levels measurement|Immunogenicity: Proportion of participants with CD8-T cell specific to PepGNP-Dengue|Proportion of participants becoming seropositive (antibodies against Dengue virus)
  Sponsor/Collaborators:        Emergex Vaccines Holding Ltd.|Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|University of Lausanne Hospitals
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   26
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    naNO-DENGUE
  Start Date:                   August 2, 2021
  Primary Completion Date:      March 11, 2022
  Completion Date:              September 15, 2022
  First Posted:                 June 23, 2021
  Results First Posted:         
  Last Update Posted:           December 5, 2022
  Locations:                    Center for Primary Care and Public Health, (Unisante), Lausanne, Vaud, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04935801

Study 7:
  NCT Number:                   NCT04133987
  Title:                        Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Tetravalent live attenuated dengue vaccine admixture TV005|Biological: Placebo
  Outcome Measures:             Proportion of study participants with solicited local and general adverse events.|Proportion of study participants with unsolicited adverse events.|Proportion of study participants with serious adverse events.|Evaluation of the immunogenicity of TV005, as assessed by PRNT50 to DENV-1, DENV-2, DENV-3, and DENV-4 at 0, 28, 56, 72 and 180 days after TV005 vaccination|Evaluation of the frequency and quantity of viremia of each monovalent component of the vaccine after vaccination.|Number of TV005 vaccinees infected with DENV-1, DENV-2, DENV-3, and DENV-4.
  Sponsor/Collaborators:        National Taiwan University Hospital|Centers for Disease Control, Taiwan
  Gender:                       All
  Age:                          50 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   252
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention
  Other IDs:                    201712180MSD
  Start Date:                   October 15, 2018
  Primary Completion Date:      April 30, 2020
  Completion Date:              June 30, 2023
  First Posted:                 October 21, 2019
  Results First Posted:         
  Last Update Posted:           October 23, 2019
  Locations:                    National Taiwan University Hospital, Taipei, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04133987

Study 8:
  NCT Number:                   NCT02372175
  Title:                        Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
  Outcome Measures:             Number of Abnormal Laboratory Measurements|Intensity of Abnormal Laboratory Measurements|Duration of Abnormal Laboratory Measurements|Occurrence of Solicited Injection Site Symptoms|Intensity of Solicited Injection Site Symptoms|Duration of Solicited Injection Site Symptoms|Occurrence of unsolicited Injection Site Symptoms|Intensity of Unsolicited Injection Site Symptoms|Duration of Unsolicited Injection Site Symptoms|Occurrence of Solicited Systemic Symptoms|Intensity of Solicited Systemic Symptoms|Duration of Solicited Systemic Symptoms|Occurrence of Unsolicited Systemic Symptoms|Intensity of Unsolicited Systemic Symptoms|Duration of Unsolicited Systemic Symptoms|Number of Serious Adverse Events|Incubation period before onset of fever|Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)|Occurrence of fever without other identifiable cause, such as strep throat or influenza|Occurrence of Headache|Grade of Headache|Occurrence of Myalgia|Grade of Myalgia|Occurrence of Rash|Grade of Rash|Occurrence of Liver Function Tests Abnormalities [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Grade of Liver Function Tests Abnormalities [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Occurrence of Leukopenia|Grade of Leukopenia|Occurrence of Thrombocytopenia|Grade of Thrombocytopenia
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|State University of New York - Upstate Medical University
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   27
  Funded Bys:                   U.S. Fed|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    S-14-09
  Start Date:                   October 2015
  Primary Completion Date:      June 28, 2019
  Completion Date:              June 28, 2019
  First Posted:                 February 26, 2015
  Results First Posted:         
  Last Update Posted:           July 15, 2019
  Locations:                    State University of New York, Upstate Medical University (SUNY-UMU), Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02372175

Study 9:
  NCT Number:                   NCT02684383
  Title:                        Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN3∆30|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse events (AEs)|Level of anti-DENV-3 neutralizing antibody
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   14
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 304
  Start Date:                   
  Primary Completion Date:      July 2016
  Completion Date:              July 2016
  First Posted:                 February 18, 2016
  Results First Posted:         
  Last Update Posted:           November 30, 2016
  Locations:                    Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont Medical Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02684383

Study 10:
  NCT Number:                   NCT02879266
  Title:                        Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV TV005|Biological: Placebo
  Outcome Measures:             Frequency of TV005-related adverse events (AEs)
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          50 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 310
  Start Date:                   February 1, 2016
  Primary Completion Date:      September 7, 2017
  Completion Date:              
  First Posted:                 August 25, 2016
  Results First Posted:         
  Last Update Posted:           April 2, 2018
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02879266

Study 11:
  NCT Number:                   NCT02873260
  Title:                        Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV-TV005|Biological: rDEN3Δ30|Biological: Placebo
  Outcome Measures:             Frequency of TV005 and rDEN3Δ30-related adverse events (AEs)|Frequency of viremia
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 309
  Start Date:                   August 2016
  Primary Completion Date:      November 2017
  Completion Date:              November 2017
  First Posted:                 August 19, 2016
  Results First Posted:         
  Last Update Posted:           March 8, 2018
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02873260

Study 12:
  NCT Number:                   NCT03869060
  Title:                        Expansion of a Dengue-1 Live Virus Human Challenge
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
  Outcome Measures:             Number of Abnormal Laboratory Parameters|Intensity of Abnormal Laboratory Parameters|Duration of Abnormal Laboratory Parameters|Occurrence of Solicited Injection site symptoms|Intensity of Solicited Injection site symptoms|Duration of Solicited Injection site symptoms|Occurrence of Unsolicited Injection site symptoms|Intensity of Unsolicited Injection site symptoms|Duration of Unsolicited Injection site symptoms|Occurrence of Solicited systemic symptoms|Intensity of Solicited systemic symptoms|Duration of Solicited systemic symptoms|Occurrence of Unsolicited systemic symptoms|Intensity of Unsolicited systemic symptoms|Duration of Unsolicited systemic symptoms|Number of Serious Adverse Events|Incubation period before onset of fever|Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)|Viremia by plaque assay|Occurrence of fever without other identifiable cause, such as strep infection or influenza|Occurrence of Headache|Grade of Headache|Occurrence of Myalgia|Grade of Myalgia|Occurrence of Rash|Grade of Rash|Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]|Occurrence of Leukopenia|Grade of Leukopenia|Occurrence of Thrombocytopenia|Grade of Thrombocytopenia
  Sponsor/Collaborators:        State University of New York - Upstate Medical University|Janssen Pharmaceutica N.V., Belgium|U.S. Army Medical Research and Development Command
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   9
  Funded Bys:                   Other|Industry|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    2018-01-UMU
  Start Date:                   February 4, 2019
  Primary Completion Date:      September 20, 2019
  Completion Date:              September 20, 2019
  First Posted:                 March 11, 2019
  Results First Posted:         
  Last Update Posted:           January 6, 2020
  Locations:                    State University of New York, Upstate Medical University (SUNY-UMU), Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03869060

Study 13:
  NCT Number:                   NCT02678455
  Title:                        Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV005 vaccine|Biological: Placebo
  Outcome Measures:             Proportion of study participants with solicited or unsolicited adverse events|Proportion of study participants who are seropositive or seroconvert following vaccination|Proportion of study participants with vaccine virus recovered following vaccination|Proportion of study participants with recoverable vaccine virus or wild-type virus after vaccination
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|University of Vermont|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          12 Months to 50 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   192
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    PR-15097|Dengue TV005 in Dhaka
  Start Date:                   March 2016
  Primary Completion Date:      August 10, 2017
  Completion Date:              February 5, 2020
  First Posted:                 February 9, 2016
  Results First Posted:         
  Last Update Posted:           August 6, 2020
  Locations:                    International Centre for Diarrhoeal Disease Research, Bangladesh, Mirpur, Dhaka, Bangladesh
  Study Documents:              "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02678455/ICF_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02678455

Study 14:
  NCT Number:                   NCT02239614
  Title:                        TDENV PIV and LAV Dengue Prime-boost Strategy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TDENV-LAV|Biological: TDENV-PIV 4 µg + alum adjuvant
  Outcome Measures:             Number of solicited adverse events|Number of unsolicited adverse events|Number of hematological and biochemistry abnormalities|Number of serious adverse events|Number of potential immune-mediated diseases|Number of medically attended adverse events|Microneutralizing (MN) dengue antibody titers
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command
  Gender:                       All
  Age:                          18 Years to 49 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   80
  Funded Bys:                   U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    S-13-10|ADVP-003|WRAIR #2136
  Start Date:                   December 2014
  Primary Completion Date:      February 17, 2016
  Completion Date:              February 17, 2017
  First Posted:                 September 15, 2014
  Results First Posted:         
  Last Update Posted:           August 15, 2018
  Locations:                    Clinical Trials Center, Walter Reed Army Institute of Research (CTC, WRAIR), Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02239614

Study 15:
  NCT Number:                   NCT02433652
  Title:                        Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Recombinant live attenuated trivalent dengue vaccine|Biological: Placebo|Biological: rDEN2Δ30-7169 vaccine
  Outcome Measures:             Frequency of trivalent dengue vaccine admixture and rDEN2Δ30-7169-related adverse events (AEs)|Dengue virus neutralizing antibody titers (measured through blood collection)
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   24
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 300
  Start Date:                   September 2015
  Primary Completion Date:      November 2016
  Completion Date:              
  First Posted:                 May 5, 2015
  Results First Posted:         
  Last Update Posted:           February 28, 2018
  Locations:                    Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02433652

Study 16:
  NCT Number:                   NCT05661877
  Title:                        Effectiveness of a Online Education Material to Improve Dengue Knowledge and Health-Seeking Intention
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Other: DengueAid mobile application|Other: MyHealth website
  Outcome Measures:             Knowledge on Dengue|Health-seeking intention when having dengue fever
  Sponsor/Collaborators:        University of Malaya
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   116
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
  Other IDs:                    2022104-11592
  Start Date:                   January 1, 2023
  Primary Completion Date:      May 6, 2023
  Completion Date:              May 6, 2023
  First Posted:                 December 22, 2022
  Results First Posted:         
  Last Update Posted:           December 22, 2022
  Locations:                    University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05661877

Study 17:
  NCT Number:                   NCT03771963
  Title:                        Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: Tetravalent Dengue Vaccine (TDV)
  Outcome Measures:             Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120|Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270|Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270|Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity|Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity|Percentage of Participants With Any Unsolicited Adverse Events Following Each Vaccination|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Medically Attended Adverse Events (MAAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    DEN-307|U1111-1222-2812
  Start Date:                   March 28, 2019
  Primary Completion Date:      October 14, 2019
  Completion Date:              March 13, 2020
  First Posted:                 December 11, 2018
  Results First Posted:         June 7, 2021
  Last Update Posted:           June 7, 2021
  Locations:                    Anaheim Clinical Trials, LLC, Anaheim, California, United States|Hutchinson Clinic, Hutchinson, Kansas, United States
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03771963/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03771963/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03771963

Study 18:
  NCT Number:                   NCT05631405
  Title:                        Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Severe Dengue
  Interventions:                Drug: Dexamethasone
  Outcome Measures:             Mortality|Length of hospital stay
  Sponsor/Collaborators:        Chulalongkorn University
  Gender:                       All
  Age:                          7 Years to 99 Years   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   200
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    IRB.436/65
  Start Date:                   October 16, 2022
  Primary Completion Date:      December 31, 2023
  Completion Date:              December 31, 2024
  First Posted:                 November 30, 2022
  Results First Posted:         
  Last Update Posted:           November 30, 2022
  Locations:                    Chulalongkorn University, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05631405

Study 19:
  NCT Number:                   NCT02450838
  Title:                        Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: V180|Biological: Alhydrogel™|Biological: Placebo
  Outcome Measures:             Virus neutralizing antibody levels, as measured by the PRNT with a 50% neutralization cutoff (PRNT50 titer)
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Merck Sharp & Dohme LLC
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 301
  Start Date:                   April 2015
  Primary Completion Date:      October 2015
  Completion Date:              October 2015
  First Posted:                 May 21, 2015
  Results First Posted:         
  Last Update Posted:           April 4, 2016
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02450838

Study 20:
  NCT Number:                   NCT04822441
  Title:                        Prospective Study on the Risks of Dengue Fever for the Fetus.
  Acronym:                      ERiDenF
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Other: data collection
  Outcome Measures:             Study the teratogenic effects of the dengue virus on the fetus|Study the maternal-fetal transmission of dengue fever during pregnancy|Study the maternal-fetal transmission of dengue fever in the peri-partum|Study the materno-placental transmission of dengue fever during pregnancy and peri-partum|Study the consequences at the placental level of dengue, in terms of anatomopathological alterations
  Sponsor/Collaborators:        Centre Hospitalier Universitaire de la Réunion
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   150
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Prospective
  Other IDs:                    2019/CHU/14
  Start Date:                   March 19, 2021
  Primary Completion Date:      January 2023
  Completion Date:              March 2023
  First Posted:                 March 30, 2021
  Results First Posted:         
  Last Update Posted:           November 4, 2021
  Locations:                    CHU de la Réunion, Saint-Pierre, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04822441

Study 21:
  NCT Number:                   NCT01563640
  Title:                        Insecticidal School Uniforms for Dengue Prevention in Thailand
  Acronym:                      DengueTools
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Other: permethrin insecticide|Other: washing
  Outcome Measures:             insecticide:placebo incidence rate-ratio (per 1,000 person-years) of laboratory-confirmed dengue cases in school-aged children|comparison between intervention and placebo groups of number of serious skin reactions to insecticide-treated uniforms
  Sponsor/Collaborators:        Umeå University|European Union
  Gender:                       All
  Age:                          7 Years to 15 Years   (Child)
  Phases:                       Not Applicable
  Enrollment:                   1825
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    282589-T
  Start Date:                   March 2012
  Primary Completion Date:      June 2013
  Completion Date:              December 2014
  First Posted:                 March 27, 2012
  Results First Posted:         
  Last Update Posted:           September 1, 2015
  Locations:                    Centre of Excellence for Vectors and Vector-Borne Diseases, Mahidol University, Salaya, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01563640

Study 22:
  NCT Number:                   NCT05268302
  Title:                        Dengue CVD 11000 (DHIM-4)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Biological: Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose|Biological: Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose
  Outcome Measures:             Number of Participants with Solicited Injection Site Adverse Events|Number of Participants with Unsolicited Injection Site Adverse Event s|Number of Participants with Solicited Systemic Adverse Events|Incidence of Abnormal Laboratory Measurements|Number of Participants with Dengue-Related Adverse Events|Number of Participants with Unsolicited Systemic Adverse Events|Number of Participants with Short-Term SAEs|Number of Participants with Long-Term SAEs|Number of Participants with Fever
  Sponsor/Collaborators:        University of Maryland, Baltimore|Medical Technology Enterprise Consortium (MTEC)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   30
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    HP-00087533
  Start Date:                   February 28, 2022
  Primary Completion Date:      December 2023
  Completion Date:              December 2023
  First Posted:                 March 7, 2022
  Results First Posted:         
  Last Update Posted:           March 7, 2022
  Locations:                    University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05268302

Study 23:
  NCT Number:                   NCT02606019
  Title:                        The Use of Biomarkers in Predicting Dengue Outcome
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                
  Outcome Measures:             Sensitivity (%) of biomarkers (PTX3 and VEGF)|Specificity (%) of biomarkers (PTX3 and VEGF)|Positive predictive value (%) of biomarkers (PTX3 and VEGF)|Negative predictive value (%) of biomarkers (PTX3 and VEGF)|Correlation of routine blood parameters with PTX 3 and VEGF.
  Sponsor/Collaborators:        Universiti Tunku Abdul Rahman|Ministry of Health, Malaysia
  Gender:                       All
  Age:                          15 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   108
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    NMRR-15-1045-25937
  Start Date:                   October 2015
  Primary Completion Date:      October 2019
  Completion Date:              October 2019
  First Posted:                 November 17, 2015
  Results First Posted:         
  Last Update Posted:           October 25, 2016
  Locations:                    Ampang Hospital, Ampang, Selangor, Malaysia|Klinik Kesihatan Ampang (Ampang Health Clinic), Ampang, Selangor, Malaysia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02606019

Study 24:
  NCT Number:                   NCT03799237
  Title:                        Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquitoes
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Other: GOS trap and dengue NS1 antigen kit
  Outcome Measures:             Change in number of weekly notified dengue cases in intervention arm|Change in the duration of dengue outbreaks in intervention arm|Change in adult Aedes density in the intervention arm|Change in level of dengue Knowledge, Attitude and Practice in the intervention arm
  Sponsor/Collaborators:        Jonathan Liew Wee Kent|Petaling Jaya City Council, Malaysia|Selangor State Health Department, Malaysia|University of Malaya
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   7979
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    GOSNS1-1|MO013-2017
  Start Date:                   October 1, 2018
  Primary Completion Date:      March 31, 2020
  Completion Date:              April 30, 2020
  First Posted:                 January 10, 2019
  Results First Posted:         
  Last Update Posted:           January 10, 2019
  Locations:                    Petaling Jaya City Council, Petaling Jaya, Selangor, Malaysia
  Study Documents:              "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03799237/ICF_000.pdf|"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03799237/Prot_SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03799237

Study 25:
  NCT Number:                   NCT05213364
  Title:                        Dengue Vaccine Hesitancy and Acceptance in Endemic Regions of Argentina: Impact of Communication Strategies
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                
  Outcome Measures:             Proportion of subjects who express acceptability to the DEN vaccine.
  Sponsor/Collaborators:        Fundacion GESICA
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   1500
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Ecologic or Community|Time Perspective: Prospective
  Other IDs:                    Dengue_VaxHes
  Start Date:                   April 2022
  Primary Completion Date:      August 2023
  Completion Date:              November 2023
  First Posted:                 January 28, 2022
  Results First Posted:         
  Last Update Posted:           January 28, 2022
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05213364

Study 26:
  NCT Number:                   NCT05229354
  Title:                        Dengue Controlled Human Infection Model in Dhaka, Bangladesh
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV005|Biological: rDEN2Δ30-7169 biotechnological synthetic attenuated virus strain
  Outcome Measures:             Frequency of viremia|Quantity of Viremia|Duration of viremia|Frequency of volunteers with adverse events
  Sponsor/Collaborators:        Beth Kirkpatrick|International Centre for Diarrhoeal Disease Research, Bangladesh|University of Vermont
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   192
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    PR-19099
  Start Date:                   December 11, 2021
  Primary Completion Date:      February 2024
  Completion Date:              July 2025
  First Posted:                 February 8, 2022
  Results First Posted:         
  Last Update Posted:           February 25, 2022
  Locations:                    Icddr,B, Dhaka, Bangladesh
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05229354

Study 27:
  NCT Number:                   NCT05505682
  Title:                        Impact of Project Wolbachia - Singapore on Dengue Incidence
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Biological (Male Wolbachia-infected Aedes aegypti)
  Outcome Measures:             Odds ratio of Wolbachia exposure distribution among laboratory-confirmed reported dengue cases compared to test-negative controls|Laboratory-confirmed reported dengue case counts normalized by population size in intervention versus non-intervention clusters|Prevalence of Ae. aegypti/Ae. albopictus mosquitoes|Public Attitudes, Perceptions & Knowledge (APK) of Wolbachia and other vector control interventions
  Sponsor/Collaborators:        National Environment Agency, Singapore|Ministry of Health, Singapore
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       Not Applicable
  Enrollment:                   2000
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    IRB024
  Start Date:                   July 28, 2022
  Primary Completion Date:      September 2024
  Completion Date:              January 2025
  First Posted:                 August 18, 2022
  Results First Posted:         
  Last Update Posted:           August 18, 2022
  Locations:                    National Environment Agency, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05505682

Study 28:
  NCT Number:                   NCT01110551
  Title:                        Tetravalent Chimeric Dengue Vaccine Trial
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: Placebo (SC)|Drug: Placebo (ID)|Biological: Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|Biological: Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
  Outcome Measures:             Number of volunteers overall and in each dose group with unsolicited vaccine-associated adverse events (AEs) in each dose group.|Number of volunteers overall and in each dose group with local or systemic vaccine reactogenicity, based on evaluation of solicited adverse events (AEs) recorded on subject memory aids or during clinical assessments.|Number of volunteers overall and in each dose group with vaccine-associated serious adverse events (SAEs).|Immunogenicity: geometric mean neutralizing antibody titers (GMT) to each of the 4 dengue serotypes.|Viremia: incidence, duration, and titer of viremia for each of the DENVax vaccine components.|Immunogenicity: durability of vaccine-induced immune responses based on neutralizing antibody titers to all 4 dengue serotypes.|Immunogenicity: proportion of subjects seroconverting to each of the 4 dengue serotypes, where seroconversion is defined as plaque reduction neutralization assay (PRNT)50 titer greater than or equal to 10.
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   72
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    09-0055|N01AI80003C
  Start Date:                   May 2010
  Primary Completion Date:      April 2012
  Completion Date:              December 2012
  First Posted:                 April 26, 2010
  Results First Posted:         
  Last Update Posted:           February 4, 2013
  Locations:                    Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01110551

Study 29:
  NCT Number:                   NCT02570152
  Title:                        A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Procedure: Blood sample collection
  Outcome Measures:             Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Dengue (LCD) Overall, and by Age Group|Incidence Rate of Acute Febrile Illness (AFI) Due to Non-Laboratory Confirmed Dengue (Non-LCD) Overall, and by Age Group|Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Sero Type 1 Dengue Overall, and by Age Group.|Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Sero Type 2 Dengue Overall, and by Age Group|Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Sero Type 3 Dengue Overall, and by Age Group|Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Sero Type 4 Dengue Overall, and by Age Group|Number of Acute Febrile Illness Due to Laboratory Confirmed Dengue Presenting a Sign or a Symptom of Interest (Any Intensity) During the 7-day Period Following the Onset of Each Episode of AFI Due to LCD.|Number of Acute Febrile Illness Due to Laboratory Confirmed Dengue Presenting a Sign or a Symptom of Interest (Grade 3) During the 7-day Period Following the Onset of Each Episode of AFI Due to LCD|Number of Acute Febrile Illness Due to Non-Laboratory Confirmed Dengue Presenting a Sign or a Symptom of Interest (Any Intensity) During the 7-day Period Following the Onset of Each Episode of AFI Due to Non-LCD|Number of Acute Febrile Illness Due to Non-Laboratory Confirmed Dengue Presenting a Sign or a Symptom of Interest (Grade 3) During the 7-day Period Following the Onset of Each Episode of AFI Due to Non-LCD|Number of Subjects With Serious Adverse Events (SAEs) Related to a Study Procedure
  Sponsor/Collaborators:        GlaxoSmithKline|Ministry of Health, Sri Lanka
  Gender:                       All
  Age:                          6 Months to 50 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   2004
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    200274
  Start Date:                   June 1, 2016
  Primary Completion Date:      June 28, 2019
  Completion Date:              June 28, 2019
  First Posted:                 October 7, 2015
  Results First Posted:         July 7, 2020
  Last Update Posted:           July 7, 2020
  Locations:                    GSK Investigational Site, Colombo, Sri Lanka
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02570152/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02570152/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02570152

Study 30:
  NCT Number:                   NCT05476757
  Title:                        Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.
  Acronym:                      DHIT
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN2Δ30-7169
  Outcome Measures:             The safety of rDEN2Δ30-7169 in flavivirus naïve participants|The frequency of viremia following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The quantity of viral genome following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The duration of viremia following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The quantity of infectious activity following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The duration of infectious activity following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The frequency of NS1 antigenemia following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The quantity of NS1 antigenemia following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The duration of NS1 antigenemia following administration with rDEN2Δ30-7169 in flavivirus naïve participants|The immunogenicity of rDEN2Δ30-7169 in Thai flavivirus naïve participants|Measurement of levels of anti-dengue virion-IgM/IgG antibodies following administration with rDEN2Δ30-7169 in flavivirus naïve participants
  Sponsor/Collaborators:        Mahidol University
  Gender:                       All
  Age:                          18 Years to 30 Years   (Adult)
  Phases:                       Early Phase 1
  Enrollment:                   5
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    022/2565(IRB1)
  Start Date:                   August 2022
  Primary Completion Date:      January 2023
  Completion Date:              March 2026
  First Posted:                 July 27, 2022
  Results First Posted:         
  Last Update Posted:           July 27, 2022
  Locations:                    Siriraj Hospital, Bangkok Noi, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05476757

Study 31:
  NCT Number:                   NCT05366439
  Title:                        Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: AT-752|Drug: Placebo Comparator
  Outcome Measures:             Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])
  Sponsor/Collaborators:        Atea Pharmaceuticals, Inc.
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   12
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    AT-02A-003
  Start Date:                   May 2022
  Primary Completion Date:      November 2022
  Completion Date:              November 2022
  First Posted:                 May 9, 2022
  Results First Posted:         
  Last Update Posted:           May 9, 2022
  Locations:                    Atea Study Site, Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05366439

Study 32:
  NCT Number:                   NCT05201794
  Title:                        A Study of JNJ-64281802 for the Prevention of Dengue Infection
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: JNJ-64281802|Drug: Placebo
  Outcome Measures:             Number of Participants with Laboratory-confirmed Dengue Virus (DENV) Infection Between Baseline and the Last Day of Dosing Among Participants Who Have No Evidence of Current DENV Infection at Baseline|Number of Participants with Laboratory-confirmed Symptomatic DENV Infection Between Baseline and the Last Day of Dosing Among All Participants|Number of Participants with Laboratory-confirmed Symptomatic DENV Infection Between Baseline and the Last Day of Dosing Among Participants With No Evidence of Current DENV Infection at Baseline|Number of Participants with Adverse Events (AEs)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Abnormalities in Physical Examinations|Number of Participants with Abnormalities in Vital Signs|Number of Participants with Abnormalities in Electrocardiograms (ECGs)|Number of Participants with Abnormalities in Clinical Laboratory Assessments|Area Under the Concentration Curve of JNJ-64281802 During One Dosing Interval (AUCtau)|Observed JNJ-64281802 Concentration Just Prior to the Beginning or at the End of a Dosing Interval (Ctrough)|Maximum Plasma Concentration (Cmax) of JNJ-64281802
  Sponsor/Collaborators:        Janssen Research & Development, LLC
  Gender:                       All
  Age:                          16 Years to 65 Years   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   1850
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CR109157|64281802DNG2004
  Start Date:                   January 18, 2023
  Primary Completion Date:      May 22, 2025
  Completion Date:              May 22, 2025
  First Posted:                 January 21, 2022
  Results First Posted:         
  Last Update Posted:           December 21, 2022
  Locations:                    Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte, Brazil|HUJM - UFMT - Hospital Universitário Júlio Müller - Universidade Federal do Mato Grosso, Cuiabá, Brazil|HUJM - UFMT - Hospital Universitário Júlio Müller - Universidade Federal do Mato Grosso, Cuiabá, Brazil|Hospital e Maternidade Sao Joao de Deus, Laranjeiras do Sul, Brazil|Fundacao De Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Mato Grosso Do Sul, Brazil|Policlínica Regional Dr Sérgio Arouca, Niterói, Brazil|UPA Unidade de Pronto Atendimento Mário Monteiro, Niterói, Brazil|Cepem - Centro de Pesquisa Em Medicina Tropical, Porto Velho, Brazil|Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto - Hospital de Base, Sao Jose do Rio Preto, Brazil|CAIMED Acacias, Acacías, Colombia|CAIMED Aguazul, Aguazul, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centre of Care and Diagnosis of the Infectious Diseases (CDI), Bucaramanga, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Yopal - Casanare, Colombia|Klinik Kesihatan Kajang, Kajang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Klinik Kesihatan Kuang, Kuang, Malaysia|Klinik Kesihatan Pandamaran, Pelabuhan Klang, Malaysia|Hospital Taiping, Taiping, Malaysia|Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico|Centro Medico Jojutla, Jojutla De Juárez, Mexico|Medical Care & Research SA de CV, Merida, Mexico|Unidad de Proyectos Clínicos de Oriente UPCO, Valladolid, Mexico|FAICIC S. de R.L. de C.V., Veracruz, Mexico|Cevaxin 24 de diciembre, Cuidad De Panama, Panama|Centro de Vacunacion Internacional CEVAXIN Av Mexico, Panama, Panama|Cevaxin La Chorrera, Panama, Panama|INDICASAT Instituto de Investigaciones Científicas y Servicios de Alta Tecnología de Panamá, Panama, Panama|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Chong Hua Hospital, Cebu City, Philippines|Philippines AFRIMS Virology Research Unit, Cebu City, Philippines|De La Salle Health Sciences Institute- DLSUMC, Dasmarinas, Philippines|Las Pinas Doctors Hospital, Las Pinas, Philippines|Tropical Disease Foundation, Makati, Philippines|Clinical Research Puerto Rico, Guayama, Puerto Rico|Ponce School of Medicine, Caimed Ctr, Ponce, Puerto Rico|Clinical Research Puerto Rico, San Juan, Puerto Rico|The Hospital for Tropical Diseases, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand|Songklanagarind hospital, Hat Yai, Thailand|Srinagarind Hospital, Muang, Thailand|Research Institute for Health Science, Chiang Mai University, Muang, Thailand|Kamphaeng Phet Hospital, Muang, Thailand|Royal Thai Army, Afrims, Ratchathewi, Thailand|National Institute of Hygiene and Epidemiology, Ha Noi, Vietnam|HCMC Hospital for Tropical Disease, Ho Chi Minh City, Vietnam|Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam|HCMC University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam|Health Center of Ninh Hoa Town, Khanh Hoa, Vietnam|Khanh Hoa provincial Department of Health, Nha Trang, Vietnam|Pasteur Institute Nha Trang, Nha Trang, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05201794

Study 33:
  NCT Number:                   NCT05580731
  Title:                        Evaluation Study of Dengue RDTs
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Diagnostic Test: Diagnostic test: 5 different Rapid diagnostic test and Reference tests
  Outcome Measures:             Point estimates of sensitivity and specificity of each RDTs to detect acute dengue with 95% confidence intervals using ELISA as reference standard.|Estimates of operational characteristics of different RDTs, based on quantitative assessment including invalid rates
  Sponsor/Collaborators:        Foundation for Innovative New Diagnostics, Switzerland|Aga Khan University
  Gender:                       All
  Age:                          2 Years to 65 Years   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   500
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    FE006B
  Start Date:                   July 31, 2022
  Primary Completion Date:      February 2023
  Completion Date:              March 2023
  First Posted:                 October 14, 2022
  Results First Posted:         
  Last Update Posted:           October 14, 2022
  Locations:                    Aga Khan University, Karachi, Sindh, Pakistan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05580731

Study 34:
  NCT Number:                   NCT04906980
  Title:                        A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: JNJ-64281802|Drug: Placebo
  Outcome Measures:             Area Under the Log10-transformed Dengue Virus (DENV) Ribonucleic Acid (RNA) Viral Load (VL) Curve from Baseline Until Day 5 (AUCD1-D5 [log10VL])|Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability|Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)|Number of Participants with Clinically Significant Abnormalities in Physical Examination|Number of Participants with Clinically Significant Abnormalities in Vital Signs|Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters|Occurrence of Detectable DENV RNA in Primary DENV Infection|Time to Undetectable DENV RNA in Primary DENV Infection|Area Under the Concentration Curve During one Dosing Interval (AUCtau) of JNJ-64281802|Maximum Observed Analyte Concentration (Cmax) of JNJ-64281802|Trough Observed Analyte Concentration (Ctrough) of JNJ-64281802
  Sponsor/Collaborators:        Janssen Research & Development, LLC
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   150
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CR108919|64281802DNG2003
  Start Date:                   January 24, 2022
  Primary Completion Date:      November 15, 2024
  Completion Date:              November 15, 2024
  First Posted:                 May 28, 2021
  Results First Posted:         
  Last Update Posted:           December 21, 2022
  Locations:                    Singapore General Hospital, Singapore, Singapore|HCMC Hospital for Tropical Disease, Ho Chi Minh City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04906980

Study 35:
  NCT Number:                   NCT03960385
  Title:                        Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: CYD-TDV
  Outcome Measures:             Dengue symptomatic case|Dengue hospitalization
  Sponsor/Collaborators:        Albert B. Sabin Vaccine Institute|Pan American Health Organization|State of Parana/Health Department of Parana|Ministry of Health of Brazil|Centro de Estudos Augusto Leopoldo Ayrosa Galvão
  Gender:                       All
  Age:                          9 Years to 44 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   1854
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Cross-Sectional
  Other IDs:                    DNG10042
  Start Date:                   August 1, 2017
  Primary Completion Date:      March 1, 2020
  Completion Date:              March 1, 2020
  First Posted:                 May 23, 2019
  Results First Posted:         
  Last Update Posted:           September 11, 2020
  Locations:                    Augusto Leopoldo Ayrosa Galvão Study Center, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03960385

Study 36:
  NCT Number:                   NCT04582474
  Title:                        Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Other: Dengue module and rapid diagnostic tests
  Outcome Measures:             Point estimates of the percentage of dengue consultations performed using the dengue module, with 95% confidence intervals|Evaluation of the adherence to the different steps of the module|Estimate of the operational characteristic, Efficacy, of the dengue module: percentage of forms emitted from the module received in the surveillance system|Estimate of the operational characteristic, Timeliness, of the dengue module: percentage of forms that are received by the surveillance system on time, as defined by the national surveillance system.|Estimate of operational characteristic, Completeness, of the dengue module: percentage of fields that are completed.|Positive predictive value of dengue rapid diagnostic test
  Sponsor/Collaborators:        Foundation for Innovative New Diagnostics, Switzerland|Ministry of Health, Burkina Faso|Terre des hommes, Burkina Faso & Switzerland
  Gender:                       All
  Age:                          6 Months and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   335
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    FE008
  Start Date:                   September 10, 2020
  Primary Completion Date:      November 2020
  Completion Date:              December 2020
  First Posted:                 October 9, 2020
  Results First Posted:         
  Last Update Posted:           October 9, 2020
  Locations:                    Centre de Santé et de Promotion Sociale (Sandogo), Ouagadougou, District Boulmiougou, Burkina Faso|Centre de Santé et de Promotion Sociale (Secteur 16), Ouagadougou, District Boulmiougou, Burkina Faso
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04582474

Study 37:
  NCT Number:                   NCT04786457
  Title:                        ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
  Outcome Measures:             Solicited Injection Site Adverse Events|Unsolicited Injection Site Adverse Events|Solicited Systemic Adverse Events|Incidence of Abnormal Laboratory Measurements|Dengue-Related Adverse Events|Unsolicited Systemic Adverse Events|Short-Term SAEs|Long-Term SAEs|Fever
  Sponsor/Collaborators:        University of Maryland, Baltimore|United States Army Medical Materiel Development Activity|Medical Technology Enterprise Consortium (MTEC)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   17
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    HP-00088798
  Start Date:                   November 30, 2020
  Primary Completion Date:      July 9, 2021
  Completion Date:              July 9, 2021
  First Posted:                 March 8, 2021
  Results First Posted:         
  Last Update Posted:           October 28, 2021
  Locations:                    University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04786457

Study 38:
  NCT Number:                   NCT01696422
  Title:                        Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue 1,2,3,4 (attenuated) vaccine|Biological: TetraVax-DV Vaccine - Admixture TV003|Other: Placebo
  Outcome Measures:             Safety|Immunogenicity
  Sponsor/Collaborators:        Butantan Institute|Banco Nacional de Desenvolvimento Economico e Social|Fundação de Amparo à Pesquisa do Estado de São Paulo|Butantan Foundation
  Gender:                       All
  Age:                          18 Years to 59 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-01-IB|U1111-1135-4553
  Start Date:                   October 2013
  Primary Completion Date:      April 2016
  Completion Date:              December 2020
  First Posted:                 October 1, 2012
  Results First Posted:         
  Last Update Posted:           January 16, 2019
  Locations:                    Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01696422

Study 39:
  NCT Number:                   NCT02766088
  Title:                        This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
  Acronym:                      
  Status:                       Terminated
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Procedure: Blood sample collection
  Outcome Measures:             Incidence Percentage of Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR) Confirmed Symptomatic Dengue Infection During the Study Period by Study Site|Number of Subjects With DENV-type Specific Confirmed Symptomatic DENV Infection|Incidence Proportion of Virologically Confirmed Symptomatic Dengue Infection During the Study Period in Mexico|Incidence Percentage of Virologically Confirmed Symptomatic Dengue Infection During the Study Period in the Philippines.|Incidence Proportion of Probable Symptomatic Dengue Infection During the Study Period.|Proportion of Subjects With Dengue Virus Antibody IgG Positive Result (ELISA) at First Visit (Indicative of Past DENV Infection), by Study Site and Age Category.|Percentage of Subjects With Dengue Virus Antibody IgG Positive Result (ELISA) at First Visit (Indicative of Past DENV Infection), by Study Site and Age Category.|Number of Suspected Dengue Cases With Temperature and Any Symptom From First and Returned Visits|Number of Suspected Dengue Cases With Severity Criteria Characteristics|Number of Subjects With Serious Adverse Events (SAEs) Related to a Study Procedure
  Sponsor/Collaborators:        GlaxoSmithKline
  Gender:                       All
  Age:                          6 Months to 50 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   850
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    200318
  Start Date:                   July 14, 2016
  Primary Completion Date:      December 14, 2018
  Completion Date:              December 14, 2018
  First Posted:                 May 9, 2016
  Results First Posted:         April 27, 2020
  Last Update Posted:           April 27, 2020
  Locations:                    GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Muntinlupa, Philippines
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02766088/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02766088/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02766088

Study 40:
  NCT Number:                   NCT00377754
  Title:                        Prospective Study of Infant Dengue
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                
  Outcome Measures:             
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          6 Weeks and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   20000
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                Time Perspective: Prospective
  Other IDs:                    06-0013
  Start Date:                   September 2006
  Primary Completion Date:      
  Completion Date:              September 2010
  First Posted:                 September 18, 2006
  Results First Posted:         
  Last Update Posted:           August 27, 2010
  Locations:                    Research Institute for Tropical Medicine, Muntinlupa City, Philippines
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00377754

Study 41:
  NCT Number:                   NCT01502735
  Title:                        Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
  Acronym:                      DENV-1 PIV
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: DENV-1 PIV, 2.5 µg|Biological: DENV-1 PIV, 5 µg
  Outcome Measures:             Number of subjects with solicited adverse events (AEs) from study day 0 to 90|Number of subjects with unsolicited AEs from study day 0 to 90|Number of subjects who experience serious adverse events (SAEs) during the study period|Number of subjects with a change in geometric mean titer of neutralizing antibody to DENV types 1,2,3, and 4
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   20
  Funded Bys:                   U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    S-10-0003|WRAIR IRB Protocol # 1856|HSRRB Protocol #: A-17104|IND 14338
  Start Date:                   December 2011
  Primary Completion Date:      September 2013
  Completion Date:              September 2013
  First Posted:                 January 2, 2012
  Results First Posted:         
  Last Update Posted:           April 22, 2015
  Locations:                    WRAIR, Clinical Trials Center (CTC), Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01502735

Study 42:
  NCT Number:                   NCT04063774
  Title:                        Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Diagnostic Test: Dengue calculator
  Outcome Measures:             Sensitivity of dengue calculator|Specificity of dengue calculator|Sensitivity in dengue and probable dengue cases
  Sponsor/Collaborators:        Lyda Osorio|COMFANDI CAJA DE COMPENSACION DEL VALLE DEL CAUCA|SISTEMA GENERAL DE REGALIAS CASANARE, SANTANDER VALLE DEL CAUCA|RED AEDES|Universidad del Valle, Colombia
  Gender:                       
  Age:                          Child, Adult, Older Adult
  Phases:                       Not Applicable
  Enrollment:                   1045
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    144-016
  Start Date:                   December 27, 2016
  Primary Completion Date:      July 15, 2018
  Completion Date:              July 15, 2018
  First Posted:                 August 21, 2019
  Results First Posted:         
  Last Update Posted:           August 21, 2019
  Locations:                    Hospital Regional de la Orinoquía, Yopal, Casanare, Colombia|Clinica y Hospital Local de Piedecuesta, Piedecuesta, Santander, Colombia|COMFANDI Torres y Alameda, Cali, Valle Del Cauca, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04063774

Study 43:
  NCT Number:                   NCT01030211
  Title:                        Adult Dengue Platelet Study
  Acronym:                      ADEPT
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Procedure: Platelet transfusion|Other: Supportive care
  Outcome Measures:             Clinical bleeding excluding petechiae with a subgroup analysis for severe clinical bleeding.|Platelet increment post-transfusion|Time to platelet > 50 x 10^3/uL|Changes in cytokines|Length of stay|Plasma leakage|DHF/DSS|ICU admission|Death|Secondary bacterial infection|Adverse events from transfusion
  Sponsor/Collaborators:        Tan Tock Seng Hospital|Singapore General Hospital|Changi General Hospital|National University Hospital, Singapore|University of Malaya
  Gender:                       All
  Age:                          21 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   372
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    TTSH ADEPT
  Start Date:                   January 2010
  Primary Completion Date:      December 2014
  Completion Date:              December 2014
  First Posted:                 December 11, 2009
  Results First Posted:         
  Last Update Posted:           August 25, 2015
  Locations:                    University Malaya Medical Centre, Kuala Lumpur, Malaysia|Tan Tock Seng Hospital, National University Health System, Singapore General Hospital, Changi General Hospital, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01030211

Study 44:
  NCT Number:                   NCT03416036
  Title:                        Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV-TV003 (TV003)|Biological: rDEN2Δ30-7169 (DENV-2)|Biological: rDEN3Δ30 (DENV-3)|Biological: Placebo
  Outcome Measures:             Frequency of rDEN2Δ30-7160 viremia|Frequency of rDEN3Δ30 viremia|Occurrence of solicited local and general adverse events (AEs)|Occurrence of unsolicited AEs|Occurrence of serious adverse events (SAEs)|Frequency of viremia after vaccination with TV003|Number of TV003 recipients infected with vaccine virus DENV-1, DENV-2, DENV-3, and DENV-4|Serum plaque reduction neutralization titer 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   64
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 323
  Start Date:                   November 28, 2017
  Primary Completion Date:      January 17, 2019
  Completion Date:              June 4, 2019
  First Posted:                 January 30, 2018
  Results First Posted:         
  Last Update Posted:           January 18, 2020
  Locations:                    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|Vaccine Testing Center, University of Vermont, Burlington, Vermont, United States
  Study Documents:              "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03416036/ICF_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03416036

Study 45:
  NCT Number:                   NCT02435615
  Title:                        Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Device: SaniSal Oral Fluid Collector
  Outcome Measures:             Dengue Immunoglobulin M (IgM) and Non-Structural Protein 1 (NS1) Concentration in Oral Fluid|Patient Acceptability of Oral Fluid Collector
  Sponsor/Collaborators:        University of Miami|Instituto Nacional de la Diabetes|Hospital Infantil Dr. Robert Reid Cabral
  Gender:                       All
  Age:                          2 Years and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   15
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic
  Other IDs:                    20140009
  Start Date:                   January 2016
  Primary Completion Date:      December 2016
  Completion Date:              December 2016
  First Posted:                 May 6, 2015
  Results First Posted:         
  Last Update Posted:           October 26, 2017
  Locations:                    Hospital Infantil, Santo Domingo, Dominican Republic
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02435615

Study 46:
  NCT Number:                   NCT04597437
  Title:                        Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
  Acronym:                      ZAP-DENGUE
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: Zanamivir|Other: Placebo
  Outcome Measures:             Incidence of Treatment-Emergent Adverse Events of intravenous zanamivir treatment versus placebo in dengue|Levels of endothelial glycocalyx biomarkers in intravenous zanamivir treatment versus placebo in dengue|Preliminary clinical efficacy of intravenous zanamivir treatment versus placebo in dengue
  Sponsor/Collaborators:        George Washington University|Naval Medical Research Center|Clinica de la Costa|Global Disease Research
  Gender:                       All
  Age:                          7 Years and older   (Child, Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   74
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    NCR203024
  Start Date:                   January 1, 2023
  Primary Completion Date:      August 30, 2023
  Completion Date:              August 30, 2023
  First Posted:                 October 22, 2020
  Results First Posted:         
  Last Update Posted:           December 6, 2022
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04597437

Study 47:
  NCT Number:                   NCT00322049
  Title:                        A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: Tetravalent live attenuated dengue vaccine|Biological: Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
  Outcome Measures:             Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine.|Geometric Mean Titers (GMT) for N Antibody to All Four Serotypes and Japanese Encephalitis (JE) Vaccine|Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dose 2|Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dengue Dose 2 (and 2 Doses of JE|JE Vaccine Response|Incidence of Dengue Specific Symptoms|Percentage of Subjects With a Dengue Viremia 10 Days Post Booster Dose
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline
  Gender:                       All
  Age:                          12 Months to 15 Months   (Child)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   51
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention
  Other IDs:                    WRAIR 824|HSRRB Log A-10064|GSK CPMS7663310/001|DEN-001
  Start Date:                   February 2004
  Primary Completion Date:      June 2009
  Completion Date:              June 2009
  First Posted:                 May 4, 2006
  Results First Posted:         July 19, 2017
  Last Update Posted:           January 19, 2018
  Locations:                    USAMC-AFRIMS/Department of Pediatrics, Pharamongkutklao Hospital, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00322049

Study 48:
  NCT Number:                   NCT04826081
  Title:                        Study on the Risks of Symptomatic Dengue on Pregnancy
  Acronym:                      ERiDenG
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue|Pregnancy
  Interventions:                Other: data collection
  Outcome Measures:             Evaluate the difference in the proportion of intrauterine growth retardation (IUGR) between the Case group and the Control group|Evaluate the difference in the proportion of prematurity between the case group and the control group|Evaluate the difference in the proportion of late miscarriage between the case group and the control group|Evaluate the difference in the proportion of fetal death in utero between the case group and the control group|Evaluate the difference in the proportion of preeclampsia between the case group and the control group|Evaluate the difference in the proportion of bleeding from delivery between the case group and the control group between the case group and the control group|Evaluate the difference in the proportion of small weight for gestational age between the case group and the control group between the case group and the control group
  Sponsor/Collaborators:        Centre Hospitalier Universitaire de la Réunion
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   336
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Prospective
  Other IDs:                    2020/CHU/41
  Start Date:                   June 15, 2021
  Primary Completion Date:      January 2024
  Completion Date:              March 2024
  First Posted:                 April 1, 2021
  Results First Posted:         
  Last Update Posted:           November 4, 2021
  Locations:                    CHU de la Réunion, Saint-Pierre, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04826081

Study 49:
  NCT Number:                   NCT03110952
  Title:                        TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TDENV-PIV|Biological: TDENV-F17|Other: Placebo
  Outcome Measures:             Number of and intensity of solicited local and general adverse events (AEs) during the 7-day follow-up period after each vaccination|Number of and intensity of unsolicited adverse events (AEs) during the 7-day follow-up period after each vaccination|Number of serious adverse events (SAEs)|Number of potential immune-mediated diseases (pIMDs) and medicall attended AEs|Geometric mean titers (GMTs) of neutralizing antibodies to each DENV serotype|Number of participants seropositive for each DENV serotype|Number of participants trivalent and tetravalent seropositive
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR)|GlaxoSmithKline
  Gender:                       All
  Age:                          18 Years to 39 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   0
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    S-14-08|DPIV-020|201126
  Start Date:                   January 2016
  Primary Completion Date:      April 2017
  Completion Date:              April 2018
  First Posted:                 April 12, 2017
  Results First Posted:         
  Last Update Posted:           April 12, 2017
  Locations:                    Upstate Medical University, SUNY, Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03110952

Study 50:
  NCT Number:                   NCT01751139
  Title:                        An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil
  Acronym:                      
  Status:                       Terminated
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Procedure: Blood sample collection|Other: Data collection
  Outcome Measures:             Incidence Rate (Per 1000 Person-years) of All Laboratory-confirmed Symptomatic Dengue Infection by Calendar Year|Incidence Rate (Per 1000 Person-years) of All Virologically-confirmed Symptomatic Dengue Infection by Calendar Year|Incidence Rate (Per 1000 Person-years) of All Laboratory-confirmed or Probable Symptomatic Dengue Infection by Study Site, and Calendar Year|Incidence Rate (Per 1000 Person-years) of All Laboratory-confirmed or Probable Symptomatic Dengue Infection by Age Category, and Calendar Year|Incidence Rate (Per 1000 Person-years) of All Laboratory-confirmed or Probable Symptomatic Dengue Infection by Gender, and Calendar Year|Number of Primary Symptomatic Dengue Infection Cases Among Laboratory-confirmed or Probable Cases|Number of Secondary Symptomatic Dengue Infection Cases Among Laboratory-confirmed or Probable Cases|Number of Subjects With Previous Dengue Infection (Dengue Seroprevalence) at Baseline, by Study Site and Overall|Number of Subjects With Previous Dengue Infection (Dengue Seroprevalence) at Baseline, by Gender|Number of Subjects With Previous Dengue Infection (Dengue Seroprevalence) at Baseline, by Age Group at Enrolment|Incidence Rate (Per 1000 Person-years) of Primary Inapparent Dengue Infection by Study Site and Calendar Year, and Overall, Among Subjects With no Seroprevalence at the First Visit|Incidence Rate (Per 1000 Person-years) of Primary Inapparent Dengue Infection by Age Category and Calendar Year, and Overall, Among Subjects With no Seroprevalence at the First Visit|Incidence Rate (Per 1000 Person-years) of Primary Inapparent Dengue Infection by Gender and Calendar Year, and Overall, Among Subjects With no Seroprevalence at the First Visit|Number of Suspected Dengue Cases With Severity Criteria|Number of Subjects With Serious Adverse Events (SAEs) Related to a Study Procedure
  Sponsor/Collaborators:        GlaxoSmithKline|Foundation of Tropical Medicine|Goncalo Moniz research center|Evandro Chagas Research Institute, Bio-Manguinhos Technology and Immunology Institute
  Gender:                       All
  Age:                          6 Months and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   3300
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    116606
  Start Date:                   February 18, 2014
  Primary Completion Date:      December 20, 2018
  Completion Date:              December 20, 2018
  First Posted:                 December 17, 2012
  Results First Posted:         March 26, 2020
  Last Update Posted:           April 27, 2020
  Locations:                    GSK Investigational Site, Manaus, Amazonas, Brazil|GSK Investigational Site, Salvador, Bahía, Brazil|GSK Investigational Site, Natal, Rio Grande Do Norte, Brazil|GSK Investigational Site, Campinas, São Paulo, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01751139/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01751139/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT01751139

Study 51:
  NCT Number:                   NCT03341637
  Title:                        Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: Tetravalent Dengue Vaccine (TDV)|Biological: Placebo
  Outcome Measures:             Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270|Seropositivity Rates for Each of the 4 Dengue Serotypes|Seropositivity Rates for Multiple (2, 3 or 4) Dengue Serotypes|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) Following Each Vaccination by Severity|Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) Following Each Vaccination by Severity|Percentage of Participants With Any Unsolicited Adverse Events (AEs) Following Each Vaccination|Percentage of Participants With Medically Attended AEs (MAAEs) Throughout the Study|Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          12 Years to 17 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   400
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    DEN-315|U1111-1192-7827|RNEC-2017-DEN-315|2018-003980-77
  Start Date:                   December 14, 2017
  Primary Completion Date:      January 26, 2019
  Completion Date:              January 26, 2019
  First Posted:                 November 14, 2017
  Results First Posted:         August 15, 2019
  Last Update Posted:           August 15, 2019
  Locations:                    Biodextra, S.A. de C.V., Ciudad de Mexico, Mexico|Instituto Nacional de Pediatria (INP), Mexico City, Mexico|Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico|Mexico Centre for Clinical Research, Mexico City, Mexico|Centro de Atencion E Investigacion Medica (CAIMED) Mexico DF, Mexico City, Mexico
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03341637/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03341637/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03341637

Study 52:
  NCT Number:                   NCT01436422
  Title:                        Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV Vaccine - Admixture TV003|Biological: TetraVax-DV Vaccine - Admixture TV005|Biological: Placebo
  Outcome Measures:             Safety of two TetraVax-DV admixtures, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity|Immunogenicity of two TetraVax-DV admixtures, as assessed by neutralizing antibody titers to DEN1, DEN2, DEN3, and DEN4|Seropositivity in those vaccinees who remained seronegative to one or more DENV serotypes following the first vaccination and who recieved a second dose of vaccine given at Day 180|Frequency of viremia following vaccination|Number of vaccinees infected with DEN1, DEN2, DEN3, and DEN4|Duration of the neutralizing antibody response 26 weeks after each vaccination|Ability of a second dose of vaccine to boost serum neutralizing antibody titers by Day 270|Evaluate the phenotype of peripheral blood mononuclear cells at primary infection with the TetraVax-DV vaccine|Evaluate the cellular immune response to primary infection with the TetraVax-DV vaccine|Evaluate the innate immune response to primary infection with the TetraVax-DV vaccine|Evaluate B and T cell memory responses following primary and secondary infections with TetraVax-DV vaccine|Quantity of viremia following vaccination|Duration of viremia following vaccination
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   112
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 279
  Start Date:                   August 2011
  Primary Completion Date:      March 2014
  Completion Date:              March 2014
  First Posted:                 September 19, 2011
  Results First Posted:         
  Last Update Posted:           August 20, 2015
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01436422

Study 53:
  NCT Number:                   NCT00239577
  Title:                        A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: Live attenuated tetravalent dengue vaccine|Biological: Placebo
  Outcome Measures:             Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Titers for DEN Neutralizing Antibodies Types 1, 2, 3 and 4|Titers for DEN Neutralizing Antibodies Types 1, 2, 3 and 4 Based on Priming Status|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Alert Values for Safety Laboratory Determinations|Number of Subjects With Abnormal Findings at Dengue Physical Examination|Number of Subjects With Suspected and Confirmed Dengue|Number of Subjects With Measurable Dengue Viremia|Number of Subjects With Safety Laboratory Determinations Outside the Normal Ranges|Number of Subjects With Antibody Titers Above the Assay Cut-off Value for Each DEN Serotype|Number of Subjects With Antibody Titers Above the Assay Cut-off Value (Tetravalent Response) for All Dengue Serotypes|Number of Subjects With Sero-response to Each DEN Type|Number of Subjects With Any, Grade 3 and Related Unsolicited AEs|Number of Subjects With SAEs|Number of Subjects With Hematological and Biochemical Determinations Within and Outside the Normal Ranges
  Sponsor/Collaborators:        GlaxoSmithKline
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   86
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention
  Other IDs:                    103996
  Start Date:                   April 5, 2006
  Primary Completion Date:      June 19, 2007
  Completion Date:              June 19, 2007
  First Posted:                 October 17, 2005
  Results First Posted:         February 19, 2019
  Last Update Posted:           February 19, 2019
  Locations:                    GSK Investigational Site, Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00239577

Study 54:
  NCT Number:                   NCT01073306
  Title:                        Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Virus
  Interventions:                Biological: Investigational Vaccine for Dengue Virus Subtype 2|Other: Placebo
  Outcome Measures:             Immunogenicity of vaccine, as assessed by neutralizing antibody titers|Safety of vaccine, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity|Number of vaccinees infected with this dengue virus subtype 2 (DEN2) candidate vaccine, as defined by either recovery of vaccine virus from the blood of vaccinated participants and/or by seroconversion to DEN2|Frequency, quantity, and duration of viremia|Comparison of infectivity rates, safety, and immunogenicity of a single dose of DEN2 vaccine from this trial to those variables on previous trials
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   18
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 254|#20081980
  Start Date:                   February 2010
  Primary Completion Date:      June 2010
  Completion Date:              June 2010
  First Posted:                 February 23, 2010
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Johns Hopkins Project SAVE, Center for Immunization Research, Washington, District of Columbia, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01073306

Study 55:
  NCT Number:                   NCT01702857
  Title:                        A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)
  Acronym:                      DPIV-002
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|Biological: Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|Other: Phosphate buffered saline|Biological: 1 µg TDENV-PIV with Alum adjuvant|Biological: 1 µg TDENV-PIV with AS01E adjuvant
  Outcome Measures:             Safety and reactogenicity of various TDENV-PIV formulations from Day 0 through 28 days after the second dose (Day 0 - Day 56)|Humoral immunogenicity to each of four DENV types of various TDENV-PIV formulations 28 days after the second dose (Day 56)|Safety of various TDENV-PIV formulations, from Day 0 to Month 13 (Visits 1-11)|Humoral immunogenicity to each of four DENV types of various TDENV-PIV formulations on Days 0, 7 and 28 and Months 7 and 13|• To evaluate the safety of various TDENV-PIV formulations from Month 14 through the end of the study (Visit 15)
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR)
  Gender:                       All
  Age:                          20 Years to 39 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   100
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    S-12-12|116614|WRAIR 1945|DPIV-002
  Start Date:                   November 2012
  Primary Completion Date:      January 20, 2017
  Completion Date:              March 23, 2017
  First Posted:                 October 10, 2012
  Results First Posted:         
  Last Update Posted:           May 23, 2017
  Locations:                    Clinical Research Center, 1st Floor University Hospital, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01702857

Study 56:
  NCT Number:                   NCT01084291
  Title:                        Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Virus
  Interventions:                Biological: Investigational Vaccine for DEN1|Other: Placebo injection
  Outcome Measures:             Frequency of vaccine-related adverse events (AEs), as classified by both severity and seriousness, through active and passive surveillance|Immunogenicity to dengue virus subtype one (DEN1), as assessed by neutralizing antibody titers|Frequency, quantity, and duration of viremia following vaccination|Number of vaccinees infected with DEN1, defined as recovery of vaccine virus from the blood or serum of a participant and/or by seroconversion to DEN1|Comparison of the infectivity rates, safety, and immunogenicity of a single dose of DEN1 vaccine to those rates of previous clinical trials
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   18
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 253
  Start Date:                   April 2010
  Primary Completion Date:      May 2010
  Completion Date:              June 2010
  First Posted:                 March 10, 2010
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Fletcher Allen Health Care (FAHC) General Clinical Research Center (GCRC), Burlington, Vermont, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01084291

Study 57:
  NCT Number:                   NCT00290147
  Title:                        Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
  Outcome Measures:             Systemic and Local Reactogenicity Rates for Ungraded Symptoms|Anti-dengue Antibody and T-cell and B-cell Responders
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|United States Army Medical Materiel Development Activity
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   22
  Funded Bys:                   U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    NMRC 2004.0002|WRAIR 1191|HSRRB A-13304|62787A 810S A0235
  Start Date:                   January 2006
  Primary Completion Date:      December 2006
  Completion Date:              April 2009
  First Posted:                 February 10, 2006
  Results First Posted:         April 14, 2017
  Last Update Posted:           June 20, 2017
  Locations:                    Walter Reed Army Institute of Research, Bldg 503, Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00290147

Study 58:
  NCT Number:                   NCT01666652
  Title:                        A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
  Acronym:                      DPIV-001
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: 4 µg TDENV-PIV with Alum adjuvant|Biological: 1 µg TDENV-PIV with AS03B1 adjuvant|Other: Phosphate buffered saline|Biological: 1 µg TDENV-PIV with Alum adjuvant|Biological: 1 µg TDENV-PIV with AS01E1 adjuvant
  Outcome Measures:             Number of Subjects With Adverse Events Within the 28 Day Follow-up|Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC)|Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC)|Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC)|Summary of Subjects With Serious Adverse Events|Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit|Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP)|Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC)
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR)
  Gender:                       All
  Age:                          18 Years to 39 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   100
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    S-11-23|WRAIR 1923|GSK 116289|A-17355.b
  Start Date:                   September 2012
  Primary Completion Date:      September 2015
  Completion Date:              November 2017
  First Posted:                 August 16, 2012
  Results First Posted:         January 25, 2019
  Last Update Posted:           January 25, 2019
  Locations:                    WRAIR, Clinical Trials Center, Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01666652

Study 59:
  NCT Number:                   NCT02392325
  Title:                        Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN1Δ30|Biological: Placebo|Biological: rDEN2Δ30-7169
  Outcome Measures:             Measurement of PRNT50 (plaque reduction neutralization titer) to DENV-1, DENV-2, DENV-3, and DENV-4|Incidence of solicited adverse events (AEs) following administration of rDEN2Δ30-7169 at Day 270|Intensity of solicited adverse events (AEs) following administration of rDEN2Δ30-7169 at Day 270
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   12
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 302
  Start Date:                   March 2015
  Primary Completion Date:      July 2016
  Completion Date:              February 2017
  First Posted:                 March 18, 2015
  Results First Posted:         
  Last Update Posted:           February 8, 2018
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02392325

Study 60:
  NCT Number:                   NCT05466240
  Title:                        Study of AT-752 in Patients With Dengue Infection
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: AT-752 750-mg|Drug: AT-752 Dose A|Drug: AT-752 Dose B|Drug: Placebo
  Outcome Measures:             Change in Dengue (DENV) viral load from Baseline|Pharmacokinetic (PK) endpoint|Evaluate safety of AT-752 versus placebo assessed by Treatment Emergent Adverse Events (TEAEs), serious adverse events (SAEs)
  Sponsor/Collaborators:        Atea Pharmaceuticals, Inc.
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    AT-02A-002
  Start Date:                   April 29, 2022
  Primary Completion Date:      December 2022
  Completion Date:              January 2023
  First Posted:                 July 20, 2022
  Results First Posted:         
  Last Update Posted:           October 17, 2022
  Locations:                    Atea Study Site, Belo Horizonte, Brazil|Atea Study Site, Campo Grande, Brazil|Atea Study Site, Cuiabá, Brazil|Atea Study Site, Manaus, Brazil|Atea Study Site, Natal, Brazil|Atea Study Site, Porto Velho, Brazil|Atea Study Site, Recife, Brazil|Atea Study Site, Ribeirão Preto, Brazil|Atea Study Site, Rio de Janeiro, Brazil|Atea Study Site, São José Do Rio Preto, Brazil|Atea Study Site, São Paulo, Brazil|Atea Study Site, Aguazul, Colombia|Atea Study Site, Antioquia, Colombia|Atea Study Site, Cali, Colombia|Atea Study Site, Girardot, Colombia|Atea Study Site, Yopal, Colombia|Atea Study Site, Machala, Ecuador|Atea Study Site, Guwahati, India|Atea Study Site, Kanpur, India|Atea Study Site, Lucknow, India|Atea Study Site, Sūrat, India|Atea Study Site, Kuala Terengganu, Malaysia|Atea Study Site, Perai, Malaysia|Atea Study Site, Ica, Peru|Atea Study Site, Iquitos, Peru|Atea Study Site, Iloilo City, Philippines|Atea Study Site, Las Piñas, Philippines|Atea Study Site, Quezon City, Philippines|Atea Study Site, Kaohsiung City, Taiwan|Atea Study Site, Bangkok, Thailand|Atea Study Site, Khon Kaen, Thailand|Atea Study Site, Hanoi, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05466240

Study 61:
  NCT Number:                   NCT04113330
  Title:                        Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
  Acronym:                      CYD00082
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Type of access to care provided for participant with confirmed dengue|Virologically-confirmed dengue cases|Suspected dengue case as per clinical diagnosis
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   918
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Prospective
  Other IDs:                    CYD00082|U1111-1215-0183
  Start Date:                   January 31, 2020
  Primary Completion Date:      October 2027
  Completion Date:              October 2027
  First Posted:                 October 2, 2019
  Results First Posted:         
  Last Update Posted:           May 9, 2022
  Locations:                    Investigational site Colombia, Colombia, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04113330

Study 62:
  NCT Number:                   NCT01072786
  Title:                        Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV Vaccine-Admixture 1|Biological: TetraVax-DV Vaccine-Admixture 2|Biological: TetraVax-DV Vaccine-Admixture 3|Biological: TetraVax-DV Vaccine-Admixture 4|Biological: Placebo|Biological: TetraVax-DV Vaccine-Admixture 5
  Outcome Measures:             Safety of five TetraVax-DV admixtures, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity|Determination of the serum plaque reduction neutralization titer 60% (PRNT_60) to DEN1, DEN2, DEN3, and DEN4 viruses|Monovalent, bivalent, trivalent, and tetravalent seropositivity and seroconversion rates|Seropositivity and seroconversion rates to greater than 60% in in the TetraVax-DV admixture 5 vaccine arm|Frequency, quantity, and duration of viremia following vaccination|Number of vaccinees infected with DEN1, DEN2, DEN3, and DEN4|Duration of the neutralizing antibody response|Safety and immunogenicity of a second dose of vaccine given 6 months after the first dose (optional substudy)|Seroconversion as assessed by a greater than or equal to 4-fold rise in DEN1, DEN2, DEN3, or DEN4 neutralizing antibody titers compared with the pre-vaccination antibody titer|Seropositivity as assessed by PRNT_60 to DEN1, DEN2, DEN3, DEN4 greater than or equal to 1:10 compared with the pre-vaccination titer
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   141
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 268
  Start Date:                   July 2010
  Primary Completion Date:      June 2012
  Completion Date:              June 2012
  First Posted:                 February 22, 2010
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Washington, District of Columbia, United States|Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01072786

Study 63:
  NCT Number:                   NCT02406729
  Title:                        Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Dengue 1,2,3,4 (attenuated) vaccine|Other: Placebo
  Outcome Measures:             Efficacy (incidence density of symptomatic dengue cases, virologically confirmed)|Safety (adverse reactions)|Efficacy (incidence density of dengue cases confirmed virologically, regarding previous exposure to dengue viruses. )|Efficacy (incidence density of dengue cases confirmed virologically, regarding the viral serotype)|Efficacy (incidence density of cases of severe dengue and/or with alarm signs, including cases hospitalized or not)|Safety ( frequency of solicited and unsolicited local and systemic adverse reactions in participants regarding previous exposure to dengue viruses )|Safety (frequency of unsolicited adverse reactions)|Immunogenicity (consistency of the immune response to different batches of the vaccine )|Immunogenicity (non-inferiority between simplified formulation vs. conventional formulation)
  Sponsor/Collaborators:        Butantan Institute
  Gender:                       All
  Age:                          24 Months to 59 Years   (Child, Adult)
  Phases:                       Phase 3
  Enrollment:                   16944
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-03-IB|U1111-1168-8679
  Start Date:                   February 2016
  Primary Completion Date:      December 2022
  Completion Date:              November 2024
  First Posted:                 April 2, 2015
  Results First Posted:         
  Last Update Posted:           November 30, 2022
  Locations:                    Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil|Instituto Gonçalo Muniz - Fiocruz Bahia, Simões Filho, BA, Brazil|Universidade Federal do Ceará, Fortaleza, CE, Brazil|Universidade de Brasília, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso, Cuiabá, Mount, Brazil|Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil|Centro de Pesquisas Aggeu Magalhães - Fiocruz Pernambuco, Recife, Pernambuco, Brazil|Hospital Escola da Universidade Federal de Pelotas (HEUFPel), Pelotas, Rio Grande Do Sul, Brazil|Universidade Federal de Roraima - UFRR, Boa Vista, Roraima, Brazil|Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM), Porto Velho, RO, Brazil|Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil|Universidade Federal de Sergipe, Laranjeiras, SE, Brazil|Santa Casa de Misericórdia de São Paulo - CSEBF, São Paulo, SP, Brazil|Faculdade de Medicina de São José do Rio Preto - FAMERP, São José Do Rio Preto, São Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil|HCFMUSP, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02406729

Study 64:
  NCT Number:                   NCT04313244
  Title:                        Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: 9vHPV vaccine|Biological: Dengue Tetravalent Vaccine (TDV)
  Outcome Measures:             Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58|Percentage of Participants with Seropositivity for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 as Measured by Immunoglobulin G Binding Assay (IgGBA) or Equivalent Assay|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes|Percentage of Participants with Seropositivity for Each of the 4 Dengue Serotypes|Percentage of Participants with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes|Percentage of Participants with Solicited Local Reactions for 7 Days Following Vaccination by Severity|Percentage of Participants with Solicited Systemic Adverse Events (AEs) for 14 days Following Vaccination by Severity|Percentage of Participants with any Unsolicited AEs for 28 days Following Vaccination|Percentage of Participants with Serious Adverse Events (SAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          9 Years to 14 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   618
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    DEN-308
  Start Date:                   May 15, 2021
  Primary Completion Date:      January 15, 2022
  Completion Date:              July 19, 2022
  First Posted:                 March 18, 2020
  Results First Posted:         
  Last Update Posted:           December 9, 2022
  Locations:                    Siriraj Hospital, Bangkoknoi, Khet Bangkok Noi, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|The Hospital for Tropical Diseases, Bangkok, Thailand|Thammasat University Hospital, Pathum Thani, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04313244

Study 65:
  NCT Number:                   NCT01550016
  Title:                        International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
  Acronym:                      IDAMS
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Other: Observation
  Outcome Measures:             Hospitalization or administration of IV fluid|Development of severe disease
  Sponsor/Collaborators:        University of Heidelberg Medical Center|European Union|University of Oxford
  Gender:                       All
  Age:                          5 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   7411
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    281803 (EU FP7-HEALTH-2011)
  Start Date:                   October 2011
  Primary Completion Date:      June 2016
  Completion Date:              October 2016
  First Posted:                 March 9, 2012
  Results First Posted:         
  Last Update Posted:           October 11, 2016
  Locations:                    International Centre for Diarrhoeal Diseases, Dhaka, Bangladesh|Fundacao Universidade Estadual do Ceara, Fortaleza, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|Angkor Hospital for Children, Siem Reap, Cambodia|Hospital National de Ninos Benjamin Bloom, San Salvador, El Salvador|Gadjah Madah University, Yogyakarta, Indonesia|University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Universidad de Carabobo, Valencia, Venezuela|Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01550016

Study 66:
  NCT Number:                   NCT04076254
  Title:                        Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Hemorrhagic
  Interventions:                Drug: Albumins|Drug: Fluid
  Outcome Measures:             Syndecan-1 level|haematocrit level|platelet count|albumin level|quantitative urinary protein level|lactate level|length of hospital stay
  Sponsor/Collaborators:        Indonesia University
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   84
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    DEN-09
  Start Date:                   October 2016
  Primary Completion Date:      September 2019
  Completion Date:              September 2019
  First Posted:                 September 3, 2019
  Results First Posted:         
  Last Update Posted:           September 3, 2019
  Locations:                    RSAB Harapan Kita, Jakarta, Indonesia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04076254

Study 67:
  NCT Number:                   NCT03746015
  Title:                        Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
  Outcome Measures:             Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 15|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 30 (Month 1)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 60 (Month 2)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 90 (Month 3)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 105|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 120 (Month 4)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 150 (Month 5)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 180 (Month 6)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 270 (Month 9)|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 360 (Month 12)|Percentage of Participants with Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)|Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMC) of IFN-γ ELISpot Responses to TDV|Phenotype Characterization of Cellular Immune Response to TDV Assessed by Intracellular Cytokine Staining (ICS)|Percentage of Participants with Vaccine Viremia for Each of the Four Vaccine Strains after Vaccination|Duration of Vaccine Viremia for Each of the Four Vaccine Strains after Vaccination|Level of Vaccine Viremia for Each of the Four Vaccine Strains after Vaccination|Number of Participants with Solicited Local (Injection Site) Reactions Following Vaccination|Number of Participants with Solicited Systemic Reactions Following Vaccination|Number of Participants with at Least one Unsolicited Adverse Events (AEs) Following Vaccination|Number of Participants with Serious Adverse Events (SAEs)|Percentage of Participants With Medically Attended AEs (MAAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   179
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    DEN-210
  Start Date:                   December 28, 2018
  Primary Completion Date:      March 1, 2021
  Completion Date:              March 1, 2021
  First Posted:                 November 19, 2018
  Results First Posted:         
  Last Update Posted:           February 25, 2022
  Locations:                    Optimal Research, Peoria, Illinois, United States|Oregon Health and Science University, Portland, Oregon, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03746015

Study 68:
  NCT Number:                   NCT02317900
  Title:                        Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV005|Biological: Placebo|Biological: rDEN2∆30-7169
  Outcome Measures:             Frequency of viremia in participants administered 10^3 PFU of rDEN2∆30-7169 at Study Day 180|Proportion of participants who received TV005 & develop rash and/or neutropenia following administration of rDEN2∆30-7169 compared to proportion of participants who received placebo & developed rash and/or neutropenia following receipt of rDEN2∆30-7169|Frequency of vaccine-related adverse events (AEs), graded by severity|Frequency of virus-related AEs, graded by severity, following primary inoculation (inoculation of those participants who received placebo at Study Day 0)|Frequency of viremia of rDEN1∆30, rDEN2/4∆30(ME), rDEN3∆30/31, and rDEN4∆30 following TV005 vaccination|Number of TV005 vaccinees infected with DENV-1, DENV-2, DENV-3, and DENV-4|Evaluation of the immunogenicity of TV005, as assessed by PRNT50 to DENV-1, DENV-2, DENV-3, and DENV-4 at 28, 56, and 90 days after TV005 vaccination|Evaluation of the immunogenicity of rDEN2∆30-7169 in flavivirus-naïve participants as assessed by the PRNT50 to DENV-2, for each participant at Study Day 0, 28, 56, and 90 post-vaccination with rDEN2∆30-7169|Number of rDEN2∆30-7169 vaccine recipients who become infected with DENV-2 following primary rDEN2∆30-7169 vaccination (placebo recipients at Study Day 0)|Evaluation of if peak neutralizing antibody titer against DENV-2 following TV005 vaccination or neutralizing antibody titer against DENV-2 measured at Day 180 correlates with protection against viremia, rash, and/or neutropenia following inoculation|Evaluation of if inoculation with rDEN2∆30-7169 at 6 months will boost neutralizing antibody titers to DENV-1, DENV-2, DENV-3, and DENV-4 in those participants who received TV005 on Study Day 0.
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 299
  Start Date:                   December 2014
  Primary Completion Date:      November 2016
  Completion Date:              
  First Posted:                 December 17, 2014
  Results First Posted:         
  Last Update Posted:           February 1, 2017
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02317900

Study 69:
  NCT Number:                   NCT05507450
  Title:                        Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Disease|Dengue Virus
  Interventions:                Biological: V181 High-Potency Level|Biological: V181 Mid-Potency Level|Biological: V181 Low-Potency Level|Biological: Placebo
  Outcome Measures:             Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)|Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)|Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)|Percentage of Participants With Solicited Systemic AEs
  Sponsor/Collaborators:        Merck Sharp & Dohme LLC
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   1265
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    V181-003|2020-004501-30
  Start Date:                   September 7, 2022
  Primary Completion Date:      August 14, 2023
  Completion Date:              June 24, 2024
  First Posted:                 August 19, 2022
  Results First Posted:         
  Last Update Posted:           December 8, 2022
  Locations:                    California Research Foundation ( Site 0114), San Diego, California, United States|Advanced Medical Research Institute ( Site 0115), Miami, Florida, United States|Rochester Clinical Research, Inc. ( Site 0122), Rochester, New York, United States|University of Texas Medical Branch ( Site 0113), Galveston, Texas, United States|IMA Clinical Research San Antonio ( Site 0111), San Antonio, Texas, United States|Alliance for Multispecialty Research LLC (AMR - Norfolk) ( Site 0123), Norfolk, Virginia, United States|Paratus Clinical Research Western Sydney ( Site 0007), Blacktown, New South Wales, Australia|Emeritus Research ( Site 0010), Botany, New South Wales, Australia|USC Clinical Trials Moreton Bay ( Site 0001), Morayfield, Queensland, Australia|USC Clinical Trials Sunshine Coast ( Site 0005), Sippy Downs, Queensland, Australia|USC Clinical Trials Brisbane (South Bank) ( Site 0006), South Brisbane, Queensland, Australia|Emeritus Research ( Site 0009), Camberwell, Victoria, Australia|Diex Recherche Joliette ( Site 0023), Saint-Charles-Borromée, Quebec, Canada|Diex Recherche Sherbrooke Inc. ( Site 0024), Sherbrooke, Quebec, Canada|Diex Recherche Victoriavile Inc. ( Site 0021), Victoriaville, Quebec, Canada|Diex Recherche Quebec Inc. ( Site 0022), Quebec, Canada|FVR, Kokkolan rokotetutkimusklinikka ( Site 0037), Kokkola, Mellersta Osterbotten, Finland|FVR, Tampereen rokotetutkimusklinikka ( Site 0039), Tampere, Pirkanmaa, Finland|FVR, Oulun rokotetutkimusklinikka ( Site 0032), Oulu, Pohjois-Pohjanmaa, Finland|FVR, Porin rokotetutkimusklinikka ( Site 0033), Pori, Satakunta, Finland|FVR, Seinäjoen rokotetutkimusklinikka ( Site 0040), Seinajoki, Sodra Osterbotten, Finland|FVR, Espoon rokotetutkimusklinikka ( Site 0036), Espoo, Uusimaa, Finland|FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0038), Helsinki, Uusimaa, Finland|FVR, Itä-Helsingin rokotetutkimusklinikka ( Site 0035), Helsinki, Uusimaa, Finland|FVR, Turun rokotetutkimusklinikka ( Site 0031), Turku, Varsinais-Suomi, Finland|Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Division of Infectious Diseases and Tropical (, München, Bayern, Germany|Berliner Centrum für Reise- und Tropenmedizin ( Site 0043), Berlin, Germany|Bernhard Nocht Institute for Tropical Medicine ( Site 0041), Hamburg, Germany|Rambam Health Care Campus-Oncology ( Site 0053), Haifa, Israel|Hadassah Medical Center-Clinical Reaserch Unit ( Site 0052), Jerusalem, Israel|Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0051), Ramat Gan, Israel|Kaohsiung Medical University Hospital-Infectious diseases Division, Department of Internal Medicine, Kaohsiung, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05507450

Study 70:
  NCT Number:                   NCT01702272
  Title:                        Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Device: Procleix Dengue Virus Assay
  Outcome Measures:             Qualitative detection of ribosomal RNA from Dengue Virus in plasma specimens from individual human donors, including volunteer donors of whole blood and blood components, and other living donors.
  Sponsor/Collaborators:        Gen-Probe, Incorporated
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   150000
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    DENVTS-US12-002
  Start Date:                   January 2013
  Primary Completion Date:      January 2014
  Completion Date:              January 2014
  First Posted:                 October 8, 2012
  Results First Posted:         
  Last Update Posted:           September 15, 2014
  Locations:                    Creative Testing Solutions - Tampa, St Petersburg, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01702272

Study 71:
  NCT Number:                   NCT01656174
  Title:                        Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Device: Procleix Dengue Virus Assay
  Outcome Measures:             Qualitative detection of ribosomal RNA from Dengue Virus in plasma specimens from individual human donors, including volunteer donors of whole blood and blood components, and other living donors.
  Sponsor/Collaborators:        Gen-Probe, Incorporated
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   35035
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    DENVTS-US12-001
  Start Date:                   August 2012
  Primary Completion Date:      December 2014
  Completion Date:              January 2015
  First Posted:                 August 2, 2012
  Results First Posted:         
  Last Update Posted:           March 20, 2015
  Locations:                    Creative Testing Solutions, Tempe, Arizona, United States|American Red Cross National Testing Laboratory, Charlotte, North Carolina, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01656174

Study 72:
  NCT Number:                   NCT02510690
  Title:                        Factors Associated With Poor Dengue Outcomes in Malaysia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Mortality rate|The proportion of dengue patient who recover from dengue and discharged|Number of participants with Disease severity
  Sponsor/Collaborators:        Clinical Research Centre, Malaysia|University of Malaya
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   20000
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    NMRR-14-1275-22205
  Start Date:                   October 2014
  Primary Completion Date:      January 2016
  Completion Date:              May 2016
  First Posted:                 July 29, 2015
  Results First Posted:         
  Last Update Posted:           February 2, 2017
  Locations:                    Clinical Research Centre, Hospital Kuala Lumpur, KualaLumpur, Malaysia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02510690

Study 73:
  NCT Number:                   NCT00384670
  Title:                        A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: Dengue Vaccine Formulation 17|Biological: Licensed Japanese Encephalitis (JE) Vaccine
  Outcome Measures:             Number of Solicited Adverse Events Within 21 Days After the First Dose of Dengue Vaccine.|Number of Unsolicited Adverse Events Within 30 Days After Each Dose of Dengue Vaccine|Number of Solicited Adverse Events for 21 Days (0-20) After the Second Dose of Dengue Vaccine|Percentage of Individuals With Neutralizing Antibody (Seroconversion) to Japanese Encephalitis (JE) and 4 Dengue Types, 30 Days After the Second Dose of JE Vaccine.|Neutralizing Antibody (GMT) to JE and 4 Dengue Types, 30 Days After the Second Dose of JE Vaccine.|Number of Solicited Symptoms 7 Days (0-6) After First Dose of Japanese Encephalitis (JE) Vaccine.|Number of Solicited Symptoms 7 Days (0-6) After Second Dose of Japanese Encephalitis (JE) Vaccine.
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline
  Gender:                       All
  Age:                          6 Years to 10 Years   (Child)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   7
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    WRAIR 1048|HSRRB#A-12189|GSK Dengue-003
  Start Date:                   August 2003
  Primary Completion Date:      May 2004
  Completion Date:              May 2004
  First Posted:                 October 6, 2006
  Results First Posted:         February 24, 2014
  Last Update Posted:           February 24, 2014
  Locations:                    Department of Pediatrics, Pharamongkutklao Hospital, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00384670

Study 74:
  NCT Number:                   NCT03423173
  Title:                        Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: TAK-003|Biological: Placebo
  Outcome Measures:             Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset|Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes at Days 120 and 270 in the Immunogenicity Subset|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Medically Attended Adverse Events (MAAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   923
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-304
  Start Date:                   February 12, 2018
  Primary Completion Date:      August 3, 2018
  Completion Date:              January 14, 2019
  First Posted:                 February 6, 2018
  Results First Posted:         October 20, 2020
  Last Update Posted:           October 20, 2020
  Locations:                    Optimal Research, Huntsville, Alabama, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Advanced Clinical Research, Boise, Idaho, United States|Optimal Research, Peoria, Illinois, United States|Synexus Limited- Council Bluffs, Council Bluffs, Iowa, United States|Heartland Research Associates LLC - Augusta, Augusta, Kansas, United States|Heartland Research Associates LLC, Park City, Kansas, United States|Optimal Research, Rockville, Maryland, United States|Synexus Limited - Minneapolis, Edina, Minnesota, United States|Synexus Limited - St. Louis, Saint Louis, Missouri, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Synexus Limited - Columbus, Columbus, Ohio, United States|Advanced Clinical Research, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03423173/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03423173/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03423173

Study 75:
  NCT Number:                   NCT01931176
  Title:                        Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN2Δ30-7169 vaccine|Biological: Placebo
  Outcome Measures:             Safety of rDEN2Δ30-7169 vaccine as assessed by the frequency of vaccine-related adverse events (AEs)|Frequency, quantity, and duration of viremia following vaccination|Immune response of the vaccine at 4 and 8 weeks post-vaccination|Titer of virus vaccine|Number of vaccinees who seroconvert to DENV-2 by study Day 56|Number of vaccinees infected with rDEN2Δ30-7169 vaccine|Comparison of infectivity rates, safety, and immunogenicity of a single dose of rDEN2Δ30 vaccine with the reported infectivity and safety of rDEN2/4Δ30 from previous clinical trials|Durability of neutralizing antibody by measuring serum neutralizing antibody to DENV-2 out to 180 days after vaccination
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   14
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 286
  Start Date:                   June 2013
  Primary Completion Date:      December 2014
  Completion Date:              May 2015
  First Posted:                 August 29, 2013
  Results First Posted:         
  Last Update Posted:           December 15, 2015
  Locations:                    John Hopkins Bloomberg School of Public Health - Center for Immunization Research (CIR), Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01931176

Study 76:
  NCT Number:                   NCT02332733
  Title:                        Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV003|Biological: Placebo for TV003
  Outcome Measures:             Occurrence of solicited local and general adverse events (AEs) within the 21-day (Days 0-20) follow-up period after each vaccine dose|Occurrence of unsolicited AEs within the 21-day (Days 0-20) follow-up period after each vaccine dose|Occurrence of serious adverse events (SAEs) throughout the entire study period|Serum plaque reduction neutralization titer 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses for each participant at baseline (Day 0) and Study Days 28, 56, 72, and 180 following each vaccination|Frequency of viremia of each monovalent component of the vaccine after the first and second doses of vaccine|Quantity of viremia of each monovalent component of the vaccine after the first and second doses of vaccine|Duration of viremia of each monovalent component of the vaccine after the first and second doses of vaccine|Number of vaccinees infected with DENV-1, DENV-2, DENV-3, and DENV-4|Duration of the antibody response in recipients of the tetravalent vaccine
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          12 Months to 50 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   266
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    WRAIR 2041
  Start Date:                   November 2014
  Primary Completion Date:      October 26, 2018
  Completion Date:              October 26, 2018
  First Posted:                 January 7, 2015
  Results First Posted:         
  Last Update Posted:           December 5, 2018
  Locations:                    Phramongkutklao Hospital, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02332733

Study 77:
  NCT Number:                   NCT02021968
  Title:                        Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV-TV003|Biological: rDEN2∆30-7169|Biological: Placebo
  Outcome Measures:             Protection against viremia induced by rDEN2∆30, determined by rDEN2∆20-7169 titer|Frequency of TV003 and rDEN2∆30-7169-related adverse events (AEs), as classified by both severity and seriousness, through active and passive surveillance|Dengue virus neutralizing antibody titer
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 287
  Start Date:                   November 2013
  Primary Completion Date:      March 2015
  Completion Date:              December 2015
  First Posted:                 December 27, 2013
  Results First Posted:         
  Last Update Posted:           December 15, 2015
  Locations:                    Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02021968

Study 78:
  NCT Number:                   NCT01421732
  Title:                        Laboratory Diagnosis and Prognosis of Severe Dengue
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Sensitivity of the NS1 detection assays for diagnosis of laboratory-confirmed severe dengue.|Specificity of the NS1 detection assays for diagnosis of laboratory-confirmed severe dengue.|Positive predictive values of the NS1 detection assays for diagnosis of laboratory-confirmed severe dengue.|Negative predictive values of the NS1 detection assays for diagnosis of laboratory-confirmed severe dengue.|Positive predictive values of the NS1 detection assays for children requiring hospitalization or parenteral fluid therapy.|Negative predictive values of the NS1 detection assays for children requiring hospitalization or parenteral fluid therapy.|Sensitivity of the NS1 detection assays to predict the requirement of hospitalization or parenteral fluid therapy.|Specificity of the NS1 detection assays to predict the dengue serotype which corresponds to the requirement of hospitalization or parenteral fluid therapy.
  Sponsor/Collaborators:        Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Children's Hospital Number 1, Ho Chi Minh City, Vietnam|Number 2 Children's Hospital, Ho Chi Minh City|Tien Giang Provincial Hospital, Tien Giang, Viet Nam|Red Cross Clinic Of District 8
  Gender:                       All
  Age:                          1 Year to 15 Years   (Child)
  Phases:                       
  Enrollment:                   8100
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Prospective
  Other IDs:                    13DX
  Start Date:                   October 2010
  Primary Completion Date:      December 2014
  Completion Date:              December 2014
  First Posted:                 August 23, 2011
  Results First Posted:         
  Last Update Posted:           September 30, 2016
  Locations:                    Hospital for Tropical Diseases, Ho chi Minh, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01421732

Study 79:
  NCT Number:                   NCT02510638
  Title:                        The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Number of participants with severity of disease
  Sponsor/Collaborators:        Clinical Research Centre, Malaysia
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   322
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    NMRR-15-452-25624
  Start Date:                   September 2015
  Primary Completion Date:      December 2015
  Completion Date:              December 2015
  First Posted:                 July 29, 2015
  Results First Posted:         
  Last Update Posted:           February 1, 2016
  Locations:                    Clinical Research Centre, Hospital Kuala Lumpur, KualaLumpur, Malaysia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02510638

Study 80:
  NCT Number:                   NCT03141138
  Title:                        Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Virus
  Interventions:                Biological: TDENV-PIV|Biological: TDENV-LAV F17
  Outcome Measures:             Number of Subjects With At Least One Local Solicited Adverse Events (AE) during the 28 Day Follow-up After Prime and Boost Vaccinations|Number of subjects reporting at least one of each type of unsolicited AE during the 28-day follow-up period after each vaccination
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command
  Gender:                       All
  Age:                          18 Years to 42 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    S-16-23
  Start Date:                   November 8, 2017
  Primary Completion Date:      October 31, 2019
  Completion Date:              December 31, 2021
  First Posted:                 May 4, 2017
  Results First Posted:         
  Last Update Posted:           March 26, 2021
  Locations:                    WRAIR, Clinical Trials Center, Silver Spring, Maryland, United States
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03141138/Prot_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03141138

Study 81:
  NCT Number:                   NCT00831012
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: rDEN3delta30/31-7164
  Outcome Measures:             Determine the safety of a single dose of the rDEN3Δ30/31-7164 vaccine, as assessed by the frequency, severity, and seriousness of vaccine related adverse events (AEs).|Determine the immunogenicity of a single dose of the rDEN3delta30/31-7164 vaccine, as assessed by neutralizing antibody titers to DEN3 at 4 weeks and 6 weeks after vaccination|Assess the frequency, quantity, and duration of viremia after a single dose of vaccine|Determine the number of vaccinees infected with rDEN3delta30/31-7164. Infection is defined as recovery of vaccine virus from the blood or serum of a volunteer and/or by seroconversion to DEN3 (a ≥4-fold rise in DEN3 neutralizing antibody titers).|Compare the infectivity rates, safety, and immunogenicity of a single dose of rDEN3delta30/31-7164 vaccine between the dose level groups.|Determine the durability of antibody response 26 weeks after vaccination|Obtain an estimate for the Human Infectious Dose-50% (HID50) if dose dependent infectivity is observed|Evaluate the phenotype of peripheral blood mononuclear cells at primary infection with the rDEN3delta30/31-7164 vaccine.|Evaluate the cellular and humoral immune response to primary infection with the rDEN3delta30/31-7164 vaccine
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   56
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 257
  Start Date:                   September 2009
  Primary Completion Date:      June 2011
  Completion Date:              
  First Posted:                 January 28, 2009
  Results First Posted:         
  Last Update Posted:           November 15, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00831012

Study 82:
  NCT Number:                   NCT00473135
  Title:                        Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN1delta30|Biological: Placebo
  Outcome Measures:             To determine the safety and immunogenicity of a two-dose regimen of the rDEN1delta30 vaccine given as two doses separated by four or six months|To determine the optimum interval between first and second dose of rDEN1delta30 vaccine, as assessed by neutralizing antibody response to DEN1 induced by the vaccine|To assess the frequency, quantity, and duration of viremia following each vaccine dose, based on the mean peak viremia, mean day of onset, and mean duration of viremia|To determine the number of vaccinees infected with rDEN1delta30 virus|To compare the infectivity rates, safety, and immunogenicity between dose 1 and 2 within a cohort and between cohorts|To evaluate the immunopathological mechanism of vaccine-associated rash in participants willing to undergo skin biopsy|To evaluate the phenotype and activation of peripheral blood mononuclear cells (PBMCs) at primary infection and challenge with DEN1
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   60
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 229|WIRB Protocol Number 20070718
  Start Date:                   May 2007
  Primary Completion Date:      January 2010
  Completion Date:              
  First Posted:                 May 14, 2007
  Results First Posted:         
  Last Update Posted:           January 13, 2010
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00473135

Study 83:
  NCT Number:                   NCT05407181
  Title:                        Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Other: Blood and Liver Function test
  Outcome Measures:             Correlation of SGPT/ALT with Lymphocytes|Correlation of SGPT/ALT with HFLC
  Sponsor/Collaborators:        Nurhasan Agung Prabowo|Universitas Sebelas Maret
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   11
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Cross-Sectional
  Other IDs:                    DHFandHFLC
  Start Date:                   June 3, 2022
  Primary Completion Date:      June 3, 2022
  Completion Date:              June 5, 2022
  First Posted:                 June 7, 2022
  Results First Posted:         
  Last Update Posted:           June 7, 2022
  Locations:                    RS UNS (Universitas Sebelas Maret Hospital), Sukoharjo, Central Java, Indonesia|Universitas Sebelas Maret Hospital, Sukoharjo, Central Java, Indonesia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05407181

Study 84:
  NCT Number:                   NCT01477580
  Title:                        Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Biological: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Biological: Medium-dose V180 (non-adjuvanted)|Biological: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Biological: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Biological: Medium-dose V180 with Alhydrogel™ adjuvant|Biological: High-dose V180 (non-adjuvanted)|Biological: High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Biological: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Biological: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Biological: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Biological: High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Biological: Placebo
  Outcome Measures:             Seroconversion rate for each serotype|Geometric mean titer (GMT) of virus neutralizing antibodies for each serotype
  Sponsor/Collaborators:        Merck Sharp & Dohme LLC
  Gender:                       All
  Age:                          18 Years to 49 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   98
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    V180-001
  Start Date:                   July 23, 2012
  Primary Completion Date:      January 23, 2014
  Completion Date:              December 11, 2014
  First Posted:                 November 22, 2011
  Results First Posted:         
  Last Update Posted:           January 15, 2019
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01477580

Study 85:
  NCT Number:                   NCT00375726
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN3/4delta30(ME)|Biological: Placebo
  Outcome Measures:             Safety, as defined by frequency of vaccine-related adverse events, as classified by both intensity and severity through active and passive surveillance|Immunogenicity, as determined by anti-DEN3 neutralizing antibody measured on Days 0, 21, 28, 42, and 180|Assess the frequency, quantity, and duration of viremia in each dose cohort studied|Determine the number of vaccinees infected with rDEN3/4delta30(ME)|Determine cellular targets of vaccine infection, including peripheral blood mononuclear cells (PBMCs) and skin from participants who are willing to undergo skin biopsy|Compare the infectivity rates, safety, and immunogenicity between dose groups|Evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   58
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 228|WIRB Protocol Number 20061667
  Start Date:                   October 2006
  Primary Completion Date:      September 2008
  Completion Date:              September 2008
  First Posted:                 September 13, 2006
  Results First Posted:         
  Last Update Posted:           December 14, 2010
  Locations:                    Center for Immunization Research, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00375726

Study 86:
  NCT Number:                   NCT00322946
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN4delta30-4995|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse events, graded by severity for each dose|Immunogenicity of the rDEN4delta30-4995 vaccine against DEN4 virus by measurement of plaque reduction neutralization titers (PRNT)|Durability of antibody responses to DEN4 virus|Frequency, quantity, and duration of viremia in each dose cohort studied based on the mean peak viremia, mean day onset of viremia, and mean duration of viremia of each dose cohort|Number of vaccinees infected with the rDEN4delta30-4995 chimeric vaccine
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   84
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 221|WIRB Protocol Number 20061807
  Start Date:                   January 2007
  Primary Completion Date:      August 2009
  Completion Date:              
  First Posted:                 May 8, 2006
  Results First Posted:         
  Last Update Posted:           August 7, 2009
  Locations:                    Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00322946

Study 87:
  NCT Number:                   NCT05607472
  Title:                        Factors Associated With Hospitalization for Dengue and Dengue Severity: Hospital-based Cohort Study on Reunion Island
  Acronym:                      DENGUE-RUN
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever With Warning Signs
  Interventions:                Other: blood sampling|Other: questionnary of health estate during 18 month
  Outcome Measures:             The relative risk for hospitalization with dengue of any risk factors measured at inclusion )
  Sponsor/Collaborators:        Centre Hospitalier Universitaire de la Réunion
  Gender:                       All
  Age:                          8 Months and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   800
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    2021/CHU/37
  Start Date:                   March 3, 2022
  Primary Completion Date:      October 1, 2023
  Completion Date:              October 1, 2023
  First Posted:                 November 7, 2022
  Results First Posted:         
  Last Update Posted:           November 7, 2022
  Locations:                    Patrick GERARDIN, Saint-Pierre, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05607472

Study 88:
  NCT Number:                   NCT04023708
  Title:                        Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Virus Infection
  Interventions:                Drug: CYD-TDV Dengue Vaccine
  Outcome Measures:             Percentage of pregnant women with maternal adverse events|Percentage of pregnant women with pregnancy related adverse events|Percentage of offsprings with adverse birth outcomes|Percentage of offsprings with adverse neonatal events|Percentage of offsprings with adverse infant events
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       Female
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   214
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Other
  Other IDs:                    DNG16
  Start Date:                   March 11, 2022
  Primary Completion Date:      February 15, 2023
  Completion Date:              February 15, 2023
  First Posted:                 July 17, 2019
  Results First Posted:         
  Last Update Posted:           December 5, 2022
  Locations:                    BRAZIL, Curitiba, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04023708

Study 89:
  NCT Number:                   NCT01506570
  Title:                        Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TetraVax-DV Vaccine - Admixture TV003|Biological: TetraVax-DV Vaccine - Admixture TV005|Biological: Placebo
  Outcome Measures:             Safety of TetraVax-DV TV003 and TV005, as assessed by the frequency of vaccine-related adverse events|Immunogenicity of TV003 and TV005, as assessed by neutralizing antibody titers to DENV-1, DENV-2, DENV-3, and DENV-4|Whether a second dose of the vaccine given at Day 180 will induce seropositivity in those participants that remained seronegative to one or more DENV serotypes following the first vaccination|Frequency, quantity, and duration of viremia following vaccination|Number of flavivirus-experienced vaccinees infected with DENV-1, DENV-2, DENV-3, and DENV-4|Duration of the neutralizing antibody response
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   58
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 280
  Start Date:                   December 2011
  Primary Completion Date:      September 2013
  Completion Date:              September 2013
  First Posted:                 January 10, 2012
  Results First Posted:         
  Last Update Posted:           August 20, 2015
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01506570

Study 90:
  NCT Number:                   NCT01917422
  Title:                        Clinical Specimens Testing Program of Dengue Antigen Detection Reagents
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Clinical specimens testing program of dengue antigen detection reagents
  Sponsor/Collaborators:        Kaohsiung Medical University Chung-Ho Memorial Hospital
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   195
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control
  Other IDs:                    KMUHIRB-2012-03-14(II)
  Start Date:                   July 2012
  Primary Completion Date:      June 2013
  Completion Date:              June 2013
  First Posted:                 August 6, 2013
  Results First Posted:         
  Last Update Posted:           August 6, 2013
  Locations:                    Kaoshing Medical University Chung-Ho Memorial Hospital, Kaoshiung, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01917422

Study 91:
  NCT Number:                   NCT01391819
  Title:                        Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Other: Data collection|Procedure: Blood sample collection
  Outcome Measures:             Incidence of All Laboratory-confirmed Symptomatic Dengue Infection|Proportion of Subjects With Prevalence of Past Dengue Infection (Dengue Seroprevalence) at Enrollment|Proportion of Subjects With Primary Asymptomatic Dengue Infection|Number of Subjects With Laboratory Confirmed or Probable Dengue Cases According Symptomatic Dengue Definition (Primary, Secondary or Unknown) Among the Suspected Dengue Cases|Incidence of All Laboratory-confirmed or Probable Symptomatic Dengue Infection|Number of Dengue Infection Cases by Virus Type (DENV)|Number of Primary Laboratory Confirmed Symptomatic Dengue Infection Cases|Number of Secondary Laboratory Confirmed Symptomatic Dengue Infection Cases|Number of Working Days Missed of Primary Care Giver 1 of Subjects With Laboratory Confirmed Symptomatic Dengue Cases|Number of Working Days Missed of Primary Care Giver 2 of Subjects With Laboratory Confirmed Symptomatic Dengue Cases|Number of Laboratory Confirmed Dengue Infection Cases Associated With Caregiver Absenteeism|Number of School Days Missed by Subjects|Number of Laboratory Confirmed Dengue Infection Cases Associated With Subjects Absenteeism|Number of Subjects With Serious Adverse Events (SAEs)|Number of Symptomatic Dengue Laboratory Confirmed Cases Associated With Hospitalization Direct Medical Resource|Number of Hospitalization Days Due to Laboratory Confirmed Dengue Cases|Number of Dengue Infection Episodes - Clinical Symptom Since Onset of Suspected Dengue Cases: Temperature|Number of Dengue Infection Episodes With Any Temperature Interval Since Onset of Suspected Dengue Cases, Among Laboratory Confirmed Dengue Cases|Number of Laboratory Confirmed Dengue Episodes Associated With Clinical Symptoms
  Sponsor/Collaborators:        GlaxoSmithKline
  Gender:                       All
  Age:                          5 Years to 13 Years   (Child)
  Phases:                       Not Applicable
  Enrollment:                   2117
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    112994
  Start Date:                   September 6, 2011
  Primary Completion Date:      January 30, 2015
  Completion Date:              January 30, 2015
  First Posted:                 July 12, 2011
  Results First Posted:         April 26, 2017
  Last Update Posted:           June 25, 2019
  Locations:                    GSK Investigational Site, Fortaleza, Ceará, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01391819

Study 92:
  NCT Number:                   NCT02045069
  Title:                        Efficacy and Safety of Ivermectin Against Dengue Infection
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: 2 days Ivermectin|Drug: 3 days Ivermectin|Drug: Placebo
  Outcome Measures:             Time to resolution of viremia|Time to clearance of NS1 antigen|Time of subsidence of fever
  Sponsor/Collaborators:        Mahidol University|Ministry of Health, Thailand
  Gender:                       All
  Age:                          15 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   360
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    ESIDEN
  Start Date:                   February 2014
  Primary Completion Date:      February 2016
  Completion Date:              March 2016
  First Posted:                 January 24, 2014
  Results First Posted:         
  Last Update Posted:           November 1, 2015
  Locations:                    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02045069

Study 93:
  NCT Number:                   NCT00883441
  Title:                        Implementation Research of New Dengue Vector Control Tools
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   DENGUE
  Interventions:                Other: Insecticide treated curtains and insecticide treated covers
  Outcome Measures:             Aedes aegypti entomological indices|uptake and acceptance of tools
  Sponsor/Collaborators:        Institute of Tropical Medicine, Belgium|European Union|Mahidol University|Universidad de los Andes, Chile
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       Not Applicable
  Enrollment:                   22
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research
  Other IDs:                    INCO-CT-2004-517708-WP4
  Start Date:                   July 2006
  Primary Completion Date:      February 2009
  Completion Date:              December 2009
  First Posted:                 April 17, 2009
  Results First Posted:         
  Last Update Posted:           January 8, 2013
  Locations:                    Faculty of Tropical Medicine, Mahidol University,, Bangkok, Thailand|Universidad de Los Andes, Research Centre, Trujillo, Trujillo, Venezuela
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00883441

Study 94:
  NCT Number:                   NCT02425098
  Title:                        Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Biological: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
  Outcome Measures:             Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 15|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 30|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 90|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 180|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 365|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 15|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 30|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 90|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 180|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 365|Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) Following Vaccination by Severity|Number of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) Following Vaccination by Severity|Number of Participants With at Least One Unsolicited Adverse Events (AEs) Following Vaccination|Number of Participants With Serious Adverse Events (SAEs)|Geometric Mean Neutralizing Antibody Titers (GMT) for Each of the Four Dengue Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status|Seropositivity Rate for Each of the Four Dengue Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status|Percentage of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination|Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination|Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          21 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   351
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-205|U1111-1166-8884
  Start Date:                   June 3, 2015
  Primary Completion Date:      September 18, 2017
  Completion Date:              September 18, 2017
  First Posted:                 April 23, 2015
  Results First Posted:         August 28, 2019
  Last Update Posted:           August 28, 2019
  Locations:                    Singapore General Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02425098/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02425098/Prot_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02425098

Study 95:
  NCT Number:                   NCT02193087
  Title:                        Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Drug: TDV Liquid Formulation 1|Drug: TDV Liquid Formulation 2|Drug: TDV IDT Lyophilized|Drug: Placebo
  Outcome Measures:             Geometric Mean Titer (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes Comparing Group D To Groups A and B Combined|Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes Comparing Group D With Group B|Percentage of Participants With a Seropositive Response for Each of the Four Dengue Serotypes Comparing Group D With Groups A and B Combined|Percentage of Participants With a Seropositive Response for Each of the Four Dengue Serotypes Comparing Group D With Group B|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs)|Percentage of Participants With Solicited Systemic Adverse Events (AEs)|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity|Percentage of Participants With Any Unsolicited Adverse Events (AEs)|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Markedly Abnormal Laboratory Values in the Safety Sub-Set
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 49 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   1002
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science
  Other IDs:                    DEN-106|U1111-1154-9746
  Start Date:                   August 6, 2014
  Primary Completion Date:      May 19, 2015
  Completion Date:              May 19, 2015
  First Posted:                 July 17, 2014
  Results First Posted:         June 29, 2016
  Last Update Posted:           July 18, 2019
  Locations:                    Hope Research Institute, Phoenix, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Tekton Research, Austin, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02193087

Study 96:
  NCT Number:                   NCT01502358
  Title:                        Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
  Acronym:                      TVDV
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Disease|Dengue Fever
  Interventions:                Biological: Tetravalent Dengue Vaccine (TVDV)|Biological: Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Biological: Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
  Outcome Measures:             Number of participants with adverse events (AEs) or serious adverse events (SAEs)|Percent of subjects (in each group) achieving tetravalent ELISA IgM seroconversion|Percent of subjects (in each group) achieving tetravalent seroconversion, by dengue plaque reduction MN50 titer|MN50 titer 1 month (Study Day 120) and Study Days 180 and 270 after vaccine regimen is complete
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|Vical|Walter Reed Army Institute of Research (WRAIR)|Naval Medical Research Center
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    S-11-0007|WRAIR #1839|NMRC 2011.0012|A-16892
  Start Date:                   December 2011
  Primary Completion Date:      December 2013
  Completion Date:              December 2013
  First Posted:                 December 30, 2011
  Results First Posted:         
  Last Update Posted:           November 4, 2016
  Locations:                    Walter Reed Army Institute of Research and Clinical Trial Center (WRAIR CTC), Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01502358

Study 97:
  NCT Number:                   NCT03342898
  Title:                        Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: YF-17D|Biological: TDV|Drug: Placebo
  Outcome Measures:             Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline|Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline|Percentage of Participants Who Are Seropositive for Multiple (2, 3 or 4) Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline|Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT|Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline|Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Following Each Vaccination Dose by Severity|Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination Dose by Severity|Percentage of Participants With Any Unsolicited Adverse Events (AEs)|Percentage of Participants With Medically Attended Adverse Events (MAAEs)|Percentage of Participants With Serious Adverse Events (SAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   900
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-305|U1111-1201-5257
  Start Date:                   February 28, 2018
  Primary Completion Date:      May 9, 2018
  Completion Date:              May 22, 2019
  First Posted:                 November 17, 2017
  Results First Posted:         October 8, 2020
  Last Update Posted:           October 8, 2020
  Locations:                    Coastal Clinical Research Inc, Mobile, Alabama, United States|Empire Clinical Research, Pomona, California, United States|Advanced Clinical Research, Meridian, Idaho, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|Meridian Clinical Research LLC, Omaha, Nebraska, United States|Regional Clinical Research Inc., Endwell, New York, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Tekton Research, Austin, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03342898/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03342898/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03342898

Study 98:
  NCT Number:                   NCT00270699
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: rDEN4delta30-200,201|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse events, as classified by intensity and severity through active and passive surveillance and separate assessments of systemic and local reactions|Determine the number of vaccinees who have seroconverted to DEN4 up to and including Day 42|Durability of antibody responses to DEN4 virus|Frequency, quantity, and duration of viremia in each dose cohort|Number of vaccinees infected with vaccine virus in each dose cohort|Duration of antibody response determined by serum neutralizing antibody|Determine cellular targets of vaccine infection in participants willing to undergo skin biopsy|Compare infectivity rates, safety, and immunogenicity between dose cohorts|Evaluate immunopathological mechanism of vaccine-associated rash in participants willing to undergo skin biopsy
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   56
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 214|WIRB Protocol Number 2006478
  Start Date:                   June 2006
  Primary Completion Date:      December 2009
  Completion Date:              December 2009
  First Posted:                 December 28, 2005
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00270699

Study 99:
  NCT Number:                   NCT00849602
  Title:                        The Effect of Chloroquine in the Treatment of Patients With Dengue
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: Placebo|Drug: Chloroquine
  Outcome Measures:             Duration of the disease|Intensity and days of fever and symptoms
  Sponsor/Collaborators:        University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   132
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    BALF-01
  Start Date:                   February 2008
  Primary Completion Date:      May 2008
  Completion Date:              June 2009
  First Posted:                 February 24, 2009
  Results First Posted:         
  Last Update Posted:           February 24, 2009
  Locations:                    São Paulo University Medical School at Ribeirão Preto, Ribeirão Preto, SP, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00849602

Study 100:
  NCT Number:                   NCT02302066
  Title:                        Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Biological: TDV Placebo
  Outcome Measures:             Geometric Mean Titers (GMTs) of Neutralizing Antibodies (Microneutralization Test [MNT50]) for Each of the Four DENV Serotypes for Participants in the Immunogenicity Subset|Seropositivity Rates For Each of the 4 Dengue Serotypes for Participants in the Immunogenicity Subset|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) by Severity in the Immunogenicity Subset of Infant/Toddler Following Each Vaccination|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) by Severity in the Immunogenicity Subset of Adult/Children Following Each Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) by Severity in the Immunogenicity Subset of Infant/Toddler Following Each Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) by Severity in the Immunogenicity Subset of Adult/Children Following Each Vaccination|Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Immunogenicity Subset Following Each Vaccination|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Febrile Episodes of Virologically Confirmed Dengue With Onset 30 Days Post-first Vaccination
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          2 Years to 17 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   1800
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-204|PHRR140804-000219|U1111-1154-2475|2018-003978-28
  Start Date:                   December 5, 2014
  Primary Completion Date:      February 18, 2019
  Completion Date:              February 18, 2019
  First Posted:                 November 26, 2014
  Results First Posted:         February 24, 2020
  Last Update Posted:           February 24, 2020
  Locations:                    Hospital Maternidad Nuestra Senora de la Altagracia, Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic|Centro De Vacunacion Internacional, S.A.(CEVAXIN), Ciudad de Panama, Panama|Dela Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02302066/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02302066/Prot_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02302066

Study 101:
  NCT Number:                   NCT03620487
  Title:                        Detection of Dengue Virus in Plasma of Patients in Nepal
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Sensitivity and Specificity of the Karius Test in detecting the Dengue Virus in plasma.
  Sponsor/Collaborators:        Karius, Inc.|Tribhuvan University, Nepal
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   500
  Funded Bys:                   Industry|Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Prospective
  Other IDs:                    012-DL-01
  Start Date:                   December 21, 2016
  Primary Completion Date:      March 2020
  Completion Date:              September 2020
  First Posted:                 August 8, 2018
  Results First Posted:         
  Last Update Posted:           August 6, 2019
  Locations:                    Tribhuvan University, Kirtipur, Nepal
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03620487

Study 102:
  NCT Number:                   NCT03875560
  Title:                        IC14 in Adult Patients With Dengue Fever
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: IC14|Drug: Placebo
  Outcome Measures:             Incidence of treatment-emergent adverse events (safety, tolerability)|Area under the curve of IC14 serum concentration|Dengue viral load|Fever|Dengue symptom score|Disease severity|Mortality
  Sponsor/Collaborators:        Implicit Bioscience
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   0
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    EDF-01
  Start Date:                   May 2019
  Primary Completion Date:      January 2020
  Completion Date:              June 2020
  First Posted:                 March 14, 2019
  Results First Posted:         
  Last Update Posted:           March 14, 2019
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03875560

Study 103:
  NCT Number:                   NCT00094705
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: rDEN2/4delta30(ME) Vaccine|Biological: Placebo
  Outcome Measures:             Frequency and severity of vaccine-related adverse effects for each dose graded by severity|Amount of dengue 2 neutralizing antibody induced by the vaccine|To assess the durability of the antibody response out to Day 180|To assess the frequency, quantity, and duration of viremia in each dose cohort studied|To determine the number of vaccinees infected with rDEN2/4delta30(ME)|To compare the T cell mediated immune response against dengue viruses of those volunteers infected with the rDEN2/4delta30(ME) vaccine virus with that of uninfected volunteers and placebo recipients|If both doses of vaccine are administered, to compare the infectivity rates, safety, and immunogenicity between dose groups|To evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 189|H.22.03.09.26.A2
  Start Date:                   January 2005
  Primary Completion Date:      April 2006
  Completion Date:              April 2006
  First Posted:                 October 22, 2004
  Results First Posted:         
  Last Update Posted:           January 21, 2008
  Locations:                    Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00094705

Study 104:
  NCT Number:                   NCT00089908
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: rDEN1delta30|Biological: Placebo
  Outcome Measures:             Determine the frequency of vaccine related AEs for each dose graded by severity|Determine the amount of dengue 1 neutralizing antibody induced by the vaccine|To assess the durability of the antibody response|To assess the frequency, quantity, and duration of viremia in each dose cohort studied|To compare the T cell mediated immune response against dengue viruses of those volunteers infected with the rDEN1delta30 vaccine virus with that of uninfected volunteers and placebo recipients|If both doses of vaccine are administered, to compare the infectivity rates, safety, and immunogenicity between dose groups|To evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 199|H.22.04.04.23.B2
  Start Date:                   September 2004
  Primary Completion Date:      November 2005
  Completion Date:              November 2005
  First Posted:                 August 19, 2004
  Results First Posted:         
  Last Update Posted:           January 18, 2008
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00089908

Study 105:
  NCT Number:                   NCT01187433
  Title:                        Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|Biological: NaCl 0.9%|Biological: Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|Biological: Meningococcal A+C vaccine
  Outcome Measures:             Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Flavivirus Immune Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Flavivirus Naïve Subjects With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Subjects With Seropositivity Against At Least 1, 2, 3, or 4 Parental Dengue Virus Serotypes Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Flavivirus Immune Subjects With Seropositivity Against At Least 1, 2, 3, or 4 Parental Dengue Virus Serotypes Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Flavivirus Naïve Subjects With Seropositivity Against At Least 1, 2, 3, or 4 Parental Dengue Virus Serotypes Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titer Ratios (GMTRs) Against Each Serotype With the Parental of Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers (GMTs) Against Each Serotype With the Parental of Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers (GMTs) of Flavivirus Immune Subjects Against Each Serotype With the Parental of Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titer Ratios (GMTRs) of Flavivirus naïve Subjects Against Each Serotype With the Parental of Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants Reporting Solicited Injection-Site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 16 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   150
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD30|UTN: U1111-1111-6073
  Start Date:                   August 2010
  Primary Completion Date:      October 2012
  Completion Date:              December 2012
  First Posted:                 August 24, 2010
  Results First Posted:         November 11, 2016
  Last Update Posted:           March 21, 2022
  Locations:                    Vitória, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01187433

Study 106:
  NCT Number:                   NCT00712803
  Title:                        Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: rDEN3-3'D4delta30
  Outcome Measures:             Safety and immunogenicity, as assessed by neutralizing antibody titers|Frequency of vaccine related adverse events as graded by severity|Frequency, quantity, and duration of viremia after a single dose of vaccine|Number of vaccines infected with rDEN3-3'D4delta30|Infectivity rates, safety, and immunogenicity of a single dose of rDEN3-3'D4delta30 vaccine|Durability of antibody response|Obtain an estimate for the Human Infectious Dose-50% (HID50) idf dose dependent infectivity is observed
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   29
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 252
  Start Date:                   December 2008
  Primary Completion Date:      September 2009
  Completion Date:              September 2009
  First Posted:                 July 10, 2008
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Washington, District of Columbia, United States|Center for Immunization Research, Johns Hopkins University of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00712803

Study 107:
  NCT Number:                   NCT02569827
  Title:                        Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: Celgosivir|Drug: Modipafant 50mg|Drug: Placebo|Drug: Modipafant 100mg
  Outcome Measures:             Viral load AUC for viremia|Platelet nadir|Fever clearance time (days)|Duration of illness|Maximum percentage haemoconcentration|Time to NS1 clearance
  Sponsor/Collaborators:        Singapore General Hospital|Duke-NUS Graduate Medical School|60 Degrees Pharmaceuticals LLC
  Gender:                       All
  Age:                          21 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   0
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    Cel01
  Start Date:                   December 2018
  Primary Completion Date:      August 8, 2019
  Completion Date:              August 8, 2019
  First Posted:                 October 7, 2015
  Results First Posted:         
  Last Update Posted:           March 23, 2020
  Locations:                    Singhealth Investigational Medicine Unit, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02569827

Study 108:
  NCT Number:                   NCT00629356
  Title:                        Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Genetic: dengue fever
  Outcome Measures:             Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
  Sponsor/Collaborators:        Kaohsiung Medical University Chung-Ho Memorial Hospital
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   0
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Retrospective
  Other IDs:                    KMUH-IRB-960195
  Start Date:                   July 2007
  Primary Completion Date:      
  Completion Date:              July 2008
  First Posted:                 March 6, 2008
  Results First Posted:         
  Last Update Posted:           April 3, 2015
  Locations:                    Kaoshing Medical University Chung-Ho Memorial Hospital, Kaoshiung, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00629356

Study 109:
  NCT Number:                   NCT00920517
  Title:                        Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: rDEN2/4delta30(ME) vaccine|Biological: Placebo
  Outcome Measures:             Determine the frequency of vaccine related AEs for each dose, graded by severity.|Compare the immunogenicity of the two 2-dose regimens of the rDEN2/4Δ30(ME) candidate vaccine as assessed by neutralizing antibody titers to DEN2|Assess the frequency, quantity, and duration of viremia after each dose of vaccine.|Determine the number of vaccinees infected with rDEN2/4Δ30(ME)|Comparison of infectivity rates, safety, and immunogenicity between dose 1 and dose 2 withhin cohort and between cohorts|Evaluation of the phenotype and activation of peripheral blood mononuclear cells at primary infection and upon reinfection with the DEN2/4Δ30(ME) vaccine.
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   25
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention
  Other IDs:                    CIR 250
  Start Date:                   January 2009
  Primary Completion Date:      January 2010
  Completion Date:              January 2010
  First Posted:                 June 15, 2009
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00920517

Study 110:
  NCT Number:                   NCT02608047
  Title:                        Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             All cause severe dengue
  Sponsor/Collaborators:        Guangzhou 8th People's Hospital
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   2000
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Retrospective
  Other IDs:                    201508020263
  Start Date:                   October 2014
  Primary Completion Date:      October 2017
  Completion Date:              October 2017
  First Posted:                 November 18, 2015
  Results First Posted:         
  Last Update Posted:           November 18, 2015
  Locations:                    Guangzhou NO 8. people's hospital, Guangzhou, Guangdong, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02608047

Study 111:
  NCT Number:                   NCT00370682
  Title:                        A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: T-DEN F17|Biological: T-DEN F-19|Other: Placebo Comparator
  Outcome Measures:             Incidence of Any Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1|Neutralizing Antibody Geometric Mean Titer (GMT) to DEN Types 1, 2, 3 and 4; 30 and 90 Days After Dose 2|Subjects With Any Adverse Events (AEs) Within 21 Days Follow-up After Dose 2 of Study Vaccine|Incidence of Unsolicited AEs Within 31 Days (Days 0-30) After Any Study Vaccine Dose|Incidence of Serious Adverse Events (SAEs) Throughout the Entire Study Period|Laboratory Values Above the Alert Values Within 31 Days (Days 0-30) After Each Vaccine Dose|Incidence of Abnormal Findings at DEN Physical Examination After Each Vaccine Dose|Incidence of Suspected and Confirmed Dengue Throughout the Entire Study Period.|Percentage of Subjects With Neutralizing Antibodies to Each DEN Type, After Each Dose of Study Vaccines|Neutralizing Antibody Sero-response to Each DEN Type (Increase Neut.) Antibody From pre-to Post-vaccination, to be Determined by a Qualified Assay) After Each Dose of Study Vaccines|Incidence of Measurable Dengue Viremia at Specified Time Points After Each Dose
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline
  Gender:                       All
  Age:                          20 Years to 25 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    WRAIR 1281|Study no: 103854 (T-DEN-002)|HSRRB A-13699
  Start Date:                   April 2007
  Primary Completion Date:      February 2008
  Completion Date:              February 2008
  First Posted:                 September 1, 2006
  Results First Posted:         May 30, 2017
  Last Update Posted:           May 30, 2017
  Locations:                    Phramongkutklao Hospital, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00370682

Study 112:
  NCT Number:                   NCT01411241
  Title:                        Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|Biological: DTaP IPV//Hib vaccine|Biological: Placebo|Biological: Measles, mumps, and rubella vaccine|Biological: Pneumococcal vaccine
  Outcome Measures:             Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio Virus (IPV)//Hib (Pentaxim™) Administered Concomitantly With CYD Dengue Vaccine|Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains Before and After a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With CYD Dengue Vaccine|Geometric Mean Titer Ratios Against Each Serotype With the Parental of Dengue Virus Strains Before and After a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With CYD Dengue Vaccine|Percentage of Participants With a Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With CYD Dengue Vaccine|Percentage of Participants With Seropositivity Against at Least One, Two, Three, or Four Serotypes With the Parental Dengue Virus Strains Before and After a Booster Injection of DTaP-IPV// Hib (Pentaxim™) Administered With CYD Dengue Vaccine|Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following the First Injection With CYD Dengue Vaccine|Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following a Booster Injection of DTaP-IPV// Hib (Pentaxim™) Administered Concomitantly With Either CYD Dengue Vaccine or a Placebo Vaccine|Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following a Second Injection of CYD Dengue Vaccine or a Placebo Vaccine|Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following a Third Injection of CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Months to 12 Months   (Child)
  Phases:                       Phase 3
  Enrollment:                   720
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD33|U1111-1115-6290
  Start Date:                   July 18, 2011
  Primary Completion Date:      February 4, 2014
  Completion Date:              April 2014
  First Posted:                 August 8, 2011
  Results First Posted:         July 29, 2019
  Last Update Posted:           March 25, 2022
  Locations:                    Acapulco, Guerrero, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Merida, Yucatan, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01411241

Study 113:
  NCT Number:                   NCT00350337
  Title:                        Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: Pre-transfection F17|Biological: Post-transfection F17|Biological: Post-transfection F19|Other: Placebo
  Outcome Measures:             N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4|Percentage of Subjects Seropositive for Dengue Serotypes 1, 2, 3 and 4|Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 of Study Vaccine|Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 2 of Study Vaccine;|Unsolicited Adverse Events Within 31 Days After Each Dose of Study Vaccine Dose|Occurrence of Serious Adverse Events (SAEs) Throughout the Entire Study Period.|Occurrence of Abnormal Findings at Physical Examination After Each Vaccine Dose|Percentage of Subjects With Suspected and Confirmed Dengue Reported During the 31-day Post-vaccination Period (Total Vaccinated Cohort)|Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose|Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose (Continued)|Occurrence of Measurable Dengue Viremia at Specified Time Points Following Each Vaccine Dose.
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline|Walter Reed Army Institute of Research (WRAIR)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   86
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    WRAIR 1151|GSK 103996|HSRRB A-13291
  Start Date:                   April 5, 2006
  Primary Completion Date:      June 20, 2007
  Completion Date:              March 13, 2008
  First Posted:                 July 10, 2006
  Results First Posted:         October 26, 2018
  Last Update Posted:           February 12, 2021
  Locations:                    Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00350337

Study 114:
  NCT Number:                   NCT00688389
  Title:                        Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Other: case/control
  Outcome Measures:             檢查肝臟、腎臟及其他生化功能，並分析宿主免疫調控及血小板變化機致
  Sponsor/Collaborators:        Kaohsiung Medical University Chung-Ho Memorial Hospital|Centers for Disease Control and Prevention
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   700
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Other
  Other IDs:                    KMUH-IRB-960195_1|CB9615
  Start Date:                   July 2007
  Primary Completion Date:      December 31, 2020
  Completion Date:              December 31, 2020
  First Posted:                 June 2, 2008
  Results First Posted:         
  Last Update Posted:           February 28, 2019
  Locations:                    Kaoshing Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00688389

Study 115:
  NCT Number:                   NCT03632486
  Title:                        Bedside Ultrasound Predicts Progression of Severity of Disease in Dengue Fever
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Fever
  Interventions:                Other: Bedside Ultrasound
  Outcome Measures:             Clinical Progression of disease
  Sponsor/Collaborators:        Timothy Gleeson|Angkor Hospital for Children|University of Massachusetts, Worcester
  Gender:                       All
  Age:                          up to 16 Years   (Child)
  Phases:                       
  Enrollment:                   250
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    H00003325
  Start Date:                   August 13, 2018
  Primary Completion Date:      October 1, 2019
  Completion Date:              October 1, 2019
  First Posted:                 August 15, 2018
  Results First Posted:         
  Last Update Posted:           October 10, 2019
  Locations:                    Angkor Hospital for Children, Siem Reap, Cambodia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03632486

Study 116:
  NCT Number:                   NCT02824198
  Title:                        Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: CYD Dengue Vaccine (5 dose formulation)|Biological: Placebo, NaCl 0.9%
  Outcome Measures:             Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD63 Compared to the Third CYD Dengue Vaccine Injection Received in Study CYD28: CYD Dengue Vaccine Booster Group|GMTs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo|GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received In Study CYD28 and Before Booster Injection With Either CYD Dengue Vaccine or Placebo in CYD63|GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD28 And Before Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD28, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          14 Years to 50 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   118
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CYD63|U1111-1161-2813
  Start Date:                   July 1, 2016
  Primary Completion Date:      March 18, 2017
  Completion Date:              January 18, 2019
  First Posted:                 July 6, 2016
  Results First Posted:         June 14, 2019
  Last Update Posted:           March 24, 2022
  Locations:                    Singapore, Singapore|Singapore, Singapore|Singapore, Singapore
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02824198/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02824198/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02824198

Study 117:
  NCT Number:                   NCT01619969
  Title:                        Celgosivir as a Treatment Against Dengue
  Acronym:                      CELADEN
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: celgosivir|Drug: placebo
  Outcome Measures:             Virological Log Reduction (Virological Endpoint)|Fever Reduction (Clinical Endpoint)|Safety-Proportion of patients experiencing adverse events and serious adverse events|Quantitative NS1 and NS1 clearance|Hematology|Pharmacokinetics - Clearance of drug (L/hr)
  Sponsor/Collaborators:        Singapore General Hospital|Duke-NUS Graduate Medical School
  Gender:                       All
  Age:                          21 Years to 60 Years   (Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   50
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    2012/025/E
  Start Date:                   July 2012
  Primary Completion Date:      March 2013
  Completion Date:              July 2013
  First Posted:                 June 15, 2012
  Results First Posted:         
  Last Update Posted:           December 2, 2013
  Locations:                    Singapore General Hospital, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01619969

Study 118:
  NCT Number:                   NCT05048875
  Title:                        An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: JNJ-64281802 (sentinel high dose)|Drug: JNJ-64281802 (remaining high dose)|Drug: JNJ-64281802 (medium/low dose)|Drug: JNJ-64281802 (dosing regimen X)|Drug: JNJ-64281802 (dosing regimen Y)|Drug: JNJ-64281802 (dosing regimen Z)|Drug: Placebo
  Outcome Measures:             Assess the antiviral activity of the study drug (JNJ 64281802) versus placebo in terms of reduction of dengue infection.|Number of adverse events to assess the safety and tolerability of the study drug (JNJ 64281802).|Physical examinations to assess the safety and tolerability of the study drug (JNJ 64281802).|Recording of vital signs to assess the safety and tolerability of the study drug (JNJ 64281802).|12-lead ECG with measurement of QTcF to assess the safety and tolerability of the study drug (JNJ 64281802).|12-lead ECG with measurement of QRS interval to assess the safety and tolerability of the study drug (JNJ 64281802).|12-lead ECG with measurement of PR interval to assess the safety and tolerability of the study drug (JNJ 64281802).|Clinical laboratory assessments to assess the safety and tolerability of the study drug (JNJ 64281802).|Assess the dengue infection-associated Adverse Events (unwanted medical occurrence).|Antiviral activity of the study drug (JNJ 64281802) versus placebo by reviewing the area under the log10-transformed DENV 3 RNA VL concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29 (AUCD1 D29 [log10 VL])|Antiviral activity of the study drug (JNJ 64281802) versus placebo by reviewing the peak of detectable DENV-3 RNA (log10 VL).|Antiviral activity of the study drug (JNJ 64281802) versus placebo for duration in days of detectable DENV-3 RNA.|Antiviral activity of the study drug (JNJ 64281802) versus placebo time to first onset by days of detectable DENV 3 RNA.|Antiviral activity of the study drug (JNJ 64281802) versus placebo based on presence of detectable DENV-3 RNA as measured by PCR (log10 VL) or culture (log10 VL).|Antiviral activity of the study drug (JNJ 64281802) versus placebo on area under the infectious viremia curves from immediately before inoculation (baseline on Day 1) until Day 29.|Antiviral activity of the study drug (JNJ 64281802) versus placebo on the area under the log10-transformed viremia curves.|Antiviral activity of the study drug (JNJ 64281802) versus placebo peak of detectable viremia level|Antiviral activity of the study drug (JNJ 64281802) versus placebo on the duration of detectable viremia.|Antiviral activity of the study drug (JNJ 64281802) versus placebo on time to first onset of detectable viremia.|Antiviral activity of the study drug (JNJ 64281802) versus placebo on presence of detectable viremia.|Assess how the body handles the study drug (JNJ-64281802) following repeated oral dosing. Using Pharmacokinetic analysis from repeated blood samples taken at specified time points after drug administration during 2 inpatient stays.|Cmax: maximum observed analyte concentration of JNJ-64281802|Cmin: minimum observed analyte concentration of JNJ-64281802|Ctrough: observed analyte concentration just before the beginning or at the end of a dosing interval of JNJ-64281802|Cavg: average analyte concentration over the dosing interval (τ) calculated as AUCτ/τ of JNJ-64281802|tmax: the actual sampling time to reach the maximum observed analyte concentration of JNJ-64281802|FI: percentage fluctuation (variation) between maximum and minimum analyte concentration at steady-state, calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802|AUCτ: area under the plasma concentration-time curve during the dosing interval (t hours); calculated by linear-linear trapezoidal summation of JNJ-64281802|Occurrence and magnitude of anti-DENV-3 total IgM antibody titers to assess the anti-Dengue immune response.|Occurrence and magnitude of anti-DENV-3 total IgG antibody titers to assess the anti-Dengue immune response.|Time to first onset of anti-DENV-3 total IgM antibody titers to assess the anti-Dengue immune response.|Time to first onset of anti-DENV-3 total IgG antibody titers to assess the anti-Dengue immune response.
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Janssen, LP|National Institutes of Health (NIH)
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   54
  Funded Bys:                   NIH|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    CIR 332|156295|64281802DNG2002
  Start Date:                   February 3, 2022
  Primary Completion Date:      June 2023
  Completion Date:              June 2023
  First Posted:                 September 17, 2021
  Results First Posted:         
  Last Update Posted:           May 12, 2022
  Locations:                    Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States|University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05048875

Study 119:
  NCT Number:                   NCT01443247
  Title:                        Role of Andi-d in Dengue Fever: a Pilot Study
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Drug: anti-d
  Outcome Measures:             to see for the number of patients attaining a platelet count ≥ 50,000 /mm3 after 48 hours of administration of anti-d in the intervention arm|the difference in two study arms with respect to: total volume of platelet concentrate transfused , duration of hospital stay , & severity of haemorrhagic manifestations
  Sponsor/Collaborators:        Postgraduate Institute of Medical Education and Research
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       Not Applicable
  Enrollment:                   30
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    dengue fever pgimer trial
  Start Date:                   September 2010
  Primary Completion Date:      September 2011
  Completion Date:              September 2011
  First Posted:                 September 29, 2011
  Results First Posted:         
  Last Update Posted:           September 29, 2011
  Locations:                    Post Graduate Institute of Medical Education and Research , Chandigarh , India, Chandigarh, India
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01443247

Study 120:
  NCT Number:                   NCT01096576
  Title:                        A Study of Balapiravir in Patients With Dengue Virus Infection
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: balapiravir [RO4588161]|Drug: placebo
  Outcome Measures:             Safety and tolerability: Adverse events, laboratory parameters, vital signs|Viral load|Pharmacokinetics: plasma concentrations of RO1042897, balapiravir and metabolites|Body temperature|Immunological parameters: plasma samples (cytokines)|Hematological parameters: blood samples (red and white blood cell count, hemoglobin, hematocrit, reticulocyte count, fibrinogen, platelet count)|Quality of life
  Sponsor/Collaborators:        Hoffmann-La Roche
  Gender:                       Male
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   64
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    PP22799
  Start Date:                   July 2010
  Primary Completion Date:      April 2011
  Completion Date:              April 2011
  First Posted:                 March 31, 2010
  Results First Posted:         
  Last Update Posted:           November 2, 2016
  Locations:                    Ho Chi Minh City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01096576

Study 121:
  NCT Number:                   NCT05034809
  Title:                        Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever With Warning Signs
  Interventions:                Drug: Melatonin 20 MG
  Outcome Measures:             Number Of Days Prior To Elevation of Platelet Count Among Dengue Fever with Warningn Signs Patient Given Melatonin 20mg.|Incidence Of Dengue Fever with Warning Signs among Pediatric Population at Ilocos Training and Regional Medical Center.|determine the effectiveness of Melatonin 20mg as adjunctive therapy for pediatric patients diagnosed with Dengue Fever with Warning Signs|Number Of Days Prior To Elevation of White Blood Cells Among Dengue Fever with Warningn Signs Patient Given Melatonin 20mg.
  Sponsor/Collaborators:        Ilocos Training and Regional Medical Center
  Gender:                       All
  Age:                          5 Years to 18 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   140
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment
  Other IDs:                    ITRMC-REC-2020-045
  Start Date:                   October 20, 2021
  Primary Completion Date:      August 30, 2022
  Completion Date:              October 30, 2022
  First Posted:                 September 5, 2021
  Results First Posted:         
  Last Update Posted:           October 13, 2021
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05034809

Study 122:
  NCT Number:                   NCT00458120
  Title:                        Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Hemorrhagic Fever
  Interventions:                Biological: rDEN1delta30|Biological: rDEN2/4delta30(ME)|Biological: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
  Outcome Measures:             Number, severity, and seriousness of vaccine-related adverse events observed through active and passive surveillance|Neutralizing antibody to all four dengue serotypes|Assess the frequency, quantity, and duration of viremia in each vaccine cohort studied|To determine if cellular targets of vaccine infection, including peripheral blood mononuclear cells and skin, are different after heterologous infection of a second dengue virus vaccine of a different serotype|Compare the safety and immunogenicity between each heterologous dengue vaccine virus cohort|Evaluate the immunopathological mechanism of heterologous vaccine virus associated rash in those volunteers who are willing to undergo skin biopsy|Characterize the antibody response after heterolouous vaccine infection
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   36
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 227|WIRB Protocol Number 20070409
  Start Date:                   March 2007
  Primary Completion Date:      August 2008
  Completion Date:              August 2008
  First Posted:                 April 9, 2007
  Results First Posted:         
  Last Update Posted:           December 14, 2010
  Locations:                    Center for Immunization Research, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00458120

Study 123:
  NCT Number:                   NCT03432442
  Title:                        Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
  Acronym:                      PKIDEN
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Hemorrhagic Fever
  Interventions:                Drug: Ivermectin
  Outcome Measures:             Pharmacokinetics of ivermectin in pediatric dengue patients|Pharmacodynamic effects of ivermectin on viral load in plasma of pediatric dengue patients|Pharmacodynamic effects of ivermectin on NS1 antigen in plasma of pediatric dengue patients|Viremia clearance|NS1 antigenemia clearance|Occurrences of adverse events|Occurrences of abnormal laboratory result
  Sponsor/Collaborators:        Mahidol University
  Gender:                       All
  Age:                          1 Year to 15 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   24
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    VIR17003
  Start Date:                   September 4, 2018
  Primary Completion Date:      September 22, 2020
  Completion Date:              September 22, 2020
  First Posted:                 February 14, 2018
  Results First Posted:         
  Last Update Posted:           February 24, 2021
  Locations:                    Faculty of Tropical Medicine Siriraj Hospital, Bangkok Noi, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03432442

Study 124:
  NCT Number:                   NCT02948933
  Title:                        Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                
  Outcome Measures:             Percentage of subjects with selected adverse events leading to a medical consultation, emergency room visit or hospitalization occurring during the short term surveillance period of 6 months after each dose of Dengvaxia®|Percentage of subjects hospitalized with dengue disease (regardless of severity and laboratory confirmation of diagnosis) after each dose of Dengvaxia®.|Percentage of subjects with any other serious adverse events (SAEs) occurring during the short term surveillance, and SAEs leading to hospitalization or death occurring during the long term surveillance
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   30000
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    DNG15|U1111-1143-8608
  Start Date:                   December 14, 2016
  Primary Completion Date:      October 18, 2024
  Completion Date:              October 18, 2024
  First Posted:                 October 31, 2016
  Results First Posted:         
  Last Update Posted:           May 9, 2022
  Locations:                    Alta, Brazil|Brasilia, Brazil|Campo Grande, Brazil|Curitiba, Brazil|Jundiai, Brazil|Largo De Roma, Brazil|Macae, Brazil|Nova Iguacu, Brazil|Santo Amaro, Brazil|São Marcos, Brazil|Investigational Site 2008-001, Cuernavaca, Mexico|Investigational Site 2011-001, Guerrero, Mexico|Investigational Site 2001-001, Mexico, Mexico|Investigational Site 2002-001, Monterrey, Mexico|Investigational Site 2007-001, Mérida, Mexico|Investigational Site 2003-001, Puerto Vallarta, Mexico|Investigational Site 2004-001, Veracruz, Mexico|Investigational Site 2006-001, Villahermosa, Mexico|Investigational Site 2010-001, Zapopan, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02948933

Study 125:
  NCT Number:                   NCT00946218
  Title:                        Diagnosis and Characterization of Dengue Fever in Children
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             To compare the sensitivity of dengue NS1 (influenze protein) Ag Enzyme-linked Immunosorbent Assay and dengue NS1 Ag STRIP and WHO clinical diagnostic criteria when applied to children in El Salvador.|To identify differences in host leukocyte gene expression in children with DF, DHF, and DSS using high throughput gene expression arrays.|To develop a clinical risk algorithm for predicting severe dengue using NS1 Ag testing techniques and clinical data.
  Sponsor/Collaborators:        St. Jude Children's Research Hospital
  Gender:                       All
  Age:                          6 Months to 11 Years   (Child)
  Phases:                       
  Enrollment:                   258
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Retrospective
  Other IDs:                    DENGEN
  Start Date:                   July 2009
  Primary Completion Date:      December 2009
  Completion Date:              December 2009
  First Posted:                 July 24, 2009
  Results First Posted:         
  Last Update Posted:           October 5, 2011
  Locations:                    St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Hospital Nacional de Ninos Benjamin Bloom, San Salvador, El Salvador
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00946218

Study 126:
  NCT Number:                   NCT02827162
  Title:                        Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Dengue Haemorrhagic Fever
  Interventions:                
  Outcome Measures:             Number of Symptomatic Virologically confirmed dengue cases having occurred during the Active Phase of the first proof of concept efficacy study after post dose 1|Neutralizing Antibody level against each of the four parental dengue virus serotype strains of Sanofi Pasteur's dengue vaccine constructs measured at 28 days post dose 3|Number of probable Dengue fever and Dengue Hemorrhagic Fever grade I, II, III, and IV occurring during the Active Phase of the first PoC efficacy study after post dose 1.|Number of Symptomatic Virologically confirmed dengue cases having occurred during the Active Phase of the first proof of concept efficacy study after post dose 3|Neutralizing Antibody level against each of the four parental dengue virus serotype strains of Sanofi Pasteur's dengue vaccine constructs measured at post dose 3
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          7 Years to 17 Years   (Child)
  Phases:                       
  Enrollment:                   334
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Prospective
  Other IDs:                    CYD59|U1111-1127-7875
  Start Date:                   March 29, 2016
  Primary Completion Date:      April 27, 2016
  Completion Date:              April 27, 2016
  First Posted:                 July 11, 2016
  Results First Posted:         
  Last Update Posted:           April 25, 2022
  Locations:                    Investigational Site, Ratchaburi, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02827162

Study 127:
  NCT Number:                   NCT01843621
  Title:                        A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue
  Interventions:                Biological: DEN vaccine F17
  Outcome Measures:             Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)|Geometric Mean Titers (GMTs) on All Subjects for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)|Solicited Local Adverse Events (AEs) Within 21 Day Follow-up|Unsolicited Adverse Events (AEs) Within 31 Days Post Vaccination|Serious Adverse Events (SAE) Within 31 Days Post Vaccination|Abnormal Findings Reported During Physical Exam 31-Days Post Vaccination|Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies 30 Days Post Booster|Presence of Dengue Viremia 10 Days After the Dengue Vaccine Dose|Flavivirus Infection in Terms of Dengue Immunoglobulin M and Immunoglobulin G Per Subject (ATP Cohort for Immunogenicity)|Subject Biochemistry and Hematology Parameters Monitored for Alert Levels
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline
  Gender:                       All
  Age:                          6 Years to 9 Years   (Child)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   7
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    A-13227|GSK 103795|WRAIR 1159
  Start Date:                   February 2005
  Primary Completion Date:      February 2005
  Completion Date:              February 2009
  First Posted:                 April 30, 2013
  Results First Posted:         November 26, 2018
  Last Update Posted:           November 26, 2018
  Locations:                    Department of Pediatrics, Phramongkutklao Hospital, Phayathai, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01843621

Study 128:
  NCT Number:                   NCT02992418
  Title:                        Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
  Acronym:                      
  Status:                       Terminated
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
  Outcome Measures:             Geometric Mean Concentrations (GMCs) of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants|Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants|Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Percentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD at Baseline and 28 Days After First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Percentage of Participants With Neutralizing Antibody Titers Above Predefined Thresholds Against at Least 1, 2, 3, or 4 Serotypes of CYD at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Geometric Mean Concentrations of Serum Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants|Percentage of Participants Achieving Serum Antibody (>=0.1 IU/mL) Against Diphtheria and Tetanus Antigens at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants|Number of Participants With Immediate Unsolicited Adverse Events (AE) Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants With Solicited Injection Site Reactions Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants With Solicited Systemic Reactions Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants Reporting Serious Adverse Events (SAEs) and Serious AESIs Following Vaccination With Tdap or CYD Dengue Vaccine|Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 60 Years   (Child, Adult)
  Phases:                       Phase 3
  Enrollment:                   688
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD66|U1111-1161-3294|2019-003136-23
  Start Date:                   December 19, 2016
  Primary Completion Date:      December 10, 2019
  Completion Date:              December 10, 2019
  First Posted:                 December 14, 2016
  Results First Posted:         August 27, 2020
  Last Update Posted:           March 25, 2022
  Locations:                    Muntinlupa, Alabang, Philippines|Manila, Philippines|Quezon City, Philippines|Quezon, Philippines
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02992418/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02992418/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02992418

Study 129:
  NCT Number:                   NCT03803618
  Title:                        Dengue Effectiveness Study in the Philippines
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue|Severe Dengue|Virologically Confirmed Dengue
  Interventions:                
  Outcome Measures:             hospitalized and / or severe virologically confirmed dengue
  Sponsor/Collaborators:        University of the Philippines|Sanofi Pasteur, a Sanofi Company|Research Institute for Tropical Medicine, Philippines
  Gender:                       All
  Age:                          9 Years to 14 Years   (Child)
  Phases:                       
  Enrollment:                   380
  Funded Bys:                   Other|Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Prospective
  Other IDs:                    UPM REB 2017-0237
  Start Date:                   September 1, 2017
  Primary Completion Date:      November 2022
  Completion Date:              November 2022
  First Posted:                 January 14, 2019
  Results First Posted:         
  Last Update Posted:           April 20, 2020
  Locations:                    Cebu Provincial Hospital - Balamban, Balamban, Cebu, Philippines|Cebu Provincial Hospital - Bogo, Bogo City, Cebu, Philippines|Cebu Provincial Hospital - Danao, Danao, Cebu, Philippines|Eversley Childs Sanitarium and General Hospital, Mandaue City, Cebu, Philippines
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03803618

Study 130:
  NCT Number:                   NCT02623725
  Title:                        Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: CYD Dengue Vaccine (5-dose formulation)|Biological: Placebo, NaCl 0.9%
  Outcome Measures:             Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group|GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine Received in CYD13/CYD30: CYD Dengue Vaccine Booster Group|GMTs of Antibodies Against Each Dengue Virus Serotype Before And Following Booster Injection (Inj.) With Either CYD Dengue Vaccine or Placebo|GMTRs of Antibodies Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Before and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seroconversion Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTRs of Antibodies Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Before Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following the Third CYD Dengue Vaccine Injection Received in Study CYD13/CYD30, and Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|GMTRs of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Booster Injection With Either CYD Dengue Vaccine or Placebo|Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Booster Injection With Either CYD Dengue Vaccine or Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          13 Years to 22 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   251
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD64|U1111-1161-2855
  Start Date:                   April 14, 2016
  Primary Completion Date:      November 23, 2016
  Completion Date:              October 28, 2018
  First Posted:                 December 8, 2015
  Results First Posted:         June 14, 2019
  Last Update Posted:           March 24, 2022
  Locations:                    Investigational Site Number 001, Vitoria, Brazil|Investigational Site Number 002, Bucaramanga, Colombia|Investigational Site Number 003, Tegucigalpa, Honduras|Investigational Site Number 004, Temixco, Mexico|Investigational Site Number 005, Carolina, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02623725

Study 131:
  NCT Number:                   NCT04048837
  Title:                        Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Hemorrhagic Fever|Dengue Shock Syndrome|Severe Dengue
  Interventions:                
  Outcome Measures:             Concentration of serum A2M, CMA1 and VEGFA will be use to predict whether a dengue patient will develop severe disease as defined by WHO 1997 and WHO 2009 classifications.|Number of participants develop Dengue Haemorrhagic fever (DHF) within study periods|Number of participants develop Dengue Shock Syndrome (DSS) within study periods|Number of participants develop Severe Dengue within study periods|Cost of dengue treatments for adoption of such a dengue prognostic technology in hospital
  Sponsor/Collaborators:        National University Hospital, Singapore|Tan Tock Seng Hospital|Ng Teng Fong General Hospital
  Gender:                       All
  Age:                          21 Years to 100 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   200
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    PrognosDen
  Start Date:                   July 30, 2018
  Primary Completion Date:      July 1, 2019
  Completion Date:              July 1, 2019
  First Posted:                 August 7, 2019
  Results First Posted:         
  Last Update Posted:           September 13, 2019
  Locations:                    Tan Tock Seng Hospital, Singapore, Singapore|Ng Teng Fong General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04048837

Study 132:
  NCT Number:                   NCT01254422
  Title:                        Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|Biological: Placebo: NaCl 0.9%
  Outcome Measures:             Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo|Percentage of Flavivirus-Immune Participants Reporting Solicited Injection Site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or Placebo Vaccine|Percentage of Flavivirus-Naïve Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or a Placebo Vaccine|Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Seropositivity Against at Least One, Two, Three, or the Four Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers (GMTs) Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Immune Participants|Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Naive Participants|GMTs of Flavivirus-Immune Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo|GMT of Flavivirus-Naïve Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          2 Years to 11 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   250
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD32|UTN: U1111-1115-6579
  Start Date:                   December 2, 2010
  Primary Completion Date:      September 28, 2012
  Completion Date:              January 2013
  First Posted:                 December 6, 2010
  Results First Posted:         July 29, 2019
  Last Update Posted:           March 25, 2022
  Locations:                    Ipoh, Perak, Malaysia|Kuala Lumpur, Malaysia|Kuching, Sarawak, Malaysia|Negeri Sembilan, Malaysia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01254422

Study 133:
  NCT Number:                   NCT02628444
  Title:                        Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Placebo (Sodium chloride 0.9%)
  Outcome Measures:             STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-I: Geometric Mean Titers Against Each Dengue Virus Serotype 1 Year After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline|STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline-Comparison Between Group 1 and Group 2|STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains in All Participants|STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains (by Baseline Dengue Status) in Participants Who Were Seropositive and Seronegative at Baseline|STAGE-II: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After Booster CYD Dengue Vaccination in Participants Seropositive at Baseline|STAGE-I: Percentage of Participants With Antibodies Titer >=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strains in All Participants|STAGE-II: Percentage of Participants With Antibodies Titer >=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strain in Participants Seropositive at Baseline|STAGE-I: Number of Participants With Immediate Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)|STAGE-II: Number of Participants With Immediate Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine|STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)|STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)|STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)|STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)|STAGE-II: Number of Participants With Solicited Injection Site Reactions Following Booster Vaccination With CYD Dengue Vaccine|STAGE-II: Number of Participants With Solicited Systemic Reactions Following Booster Vaccination With CYD Dengue Vaccine|STAGE-I: Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo|STAGE-II: Number of Participants Reporting Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine|STAGE-I: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Event of Special Interests (AESI) Following Vaccination With CYD Dengue Vaccine or Placebo|STAGE-II: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Events Special Interest Following Booster Vaccination With CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 50 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   1050
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD65|U1111-1161-3242|2020-002854-25
  Start Date:                   May 2, 2016
  Primary Completion Date:      April 29, 2020
  Completion Date:              April 29, 2020
  First Posted:                 December 11, 2015
  Results First Posted:         February 23, 2021
  Last Update Posted:           March 24, 2022
  Locations:                    Investigational Site 102, Barranquilla, Colombia|Investigational Site 101, Cali, Colombia|Investigational Site 103, Medellin, Colombia|Investigational Site 203, Manila, Philippines|Investigational Site 204, Manila, Philippines|Investigational Primary Site Muntinlupa 201_Satellite Site San Pablo 202, Muntinlupa, Philippines
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02628444/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02628444/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02628444

Study 134:
  NCT Number:                   NCT01134263
  Title:                        Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|Biological: Placebo: NaCl 0.9%
  Outcome Measures:             Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine|Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine|Number of Participants With Solicited Injection Site Reactions After Any Vaccination|Number of Participants With Solicited Systemic Reactions After Any Vaccination
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   715
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD17|U1111-1114-7646
  Start Date:                   October 5, 2010
  Primary Completion Date:      November 2012
  Completion Date:              February 2013
  First Posted:                 May 31, 2010
  Results First Posted:         July 24, 2019
  Last Update Posted:           July 24, 2019
  Locations:                    Adelaide, Australia|Carina Heights, Australia|Enoggera, Australia|Heidelberg, Australia|Herston, Australia|Herston, Australia|Subiaco, Australia|Westmead, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01134263

Study 135:
  NCT Number:                   NCT04837430
  Title:                        NT-proBNP and Troponin I in Dengue Children
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Shock Syndrome|Children, Only
  Interventions:                
  Outcome Measures:             Concentration of NT-proBNP|Concentration of Troponin I|Cut-off value of NT-proBNP for fluid overload|Correlation between concentration of NT-proBNP|Correlation between concentration of Troponin I|Rate of clinical manifestations|Rate of abnormal laboratory exam|Rate of abnormal liver, kidney, hematology laboratory exam|Rate of NS1 Dengue|Rate of MAC ELISA IgM Dengue|Rate of complications|Rate of respiratory support|Rate of intubation|Rate of mode of ventilation|Total fluid administration|Time for IV fluid administration|Rate and kind of cephalosporin using|Rate and kind of Carbapenem using|Rate and kind of Vancomycin using|Rate of intraperitoneal fluid drainage|Rate of CRRT
  Sponsor/Collaborators:        Le Phuoc Truyen|University of Medicine and Pharmacy at Ho Chi Minh City
  Gender:                       All
  Age:                          1 Month to 18 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   90
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Crossover|Time Perspective: Prospective
  Other IDs:                    2130-DHYD
  Start Date:                   April 2, 2021
  Primary Completion Date:      December 31, 2022
  Completion Date:              December 31, 2022
  First Posted:                 April 8, 2021
  Results First Posted:         
  Last Update Posted:           April 8, 2021
  Locations:                    University of medicine and pharmacy at Ho Chi Minh city, Ho Chi Minh City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04837430

Study 136:
  NCT Number:                   NCT01104740
  Title:                        Dengue Seroprevalence Study in Blood Donors in the French West Indies
  Acronym:                      DengSeroprevAn
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Blood Donors|Dengue
  Interventions:                Other: Biological sample collection
  Outcome Measures:             Presence or not of dengue virus-specific immunoglobulin G antibodies|Characterization of dengue virus serotype-specific IgG
  Sponsor/Collaborators:        Etablissement Français du Sang, Martinique|Sanofi Pasteur, a Sanofi Company|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   817
  Funded Bys:                   Other|Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    10/B/01|2010-A00385-34
  Start Date:                   May 2011
  Primary Completion Date:      May 2011
  Completion Date:              May 2012
  First Posted:                 April 15, 2010
  Results First Posted:         
  Last Update Posted:           August 20, 2021
  Locations:                    French Blood Establishment of Guadeloupe, Pointe-à-Pitre, Guadeloupe|French Blood Establishment of Martinique, Fort-de-France, Martinique
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01104740

Study 137:
  NCT Number:                   NCT01064141
  Title:                        A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|Biological: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
  Outcome Measures:             To provide information concerning the safety in terms of solicited and unsolicited adverse events after primary administration of CYD Dengue vaccine.|To provide information concerning the immunogenicity of CYD Dengue vaccine after each dose of primary vaccination.|To provide information concerning the immunogenicity of childhood vaccines after primary vaccination.
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          12 Months to 15 Months   (Child)
  Phases:                       Phase 2
  Enrollment:                   210
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD08|UTN: U1111-1111-5855
  Start Date:                   January 2010
  Primary Completion Date:      September 2012
  Completion Date:              November 2012
  First Posted:                 February 8, 2010
  Results First Posted:         
  Last Update Posted:           February 6, 2013
  Locations:                    San Pablo City, Philippines
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01064141

Study 138:
  NCT Number:                   NCT00966628
  Title:                        Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Shock Syndrome
  Interventions:                Drug: Hypertonic sodium lactate|Drug: Ringer's lactate
  Outcome Measures:             To assess the effect of solution containing half molar sodium lactate (Totilac™) infusion on the plasma sVCAM-1 level|To assess the effect of solution containing half molar sodium lactate (Totilac™) infusion on other efficacy and safety parameters
  Sponsor/Collaborators:        Innogene Kalbiotech Pte. Ltd
  Gender:                       All
  Age:                          2 Years to 14 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   50
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    006/IGK-KAL/08
  Start Date:                   May 2008
  Primary Completion Date:      April 2009
  Completion Date:              December 2009
  First Posted:                 August 27, 2009
  Results First Posted:         
  Last Update Posted:           August 28, 2009
  Locations:                    Hasan Sadikin Hospital, Dept. of Pediatrics, Bandung, West Java, Indonesia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00966628

Study 139:
  NCT Number:                   NCT04514107
  Title:                        A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Other: Brazilian National Dengue Control Program|Other: Wolbachia-infected Aedes aegypti
  Outcome Measures:             Incidence of arbovirus (ARBV) infection|Incidence of arbovirus (ARBV) infections, specifically due to flavivirus (FLAV) or chikungunya virus (CHIKV)|Incidence of chikungunya virus (CHIKV) infection|Incidence of dengue virus (DENV) infection|Incidence of flavivirus (FLAV) infection|Incidence of infection with a dengue virus (DENV) serotype in the sub-group of participants who are seropositive to another DENV serotype(s)|Incidence of zika virus (ZIKV) infection|Proportion of Wolbachia-infected Aedes aegypti (wMel) adults in control clusters|Proportion of Wolbachia-infected Aedes aegypti (wMel) adults in intervention clusters|Sero-incidence of flavivirus (FLAV) or chikungunya virus (CHIKV) infection in the sub-group of participants who are FLAV or CHIKV seronegative to each of these families of viruses, respectively
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          6 Years to 11 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   3480
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    17-0111|HHSN272201300018I
  Start Date:                   September 9, 2020
  Primary Completion Date:      January 1, 2025
  Completion Date:              January 1, 2025
  First Posted:                 August 14, 2020
  Results First Posted:         
  Last Update Posted:           January 2, 2023
  Locations:                    Universidade Federal de Minas Gerais, Instituto de Ciencias Biologicas, Department of Biochemistry and Immunology, Belo Horizonte, Minas Gerais, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04514107

Study 140:
  NCT Number:                   NCT01293331
  Title:                        Study of Febrile Illness for Dengue-Endemic Areas in Latin America
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Fever
  Interventions:                
  Outcome Measures:             Identification of acute febrile episodes in the cohort|Detection of confirmed or probable dengue infection in the cohort
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          9 Years to 16 Years   (Child)
  Phases:                       
  Enrollment:                   3000
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    CYD35|U1111-1112-8481
  Start Date:                   August 2010
  Primary Completion Date:      December 2011
  Completion Date:              April 2012
  First Posted:                 February 10, 2011
  Results First Posted:         
  Last Update Posted:           June 17, 2015
  Locations:                    Campo Grande, Brazil|Goiania, Brazil|Natal-RN, Brazil|Vitoria, Brazil|Acacias Meta, Colombia|Aguazul (Casanare), Colombia|Bogota, Colombia|Calarco (Quindio), Colombia|Girardot (Cundinamarca), Colombia|La Tebaida (Quindio), Colombia|Montenegro (Quindio), Colombia|Yopal (Casanare), Colombia|Minatitlan, Veracruz Mexico, Mexico|Veracruz, Veracruz Mexico, Mexico|Municipio de Cd. Mante Tamaulipas, Mexico|Quintana Roo., Mexico|Guayama, Puerto Rico|San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01293331

Study 141:
  NCT Number:                   NCT01218906
  Title:                        Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Fever
  Interventions:                
  Outcome Measures:             To provide information on the incidences of febrile episodes and confirmed and probable Dengue fever, and to determine other causes of febrile episodes in the cohort population
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          2 Years to 14 Years   (Child)
  Phases:                       
  Enrollment:                   1500
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    CYD34|U1111-1112-8378
  Start Date:                   August 2010
  Primary Completion Date:      November 2011
  Completion Date:              March 2012
  First Posted:                 October 11, 2010
  Results First Posted:         
  Last Update Posted:           January 16, 2018
  Locations:                    Bali, Indonesia|Bandung, Indonesia|Jakarta, Indonesia|Kuala Lumpur, Malaysia|Penang, Malaysia|Putrajaya, Malaysia|Cebu City, Philippines|Muntinlupa City, Philippines|San Pablo, Philippines|Bangkok, Thailand|My Tho City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01218906

Study 142:
  NCT Number:                   NCT04673422
  Title:                        Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue|Dengue With Warning Signs|Dengue Shock Syndrome
  Interventions:                Drug: Montelukast|Drug: Placebo
  Outcome Measures:             Rate of dengue with warning signs|Rate of each component of composite outcome of dengue with warning signs|Rate of hospitalization|Length of hospital stay|Rate of severe dengue|Rate of dengue shock|30-day mortality
  Sponsor/Collaborators:        Phramongkutklao College of Medicine and Hospital
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   358
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    AMEDDengue2020
  Start Date:                   January 15, 2021
  Primary Completion Date:      January 31, 2024
  Completion Date:              February 28, 2024
  First Posted:                 December 17, 2020
  Results First Posted:         
  Last Update Posted:           June 30, 2022
  Locations:                    Hatyai Hospital, Hat Yai, Songkhla, Thailand|Phramongkutklao Hospital, Bangkok, Thailand|Ananda Mahidol Hospital, Lopburi, Thailand|Fort Suranari Hospital, Nakhon Ratchasima, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04673422

Study 143:
  NCT Number:                   NCT01477671
  Title:                        Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                
  Outcome Measures:             Prevalence of positive samples with dengue specific serotype DENV 1, 2,3 and/or 4|Prevalence of positive serum samples with JEV specific IgG antibodies
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          5 Years to 10 Years   (Child)
  Phases:                       
  Enrollment:                   667
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Ecologic or Community|Time Perspective: Prospective
  Other IDs:                    DNG10|U1111-1124-7423
  Start Date:                   September 2011
  Primary Completion Date:      September 2012
  Completion Date:              December 2013
  First Posted:                 November 22, 2011
  Results First Posted:         
  Last Update Posted:           January 11, 2018
  Locations:                    Kalyani, West Bengali, India|Bangalore, India|Hyderabad, India|New Delhi, India
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01477671

Study 144:
  NCT Number:                   NCT01782300
  Title:                        Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV003 Vaccine|Biological: Placebo Vaccine
  Outcome Measures:             Frequency of vaccine-related adverse events (AEs), graded by severity|Measurement of neutralizing antibody titers to DEN1, DEN2, DEN3, and DEN4 at Day 0 and 28, 56, and 90 days after each vaccination|Determination if a second dose of vaccine given at Day 360 will induce seropositivity in those vaccinees who remained seronegative to one or more DENV serotypes following the first vaccination|Frequency, quantity, and duration of viremia following each vaccination|Number of vaccinees infected with DEN1, DEN2, DEN3, and DEN4|Duration of the antibody response in recipients of the tetravalent vaccine|Greater than or equal to 4-fold rise in serum neutralizing antibody titer by Day 450 compared with Day 360
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 283
  Start Date:                   January 2013
  Primary Completion Date:      March 2015
  Completion Date:              September 2016
  First Posted:                 February 1, 2013
  Results First Posted:         
  Last Update Posted:           June 14, 2017
  Locations:                    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01782300

Study 145:
  NCT Number:                   NCT02134652
  Title:                        Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever
  Acronym:                      
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Dengue|Disease Progression
  Interventions:                Other: diagnostic bedside ultrasound
  Outcome Measures:             Progression of Disease|Clinical Care
  Sponsor/Collaborators:        University of Massachusetts, Worcester
  Gender:                       All
  Age:                          3 Months to 16 Years   (Child)
  Phases:                       
  Enrollment:                   0
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Time Perspective: Prospective
  Other IDs:                    EUS-3325
  Start Date:                   January 2015
  Primary Completion Date:      June 2016
  Completion Date:              June 2016
  First Posted:                 May 9, 2014
  Results First Posted:         
  Last Update Posted:           June 11, 2015
  Locations:                    Angkor Hospital for Children, Siem Reap, Cambodia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02134652

Study 146:
  NCT Number:                   NCT02421367
  Title:                        Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
  Outcome Measures:             Number of solicited local adverse events related to product|Intensity of solicited local adverse events related to product|Number of unsolicited adverse events related to product|Intensity of unsolicited adverse events related to product|Number of Grade 2 laboratory abnormalities|Number of Grade 3 laboratory abnormalities|Number of serious adverse events from day 0 through 28 days after the last dose|Number of potential immune-mediated diseases from Day 0 through 28 days after the last dose|Neutralizing antibody titers to each DENV type|Number of general adverse events related to product|Intensity of solicited general adverse events related to product|Number of medically attended AEs related to product|Number of potential immune-mediated diseases from post Month 7 to Study End|Number of serious adverse events related to product|Seropositivity status for each DENV type|Number of medically attended AEs from post Month 7 to Study End|Neutralizing antibody titers to each DENV type for the TDENV-PIV (0-1-6) group|Seropositivity status for each DENV type for the TDENV-PIV (0-1-6) group
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR)|GlaxoSmithKline
  Gender:                       All
  Age:                          20 Years to 49 Years   (Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   140
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention
  Other IDs:                    S-14-13|WRAIR # 2195|201658
  Start Date:                   August 2015
  Primary Completion Date:      December 2016
  Completion Date:              March 2018
  First Posted:                 April 20, 2015
  Results First Posted:         
  Last Update Posted:           September 25, 2019
  Locations:                    University of Maryland, Center for Vaccine Development,, Baltimore, Maryland, United States|WRAIR, Clinical Trials Center, Silver Spring, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02421367

Study 147:
  NCT Number:                   NCT03999996
  Title:                        Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: Tetravalent Dengue Vaccine (TDV)|Biological: Placebo
  Outcome Measures:             Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 0|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 12|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 15|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for Participants in the Current Trial From Parent Trial DEN-315 (Mexico) at Month 24|Percentage of Participants with Seropositivity for Each of the 4 Dengue Serotypes at Month 0|Percentage of Participants with Seropositivity for Each of the 4 Dengue Serotypes at Month 12|Percentage of Participants with Seropositivity for Each of the 4 Dengue Serotypes at Month 15|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Each of the 4 Dengue Serotypes at Month 24|Percentage of Participants with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 0|Percentage of Participants with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 12|Percentage of Participants with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 15|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 24|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for Participants in the Current Trial From Parent Trial DEN-304 (US) at Month 16|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for Participants in the Current Trial From Parent Trial DEN-304 (US) at Month 21|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for Participants in the Current Trial From Parent Trial DEN-315 (Mexico) at Month 25|GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes for Participants in the Current Trial From Parent Trial DEN-315 (Mexico) at Month 30|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Seropositivity for Each of the 4 Dengue Serotypes at Month 16|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Seropositivity for Each of the 4 Dengue Serotypes at Month 21|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Each of the 4 Dengue Serotypes at Month 25|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Each of the 4 Dengue Serotypes at Month 30|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 16|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 21|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 25|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Seropositivity for Multiple (2, 3 or 4) Dengue Serotypes at Month 30|Geometric Mean Ratio (GMR) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 0 vs Month 12|GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 4 vs Month 15/24|GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 9 vs Months 0 and 12|GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 4 vs Month 16 and Month 21 or Month 4 vs Month 25 and Month 30|GMR of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Month 15 vs Month 16/21; Month 16 vs Month 21 and Month 24 vs Month 25/30; Month 25 vs Month 30|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Solicited Local Injection Site Adverse Events (AEs) by Severity, by Trial Group|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Solicited Local Injection Site AEs by Severity, by Trial Group|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Solicited Systemic AEs by Severity, by Trial Group|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with Solicited Systemic AEs by Severity, by Trial Group|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with any Unsolicited AEs|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with any Unsolicited AEs|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Medically Attended AEs (MAAEs)|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with MAAEs|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with Serious Adverse Events (SAEs)|Percentage of Participants in the Current Trial From Parent Trial DEN-315 (Mexico) with SAEs|Percentage of Participants in the Current Trial From Parent Trial DEN-304 (US) with SAEs
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          13 Years to 63 Years   (Child, Adult)
  Phases:                       Phase 3
  Enrollment:                   365
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-303
  Start Date:                   November 12, 2019
  Primary Completion Date:      January 16, 2023
  Completion Date:              January 16, 2023
  First Posted:                 June 27, 2019
  Results First Posted:         
  Last Update Posted:           December 7, 2022
  Locations:                    Synexus - Optimal Research - Huntsville, Huntsville, Alabama, United States|Synexus - Optimal Research - Peoria, Peoria, Illinois, United States|Heartland Research Associates LLC, Newton, Kansas, United States|Optimal Research, Rockville, Maryland, United States|Synexus Clinical Research US, Inc. Minneapolis, Richfield, Minnesota, United States|Synexus Clinical Research US, Inc. - St. Louis, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc. - Omaha, Omaha, Nebraska, United States|Advanced Clinical Research - Meridian - ERN-PPDS, Taylorsville, Utah, United States|Instituto Nacional de Pediatria, Mexico City, Mexico|CAIMED Investigacion en Salud, S. A. de C. V., Mexico City, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03999996

Study 148:
  NCT Number:                   NCT01943825
  Title:                        Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Japanese Encephalitis Vaccine
  Outcome Measures:             Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains|Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains|Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4|Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains|Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia|Number of Participants With Detectable Serotype-Specific Vaccine Viremia|Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4|Number of Participants With Solicited Injection Site Reactions|Number of Participants With Solicited Systemic Reactions
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|United States Department of Defense|Sanofi
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   90
  Funded Bys:                   Industry|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD56|U1111-1143-8391
  Start Date:                   November 5, 2013
  Primary Completion Date:      November 25, 2015
  Completion Date:              November 25, 2015
  First Posted:                 September 17, 2013
  Results First Posted:         February 5, 2020
  Last Update Posted:           March 24, 2022
  Locations:                    Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01943825

Study 149:
  NCT Number:                   NCT03883620
  Title:                        Safety Study of Dengushield in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Phase 1|Dengue
  Interventions:                Biological: Dengushield 1 mg/kg (Cohort 1) intravenous|Biological: Dengushield 3 mg/kg (Cohort 2) intravenous|Biological: Placebo 3 mg/kg (Cohort 2) intravenous|Biological: Dengushield 7 mg/kg (Cohort 3) intravenous|Biological: Placebo 7 mg/kg (Cohort 3) intravenous|Biological: Dengushield 12 mg/kg (Cohort 4) intravenous|Biological: Placebo 12 mg/kg (Cohort 4) intravenous
  Outcome Measures:             The proportion of participants with post-injection/ infusion adverse events (AEs) including hypersensitivity reaction, anaphylactic reaction and other AEs occurring within 4 hours of the start of dosing|The proportion of participants with AEs, discontinuations due to AEs, and serious adverse events (SAEs)|Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings|Time to maximum serum concentration of Dengushield - Tmax|Presence or absence of anti-Dengushield antibody in sera samples|Maximum serum concentration of dengushield - Cmax|AUC from time 0 to infinity of Dengushield|AUC from time 0 to 84 days of Dengushield|Half life of Dengushield - t1/2|Volume of distribution of Dengushield|Clearance of dengushield|Elimination rate constant of dengushield
  Sponsor/Collaborators:        Serum Institute of India Pvt. Ltd.|PPD
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    Dengushield-01
  Start Date:                   March 22, 2019
  Primary Completion Date:      December 23, 2019
  Completion Date:              December 23, 2019
  First Posted:                 March 21, 2019
  Results First Posted:         
  Last Update Posted:           February 18, 2020
  Locations:                    CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03883620

Study 150:
  NCT Number:                   NCT01224639
  Title:                        Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: TDV - Low Dose|Biological: TDV - High Dose|Biological: Placebo
  Outcome Measures:             Number of Participants With Local Injection Site Reaction by Severity|Number of Participants With Systemic Adverse Events (AEs) by Severity|Number of Participants With Solicited Local and Systemic AEs|Number of Participants With Unsolicited Local and Systemic AEs|Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes After First Vaccination|GMTs of All Four Dengue Serotypes After Second Vaccination|Rate of Seroconversion to Each of Four Dengue Serotypes After the First Vaccination|Rate of Seroconversion to Each of Four Dengue Serotypes After the Second Vaccination|Percentage of Participants With Durability of Immune Response|Number of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strain Serotypes After the First and Second Vaccination|Duration of Vaccine Viremia|Titers of Vaccine Viremia
  Sponsor/Collaborators:        Inviragen Inc.|Takeda
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   96
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    INV-DEN-102|U1111-1181-8290
  Start Date:                   October 11, 2010
  Primary Completion Date:      June 9, 2011
  Completion Date:              November 9, 2011
  First Posted:                 October 20, 2010
  Results First Posted:         February 27, 2017
  Last Update Posted:           June 19, 2018
  Locations:                    Program For The Study and Control of Tropical Diseases, Medellin, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01224639

Study 151:
  NCT Number:                   NCT01983553
  Title:                        Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                
  Outcome Measures:             Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23)|Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23)|Number of Episodes of Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23)|Event Rate Per 100 Participant-years for Hospitalized VCD Cases Due to Any and Each Serotype Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Episodes of Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Event Rate Per 100 Participant-years for Clinically Severe Hospitalized VCD Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Clinically Severe Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Episodes of Clinically Severe Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Cases of Non-Serotype Specific Dengue Viremia Among Hospitalized VCD Cases Following Vaccination With CYD Dengue Vaccine or Placebo in Previous Study (CYD23)|Non-Serotype Specific Dengue Viremia Among Hospitalized VCD Cases Following Vaccination With CYD Dengue Vaccine or Placebo in Previous Study (CYD23)|Event Rate Per 100 Participant-years for Hospitalized VCD Cases Due to Any and Each Serotype and Meeting World Health Organization (WHO) 1997 Criteria Collected Following Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) and Meeting WHO 1997 Criteria Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)|Number of Episodes of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) and Meeting WHO 1997 Criteria Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23)
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          7 Years to 16 Years   (Child)
  Phases:                       
  Enrollment:                   3203
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    CYD57|U1111-1127-7380
  Start Date:                   September 10, 2013
  Primary Completion Date:      June 15, 2016
  Completion Date:              August 2016
  First Posted:                 November 14, 2013
  Results First Posted:         July 29, 2019
  Last Update Posted:           March 29, 2022
  Locations:                    Ratchaburi, Muang District, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01983553

Study 152:
  NCT Number:                   NCT03465254
  Title:                        Dengue Serostatus Study in the Philippines
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue|Severe Dengue|Dengue Fever|Virologically-confirmed Dengue
  Interventions:                
  Outcome Measures:             virologically-confirmed dengue (VCD)
  Sponsor/Collaborators:        University of the Philippines|Department of Health, Philippines|World Health Organization|Research Institute for Tropical Medicine, Philippines|University of North Carolina|La Jolla Institute for Allergy & Immunology|International Vaccine Institute
  Gender:                       All
  Age:                          9 Years to 14 Years   (Child)
  Phases:                       
  Enrollment:                   2996
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    UPM REB 2016-435-01
  Start Date:                   November 2016
  Primary Completion Date:      October 2022
  Completion Date:              October 2022
  First Posted:                 March 14, 2018
  Results First Posted:         
  Last Update Posted:           April 20, 2020
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03465254

Study 153:
  NCT Number:                   NCT03055585
  Title:                        Applying Wolbachia to Eliminate Dengue
  Acronym:                      AWED
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Dengue|Zika Virus Infection|Chikungunya Fever
  Interventions:                Biological: Wolbachia-infected Aedes aegypti mosquitoes|Other: standard practice dengue control
  Outcome Measures:             Relative risk of dengue in Wolbachia-treated versus untreated clusters|Relative risk of serotype-specific dengue in Wolbachia-treated versus untreated clusters|Relative risk of Zika in Wolbachia-treated versus untreated clusters|Relative risk of Chikungunya in Wolbachia-treated versus untreated clusters
  Sponsor/Collaborators:        Gadjah Mada University|Monash University|The Tahija Foundation
  Gender:                       All
  Age:                          3 Years to 45 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   8173
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    UGM_KE/FK/105/EC
  Start Date:                   November 8, 2017
  Primary Completion Date:      March 18, 2020
  Completion Date:              April 8, 2020
  First Posted:                 February 16, 2017
  Results First Posted:         
  Last Update Posted:           June 9, 2020
  Locations:                    Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, DIY, Indonesia
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03055585/SAP_002.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03055585

Study 154:
  NCT Number:                   NCT01728792
  Title:                        Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever
  Interventions:                Biological: TDV
  Outcome Measures:             Number of Participants With Solicited Local (Injection Site) Reactions Following Either Vaccine Administration (Day 0 or Day 90) by Maximum Severity as Assessed by the Investigator|Number of Participants With Solicited Participant-Reported Local (Injection Site) Reactions Following Either Vaccine by Maximum Severity|Number of Participants With Solicited Participant-Reported Systemic Adverse Events (AEs) Following Either Vaccine by Maximum Severity|Number of Participants With at Least 1 Unsolicited Related Adverse Event Following Either Vaccine Dose|Number of Participants With at Least 1 Serious Adverse Event During the Study|Seroconversion Rate to Each of Four Dengue Serotypes|Number of Participants With Detected Viral RNA for Each TDV Component After First and Second Vaccinations|Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes
  Sponsor/Collaborators:        Takeda|Walter Reed Army Institute of Research (WRAIR)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   80
  Funded Bys:                   Industry|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    INV-DEN-105|U1111-1181-0251
  Start Date:                   January 22, 2013
  Primary Completion Date:      November 1, 2013
  Completion Date:              November 21, 2013
  First Posted:                 November 20, 2012
  Results First Posted:         January 4, 2017
  Last Update Posted:           July 18, 2019
  Locations:                    SUNY Upstate Medical University, Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01728792

Study 155:
  NCT Number:                   NCT02673840
  Title:                        Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
  Acronym:                      KETODEN
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Pleural Effusion
  Interventions:                Drug: Ketotifen|Drug: Placebo
  Outcome Measures:             reduced fluid accumulation in the pleural cavity|reduced serum biomarker chymase|reduced hemoconcentration|Number of patients with symptoms associated with DF|time to viral clearance
  Sponsor/Collaborators:        National University Hospital, Singapore|Duke-NUS Graduate Medical School|Singapore General Hospital
  Gender:                       All
  Age:                          21 Years to 60 Years   (Adult)
  Phases:                       Phase 4
  Enrollment:                   110
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    EID-DF-02
  Start Date:                   March 2015
  Primary Completion Date:      July 2016
  Completion Date:              July 2017
  First Posted:                 February 4, 2016
  Results First Posted:         
  Last Update Posted:           February 4, 2016
  Locations:                    National University Hospital (Investigational Medicine Unit), Singapore, Singapore|Singapore General Hospital, Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02673840

Study 156:
  NCT Number:                   NCT00617344
  Title:                        Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus
  Interventions:                Biological: Tetravalent CYD Dengue Vaccine , 5555 formulation|Biological: Tetravalent CYD Dengue Vaccine , 5553 formulation|Biological: Tetravalent CYD Dengue Vaccine, 4444 formulation
  Outcome Measures:             Percentage of Participants With Antibody Titers of >= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain: CYD Vaccine 5555 and 5553 Formulation|Percentage of Participants With Antibody Titers of >=10 1/Dil Against Each Dengue Virus Serotype Strain|Percentage of Participants With Antibody Titers >=10 1/Dil Against At Least Any 1, 2, 3 or All 4 Dengue Virus Serotypes|Geometric Means of Titers of Antibodies Against Each Dengue Virus Serotype Strain|Number of Participants With Solicited Injection Site Reactions After Any Vaccination|Number of Participants With Solicited Systemic Reactions After Any Vaccination|Number of Participants With Vaccine Viremia
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   260
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CYD12
  Start Date:                   April 17, 2008
  Primary Completion Date:      December 2009
  Completion Date:              February 2010
  First Posted:                 February 18, 2008
  Results First Posted:         June 11, 2019
  Last Update Posted:           June 11, 2019
  Locations:                    Investigational Site 004, Hoover, Alabama, United States|Investigational Site 002, San Diego, California, United States|Investigational Site 005, Vallejo, California, United States|Investigational Site 001, New Orleans, Louisiana, United States|Investigational Site 003, Springfield, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00617344

Study 157:
  NCT Number:                   NCT01550289
  Title:                        Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|Biological: Placebo: NaCl 0.9% solution
  Outcome Measures:             Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Virus Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Virus Serotypes Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Percentage of Participants With Solicited Injection-site and Systemic Reactions After Any and Each Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo|Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo|Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo|Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo|Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo|Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   189
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD47|UTN: U1111-1114-7909
  Start Date:                   March 2012
  Primary Completion Date:      December 2013
  Completion Date:              February 2014
  First Posted:                 March 9, 2012
  Results First Posted:         November 3, 2016
  Last Update Posted:           April 5, 2022
  Locations:                    Bangalore, Karnataka, India|Ludhiana, Punjab, India|Kolkata, West Bengal, India|New Delhi, India|Pune, India
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01550289

Study 158:
  NCT Number:                   NCT01373281
  Title:                        Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever
  Interventions:                Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus|Biological: Placebo: Sodium chloride (NaCl) 0.9%
  Outcome Measures:             Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo|Percentage of Participants With Antibody Titers >= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain Before and Following Inj. With CYD Dengue Vaccine or Placebo|Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Due to Any Serotype 28 Days Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase in Either CYD Dengue Vaccine or Placebo Group|Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Participants With Solicited Injection Site Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Participants With Systemic Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          2 Years to 14 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   10275
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD14|UTN: U1111-1116-4957|2014-001708-24
  Start Date:                   June 3, 2011
  Primary Completion Date:      August 1, 2014
  Completion Date:              November 21, 2017
  First Posted:                 June 14, 2011
  Results First Posted:         November 16, 2015
  Last Update Posted:           March 21, 2022
  Locations:                    Denpasar, Bali, Indonesia|Bandung, West Java, Indonesia|Jakarta, Indonesia|Kuala Lumpur, Malaysia|Pulau Pinang, Malaysia|Cebu City, Philippines|San Pablo City, Philippines|Nai Muang, Kamphaeng Phet Province, Thailand|Ban Pong, Ratchaburi Province, Thailand|Photharam, Ratchaburi Province, Thailand|Long Xuyên, An Giang Province, Vietnam|Mỹ Tho, Tien Giang Province, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01373281

Study 159:
  NCT Number:                   NCT03485144
  Title:                        A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Biological: TV003|Biological: Placebo for TV003
  Outcome Measures:             Immunogenicity of TetraVax-DV assessed by plaque reduction neutralization titer 50% (PRNT50)|Immunogenicity of TetraVax-DV assessed by response rates|Duration of immunogenicity of TetraVax-DV assessed by PRNT50|Frequency of viremia following vaccination|Quantity of viremia following vaccination|Duration of viremia following vaccination|Determine the number of vaccinees with recoverable dengue virus.|Determine the safety of TetraVax-DV assessed by frequency of solicited local adverse reactions.|Determine the safety of TetraVax-DV assessed by frequency of solicited systemic and unsolicited adverse reactions.|Determine the safety of TetraVax-DV assessed by occurrence of adverse events and serious adverse events.
  Sponsor/Collaborators:        Medigen Vaccine Biologics Corp.
  Gender:                       All
  Age:                          20 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   54
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CT-DV-21
  Start Date:                   December 12, 2017
  Primary Completion Date:      May 10, 2019
  Completion Date:              May 10, 2019
  First Posted:                 April 2, 2018
  Results First Posted:         
  Last Update Posted:           August 14, 2019
  Locations:                    National Taiwan University Hospital, Taipei, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03485144

Study 160:
  NCT Number:                   NCT04422782
  Title:                        New Tools for Predicting Capillary Leak Shock During Dengue Fever
  Acronym:                      PrediDengue
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Children|Adults
  Interventions:                Other: For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine
  Outcome Measures:             Occurrence of a shock|Predictive value of plasma hypo-osmolarity|Validation of the clinical-biological prognostic score|Relationship between the measurements obtained by osmolarity and capillary leakage|Evaluation of the sensitivity / specificity and predictive values of osmolarity and capillary leakage|How long before the shock these measures (osmolarity, score) allow to predict an unfavorable evolution|Association between the factor "Presence of sickle cell disease" and "occurrence of severe dengue"
  Sponsor/Collaborators:        Centre Hospitalier de Cayenne|European Regional Development Fund
  Gender:                       All
  Age:                          5 Years and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   342
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    PrediDengue
  Start Date:                   May 14, 2020
  Primary Completion Date:      May 14, 2022
  Completion Date:              May 14, 2023
  First Posted:                 June 9, 2020
  Results First Posted:         
  Last Update Posted:           December 10, 2020
  Locations:                    General Hospital of Cayenne, Cayenne, French Guiana, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04422782

Study 161:
  NCT Number:                   NCT01374516
  Title:                        Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Dengue
  Interventions:                Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus|Biological: Placebo: (NaCl) 0.9% solution
  Outcome Measures:             Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Due to Any Serotype Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Meeting World Health Organization (WHO) Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases Meeting WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Antibody Titers >=10 1/Dil Against Each Dengue Virus Serotype Before and Following Injection (Inj.) With CYD Dengue Vaccine or Placebo|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo|Number of Participants With Solicited Injection Site Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo|Number of Participants With Solicited Systemic Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 16 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   20869
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD15|UTN: U1111-1116-4986
  Start Date:                   June 8, 2011
  Primary Completion Date:      November 2014
  Completion Date:              March 5, 2018
  First Posted:                 June 16, 2011
  Results First Posted:         March 27, 2019
  Last Update Posted:           March 21, 2022
  Locations:                    Fortaleza, CE, Brazil|Vitória, ES, Brazil|Goiania, GO, Brazil|Campo Grande, MS, Brazil|Natal, RN, Brazil|Aguazul, Casanare, Colombia|Yopal, Casanare, Colombia|Girardot, Cundinamarca, Colombia|Acacias, Meta, Colombia|Armenia, Quindío, Colombia|Calarcá, Quindío, Colombia|La Tebaida, Quindío, Colombia|Montenegro, Quindío, Colombia|Bucaramanga, Santander, Colombia|Tegucigalpa, Municipalidad Del Distrito Central, Honduras|Temixco, Morelos, Mexico|Municipio De Cd. Mante, Tamaulipas, Mexico|Veracruz Puerto, Veracruz, Mexico|Tizimin, Yucatán, Mexico|Valladolid, Yucatán, Mexico|Guayama, Puerto Rico|San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01374516

Study 162:
  NCT Number:                   NCT02741128
  Title:                        Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Human Immunodeficiency Virus
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Placebo (NaCl 0.9%) vaccine group
  Outcome Measures:             Number of participants reporting unsolicited systematic AE, solicited injection site reactions, solicited systemic reactions, unsolicited AEs, serious and non-serious AEs of special interests, SAE and hospitalized virologically confirmed dengue cases|Summary of Neutralizing antibody levels against each dengue virus serotype at baseline and 28 days after each injection in each group|Summary of CYD dengue vaccinal viremia following first vaccination with CYD dengue vaccine or placebo injection|Summary of CD4 count after each injection of CYD dengue vaccine|Summary of HIV RNA viral load after each injection of CYD dengue vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   150
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD50|U1111-1174-4398
  Start Date:                   October 28, 2019
  Primary Completion Date:      January 10, 2023
  Completion Date:              January 10, 2023
  First Posted:                 April 18, 2016
  Results First Posted:         
  Last Update Posted:           June 2, 2022
  Locations:                    Investigational Site Number :0760002, Nova Iguaçu, Rio De Janeiro, Brazil|Investigational Site Number :0760004, Natal, Rio Grande Do Norte, Brazil|Investigational Site Number :0760003, Sao Paulo, Brazil|Investigational Site Number :0760001, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02741128

Study 163:
  NCT Number:                   NCT02993757
  Title:                        Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Human Papillomavirus Disease
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
  Outcome Measures:             Geometric Mean Titers (GMTs) Against Each Gardasil Vaccine Human Papillomavirus (HPV) Antigen (HPV-6, HPV-11, HPV-16, HPV-18) 28 Days After Last Gardasil Vaccination in the Previously Dengue Immune Participants|Geometric Mean Titers Against Each Parental Dengue Virus Serotype 28 Days After Third CYD Dengue Vaccination in the Previously Dengue Immune Participants|Percentage of Participants With Seroconversion Against Each Gardasil HPV Antigen (HPV-6, HPV-11, HPV-16, HPV-18) 28 Days After Last Dose of Gardasil in the Previously Dengue Immune Participants|Geometric Mean Titers Against Each Gardasil HPV Antigen (HPV-6, HPV-11, HPV-16, HPV-18) at Day 0 and 28 Days After Each Dose of Gardasil in the Previously Dengue Immune Participants|Geometric Mean Titers Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Percentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants|Percentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against at Least 1,2,3,or4 Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Immune Participants|Number of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Solicited Systemic Reactions Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Serious Adverse Events (SAEs) Including Serious Adverse Event of Special Interests Following Vaccination With Gardasil or CYD Dengue Vaccine|Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Gardasil or CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 13 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   528
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD67|U1111-1161-3376|2019-003135-36
  Start Date:                   December 1, 2016
  Primary Completion Date:      May 27, 2019
  Completion Date:              May 27, 2019
  First Posted:                 December 15, 2016
  Results First Posted:         June 11, 2020
  Last Update Posted:           March 25, 2022
  Locations:                    Sanofi Pasteur Investigational Site 004, Klang, Malaysia|Sanofi Pasteur Investigational Site 005, Kuala Lumpur, Malaysia|Sanofi Pasteur Investigational Site 001, Kuala Lumpur, Malaysia|Sanofi Pasteur Investigational Site 003, Kuantan, Malaysia|Sanofi Pasteur Investigational Site 002, Sibu, Malaysia
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02993757/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02993757/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02993757

Study 164:
  NCT Number:                   NCT02979535
  Title:                        Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Human Papillomavirus Disease
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
  Outcome Measures:             Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants|GMTs Against Each Dengue Virus Serotype 28 Days After the Third CYD Dengue Vaccination in the Previously Dengue Seropositive Participants|GMTs Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) at Day 0 and 28 Days After Each Cervarix Vaccination in the Previously Dengue Seropositive Participants|Percentage of Participants With Seroconversion Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) 28 Days After Each Dose of Cervarix Vaccination in the Previously Dengue Seropositive Participants|GMTs Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants|Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants|Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against At Least 1,2,3,or4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Seropositive Participants|Percentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against Each Dengue Virus Serotypes of CYD at Baseline And 28 Days After Each Dose of CYD Dengue Vaccination in Dengue Seropositive Participants|Number of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Solicited Systemic Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Unsolicited AEs Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Serious Adverse Events (SAEs) Including Serious AESIs Following Vaccination With Cervarix or CYD Dengue Vaccine|Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       Female
  Age:                          9 Years to 14 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   480
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD71|U1111-1161-3455|2019-000994-22
  Start Date:                   November 16, 2016
  Primary Completion Date:      March 25, 2019
  Completion Date:              March 25, 2019
  First Posted:                 December 1, 2016
  Results First Posted:         March 9, 2020
  Last Update Posted:           March 25, 2022
  Locations:                    Mexico City, Mexico
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02979535/Prot_001.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02979535/SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02979535

Study 165:
  NCT Number:                   NCT00468858
  Title:                        A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Dengue Shock Syndrome
  Interventions:                Other: Placebo|Biological: T-DEN-Post-Transfection F17|Biological: T-DEN-Post-Transfection F19
  Outcome Measures:             Safety: Incidence of All and Grade 3 Solicited Local Symptoms|Safety: Summary of Unsolicited Adverse Events Within the 31-day Post-vaccination Period|Safety: Occurrence of Serious Adverse Events (SAEs)|Incidence of Suspected and Laboratory Confirmed Dengue|GMTs for Antibody Titer Above the Assay Cut Off to Each DEN Serotype for Unprimed and Primed Subjects|Percent of Subjects With Neut. Antibody Titer Above the Assay Cut-off to All Dengue Serotypes|Percent of Subjects With Neut. Sero-response to Each DEN Serotype|Vaccine Response to DEN Antibody at Post Dose 1, Month 3|Vaccine Response to DEN Antibody at Post Dose 2, Month 7
  Sponsor/Collaborators:        U.S. Army Medical Research and Development Command|GlaxoSmithKline
  Gender:                       All
  Age:                          12 Months to 50 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   636
  Funded Bys:                   U.S. Fed|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    A-14040|WIRB number 20070071|106405|T-DEN-003
  Start Date:                   July 2007
  Primary Completion Date:      April 2010
  Completion Date:              April 2010
  First Posted:                 May 3, 2007
  Results First Posted:         June 6, 2017
  Last Update Posted:           July 2, 2017
  Locations:                    San Juan Batista Medical School, Caguas, Puerto Rico|Private Practice, Carolina, Puerto Rico|St Luke's Memorial Hospital, Ponce, Puerto Rico|Caparra Internal Medicine Research Center, Rio Grande, Puerto Rico|Private Practice, Rio Piedras, Puerto Rico|RCMI Clinical Research Center, Rio Piedras, Puerto Rico|Torre Medica San Vicente de Paul, San German, Puerto Rico|Clinical Research PR, San Juan, Puerto Rico|Centro de Neumologia Pediatricia, San Juan, Puerto Rico|Private Practice, San Juan, Puerto Rico|Dept Pediatria, Esc. De Medicina, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00468858

Study 166:
  NCT Number:                   NCT01436396
  Title:                        Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Hemorrhagic Fever|Yellow Fever
  Interventions:                Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus|Biological: Yellow fever vaccine|Biological: Measles, mumps, and rubella (MMR) vaccine|Biological: Pneumococcal Conjugated Vaccine|Biological: Hepatitis A Pediatric Vaccine|Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|Biological: Yellow Fever Vaccine|Biological: Placebo (NaCl)|Biological: Measles, mumps, and rubella vaccine
  Outcome Measures:             Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|GMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|GMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|GMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|GMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          12 Months to 13 Months   (Child)
  Phases:                       Phase 3
  Enrollment:                   792
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD29|U1111-1116-4913|2014-001714-26
  Start Date:                   September 7, 2011
  Primary Completion Date:      September 2013
  Completion Date:              September 2, 2013
  First Posted:                 September 19, 2011
  Results First Posted:         July 29, 2019
  Last Update Posted:           March 25, 2022
  Locations:                    Cali, Colombia|Lima, Peru
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01436396

Study 167:
  NCT Number:                   NCT02833584
  Title:                        Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Transaminitis
  Interventions:                Drug: Paracetamol|Drug: Placebo
  Outcome Measures:             Proportion of subjects with abnormal serum transaminase levels on the last day of fever|Mean serum transaminase level|Mean change in serum transaminase levels|Body temperature|Duration of fever|Length of stay|Number of drug tablet used
  Sponsor/Collaborators:        Phramongkutklao College of Medicine and Hospital
  Gender:                       All
  Age:                          18 Years to 99 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   123
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    AMED2016
  Start Date:                   September 2016
  Primary Completion Date:      December 2017
  Completion Date:              January 2018
  First Posted:                 July 14, 2016
  Results First Posted:         
  Last Update Posted:           April 23, 2019
  Locations:                    Phramongkutklao College of Medicine and Hospital, Bangkok, Thailand|Anandamahidol Hospital, Lopburi, Thailand|Fort Adisorn Hospital, Saraburi, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02833584

Study 168:
  NCT Number:                   NCT00919178
  Title:                        Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Shock Syndrome|Dengue Hemorrhagic Fever
  Interventions:                Biological: DEN4 Vaccine Candidate|Biological: DEN4 Vaccine Placebo
  Outcome Measures:             Immunogenicity of vaccine candidate, as assessed by neutralizing antibody titers to DEN4|Safety of vaccine candidate, as assessed by the frequency of vaccine-related adverse events, graded by severity|Frequency, quantity, and duration of viremia following vaccination|Number of vaccinees infected with vaccine virus|Infectivity rates, safety, and immunogenicity of a single dose of candidate vaccine compared with previous rates from a previous lot of similar vaccine|Durability of antibody response|Phenotype of peripheral blood mononuclear cells at primary infection with the rDEN4delta30 vaccine|Immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy|Cellular immune response to primary infection with the rDEN4delta30 vaccine
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   70
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 256
  Start Date:                   July 2009
  Primary Completion Date:      May 2010
  Completion Date:              May 2010
  First Posted:                 June 12, 2009
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States|University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00919178

Study 169:
  NCT Number:                   NCT00730288
  Title:                        Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus
  Interventions:                Biological: Chimeric dengue serotype (1, 2, 3, 4)
  Outcome Measures:             Immunogenicity: To provide information concerning the immunogenicity of ChimeriVax™|Safety: To provide information concerning the safety of ChimeriVax™
  Sponsor/Collaborators:        Sanofi
  Gender:                       All
  Age:                          18 Years to 40 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   35
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD10
  Start Date:                   August 2006
  Primary Completion Date:      August 2007
  Completion Date:              January 2008
  First Posted:                 August 8, 2008
  Results First Posted:         
  Last Update Posted:           February 27, 2018
  Locations:                    Adelaide, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00730288

Study 170:
  NCT Number:                   NCT04478370
  Title:                        Characterizing Humoral Immune Response to Mosquito Bites
  Acronym:                      SG6
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malaria|Dengue
  Interventions:                Biological: Mosquito bites
  Outcome Measures:             Levels of specific antibody titers against candidate peptides before and during repeated exposure to laboratory-reared mosquito bites determined by ELISA and mesoscale screening.|Kinetics of specific antibody titers against candidate peptides before and during repeated exposure to laboratory-reared mosquito bites determined by ELISA and mesoscale screening.|Sequence of saliva antigens determined with an immuno-proteomic method (2D gel electrophoresis of salivary gland protein extracts, Western blot and mass spectrometry).|Comparison of the antibody titers determined in subgroups corresponding to different level of exposure.|Comparison of the antibody titers determined in DBS and venous blood samples.
  Sponsor/Collaborators:        University of Oxford|National Health and Medical Research Council, Australia|Burnet Institute|Agency for Science, Technology and Research
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   150
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    MAL19009
  Start Date:                   January 21, 2021
  Primary Completion Date:      December 2023
  Completion Date:              December 2023
  First Posted:                 July 20, 2020
  Results First Posted:         
  Last Update Posted:           August 16, 2021
  Locations:                    Shoklo Malaria Research unit (SMRU), Mae Sot, Tak, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04478370

Study 171:
  NCT Number:                   NCT00740155
  Title:                        Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Virus|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Diseases
  Interventions:                Biological: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|Biological: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|Biological: Tetravalent CYD-1,2,3,4 Dengue (Vero)|Biological: JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)
  Outcome Measures:             Safety: To provide information concerning the safety of ChimeriVax™ Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   154
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD11
  Start Date:                   August 2008
  Primary Completion Date:      October 2009
  Completion Date:              January 2010
  First Posted:                 August 22, 2008
  Results First Posted:         
  Last Update Posted:           March 3, 2015
  Locations:                    Tlalpan, Mexico|Valle de Chalco, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00740155

Study 172:
  NCT Number:                   NCT00842530
  Title:                        Efficacy and Safety of Dengue Vaccine in Healthy Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Virus|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Diseases
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Inactivated rabies virus vaccine|Biological: Placebo
  Outcome Measures:             Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Severe VCD Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo|Number of Symptomatic VCD Cases During the Active Phase Following at Least Two Inj. With Either CYD Dengue Vaccine or a Placebo|Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo|GMTs of Antibodies Against Each Serotype With the Parental Dengue Virus Strain in Dengue-Immune Participants Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo|GMTs of Antibodies Against Each Serotype With the Parental Dengue Virus Strain in Dengue Non-Immune Participants Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Solicited Inj. Site Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo|Percentage of Participants With Solicited Systemic Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          4 Years to 11 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   4002
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CYD23|2014-001710-25
  Start Date:                   February 2009
  Primary Completion Date:      September 2013
  Completion Date:              February 2014
  First Posted:                 February 12, 2009
  Results First Posted:         July 26, 2019
  Last Update Posted:           April 5, 2022
  Locations:                    Sanofi Pasteur Investigational Site, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00842530

Study 173:
  NCT Number:                   NCT01601613
  Title:                        Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Acquired Bleeding Disorder|Dengue Haemorrhagic Fever
  Interventions:                Drug: activated recombinant human factor VII|Drug: placebo
  Outcome Measures:             Proportion of subjects with evidence of bleeding as assessed at 2 hours after first trial product administration|Proportion of subjects requiring standard haemostatic replacement therapy during 2 hours after first trial product administration|Proportion of subjects with effective haemostatic efficacy at 2 hours after first trial product administration|Coagulation related variables|Adverse events
  Sponsor/Collaborators:        Novo Nordisk A/S
  Gender:                       All
  Age:                          up to 18 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   28
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    F7-3015
  Start Date:                   July 2001
  Primary Completion Date:      November 2002
  Completion Date:              November 2002
  First Posted:                 May 18, 2012
  Results First Posted:         
  Last Update Posted:           January 11, 2017
  Locations:                    Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Muntinlupa City, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Khon Kean, Thailand|Novo Nordisk Investigational Site, Pisanulok, Thailand|Novo Nordisk Investigational Site, Ubonratchathani, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01601613

Study 174:
  NCT Number:                   NCT00993447
  Title:                        Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Hemorrhagic Fever|Dengue Virus|Dengue Fever
  Interventions:                Biological: CYD Dengue Vaccine|Biological: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
  Outcome Measures:             Percentage of Participants With Antibody Titers of ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Percentage of Flavi Virus-Immune Participants at Baseline With Antibody Titers ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Percentage of Flavi Virus-Naive Participants at Baseline With Antibody Titers ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Percentage of Participants With Antibody Titers of ≥10 1/Dil Against At Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strain Before and Following Each Injection With Either Sanofi Pasteur's CYD Dengue Vaccine or A Placebo Vaccine|Percentage of Flavi Virus-Immune Participants With Antibody Titers of ≥10 1/Dil Against At Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strain Pre and Post-Injection With Either Sanofi Pasteur's CYD Dengue Vaccine or A Placebo Vaccine|Percentage of Flavi Virus-Naive Participants With Antibody Titers of ≥10 1/Dil Against At Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strain Pre and Post-Injection With Either Sanofi Pasteur's CYD Dengue Vaccine or A Placebo Vaccine|Summary of Geometric Mean Titers (GMTs) of Antibodies Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Summary of Geometric Mean Titers Ratios of Antibodies Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Summary of Geometric Mean Titers (GMTs) of Antibodies in Flavivirus-Immune Participants at Baseline Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Summary of Geometric Mean Titers Ratios of Antibodies in Flavivirus-Immune Participants at Baseline Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Summary of Geometric Mean Titers (GMTs) of Antibodies in Flavivirus-Naïve Participants at Baseline Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Summary of Geometric Mean Titer Ratios of Antibodies in Flavivirus-Naive Participants at Baseline Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine|Number of Participants Reporting a Solicited Injection-site or Systemic Reactions Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          9 Years to 16 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   600
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD13|UTN: U1111-1111-5511
  Start Date:                   October 2009
  Primary Completion Date:      September 2011
  Completion Date:              March 2012
  First Posted:                 October 12, 2009
  Results First Posted:         November 29, 2016
  Last Update Posted:           March 24, 2022
  Locations:                    Bucaramanga, Colombia|Tegucigalpa, Honduras|Cuernavaca, Mexico|San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00993447

Study 175:
  NCT Number:                   NCT00875524
  Title:                        Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Virus|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Disease
  Interventions:                Biological: CYD dengue vaccine serotypes (1, 2, 3, 4).|Biological: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
  Outcome Measures:             Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain Before and Following Injection (Inj.) With CYD Dengue Tetravalent Vaccine|Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain During the Follow-up Period|Percentage of Participants With Antibody Titers >= 10 (1/Dil) Against Each Serotypes of the Parental Dengue Virus Strains Following Inj. With CYD Dengue Tetravalent Vaccine|Percentage of Participants With Antibody Titers >= 10 (1/Dil) Against Each Serotypes of the Parental Dengue Virus Strains Following Inj. With CYD Dengue Tetravalent Vaccine During the Follow-up Period|Percentage of Participants With Solicited Inj. Site Reactions Following Any and Each Inj. With CYD Dengue Tetravalent Vaccine|Percentage of Participants With Solicited Systemic Reactions Following Any and Each Inj. With CYD Dengue Tetravalent Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          2 Years to 45 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   180
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD22|2014-001709-41
  Start Date:                   March 2009
  Primary Completion Date:      August 2014
  Completion Date:              December 2014
  First Posted:                 April 3, 2009
  Results First Posted:         July 24, 2019
  Last Update Posted:           April 5, 2022
  Locations:                    Sanofi Pasteur Investigational Site, Long Xuyên, An Giang Province, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00875524

Study 176:
  NCT Number:                   NCT00880893
  Title:                        Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus|Dengue Diseases
  Interventions:                Biological: CYD Dengue vaccine|Biological: NaCl + influenza virus or hepatitis A vaccine
  Outcome Measures:             Percentage of All Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo|Percentage of Participants by Age Group (2-11 Years, 12-17 Years, 18-45 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or Placebo|Percentage of All Participants Who Achieved Seropositivity Against Each of the Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants by Age Group (2-11 Years, 12-17 Years, 18-45 Years) Who Achieved Seropositivity Against Each of the Dengue Virus Serotypes Before and After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants by Age Group (2-11 Years, 12-17 Years, 18-45 Years) Who Achieved Seropositivity Against at Least 1, 2, 3, or 4 of the Dengue Virus Serotypes Before and After the Third Vaccination With CYD Dengue Vaccine or Placebo|Geometric Mean Titers (GMTs) of Antibodies in All Participants Against Each Serotype With the Parental Dengue Virus Strain Before and Following Each Vaccination With CYD Dengue Vaccine or Placebo|GMTs of Antibodies by Age Groups (2-11 Years, 12-17 Years, 18-45 Years) Against Each Serotype With the Parental Dengue Virus Strain Before and Following the Third Vaccination With CYD Dengue Vaccine|Percentage of Participants Aged 2 to 11 Years Who Achieved Seropositivity Against Each of the Dengue Virus Serotypes Before and up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants Aged 12 to 17 Years Old Who Achieved Seropositivity Against Each of the Dengue Virus Serotypes Before and up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants Aged 18 to 45 Years Who Achieved Seropositivity Against Each of the Dengue Virus Serotypes Before and up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants Aged 2 to 11 Years Old Who Achieved Seropositivity Against At Least 1, 2, 3, or 4 of the Dengue Virus Serotypes Before and After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants Aged 12 to 17 Years Old Who Achieved Seropositivity Against at Least 1, 2, 3, or 4 of the Dengue Virus Serotypes Before and After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants Aged 18 to 45 Years Old Who Achieved Seropositivity Against at Least 1, 2, 3, or 4 of the Dengue Virus Serotypes Before and After the Third Vaccination With CYD Dengue Vaccine or Placebo|GMTs of Antibodies in Participants 2 to 11 Years Old Against Each Serotype With the Parental Dengue Virus Strain Before and Following the Third Vaccination With CYD Dengue Vaccine|GMTs of Antibodies in Participants 12 to 17 Years Old Against Each Serotype With the Parental Dengue Virus Strain Before and Following the Third Vaccination With CYD Dengue Vaccine or Placebo|GMTs of Antibodies in Participants 18 to 45 Years Old Against Each Serotype With the Parental Dengue Virus Strain Before and Following the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 11 Years) Immune to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 11 Years) Naïve to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 12 to 17 Years) Immune to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 12 to 17 Years) Naïve to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 18 to 45 Years) Immune to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 18 to 45 Years) Naïve to Dengue at Baseline Who Are Seropositive for Each of the Dengue Virus Serotypes up to 4 Years After the Third Vaccination With CYD Dengue Vaccine or Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          2 Years to 45 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   1198
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD28|2014-001713-26
  Start Date:                   April 7, 2009
  Primary Completion Date:      October 2014
  Completion Date:              October 14, 2014
  First Posted:                 April 14, 2009
  Results First Posted:         July 29, 2019
  Last Update Posted:           March 21, 2022
  Locations:                    Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00880893

Study 177:
  NCT Number:                   NCT04989673
  Title:                        Materno-fetal Consequences of Symptomatic Dengue in Pregnant Wowen in French Guiana
  Acronym:                      CMFdeng
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Pregnancy Preterm|Women|Fever|Parturition; Precipitate|Infant, Newborn
  Interventions:                Other: Biological sampling and collection (serum)|Other: Biological sampling and collection (placenta)|Other: Questionnaire|Other: Data collection
  Outcome Measures:             Prematurity rate|Threatened Premature Delivery (PAD) rate in each group|Fetal hypotrophy rate|Low birth weight|Postpartum hemorrhage rate|Rate of preeclampsia|Rate of eclampsia|Rate of fetal death in utero|Spontaneous abortion rate
  Sponsor/Collaborators:        Centre Hospitalier de Cayenne|Centre Hospitalier de Kourou|Centre Hospitalier de l'Ouest Guyanais|Centres de Protection Maternelle Infantile Cayenne, Kourou et Saint-Laurent du Maroni|Private physicians Cayenne, Kourou et Saint-Laurent du Maroni|Private midwife Cayenne, Kourou et Saint-Laurent du Maroni
  Gender:                       Female
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   628
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Prospective
  Other IDs:                    CMFdeng
  Start Date:                   July 11, 2012
  Primary Completion Date:      February 12, 2015
  Completion Date:              July 11, 2015
  First Posted:                 August 4, 2021
  Results First Posted:         
  Last Update Posted:           August 4, 2021
  Locations:                    General Hospital of Cayenne, Cayenne, French Guiana
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04989673

Study 178:
  NCT Number:                   NCT04722627
  Title:                        Study of AT-752 in Healthy Subjects
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: AT-752|Drug: Placebo
  Outcome Measures:             Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events|Pharmacokinetics (PK) of AT-752 of single and multiple ascending oral doses|Effect of food on Pharmacokinetics (PK) of AT-752 of a single oral dose
  Sponsor/Collaborators:        Atea Pharmaceuticals, Inc.
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   65
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    AT-02A-001
  Start Date:                   March 9, 2021
  Primary Completion Date:      November 14, 2021
  Completion Date:              November 14, 2021
  First Posted:                 January 25, 2021
  Results First Posted:         
  Last Update Posted:           October 17, 2022
  Locations:                    Atea Study Site, Melbourne, Victoria, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04722627

Study 179:
  NCT Number:                   NCT00788151
  Title:                        Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue Virus|Dengue Fever|Dengue Hemorrhagic Fever|Dengue Diseases
  Interventions:                Biological: CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|Biological: Pneumococcal polysaccharide vaccine
  Outcome Measures:             Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 5 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 6 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 11 Years) Seropositive for Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 5 Years) Seropositive for Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 6 to 11 Years) Seropositive for Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 11 Years) Seropositive for Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 5 Years) Seropositive for Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 6 to 11 Years) Seropositive for Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 11 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 2 to 5 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine or Placebo|Percentage of Participants (Aged 6 to 11 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Each Vaccination With CYD Dengue Vaccine|Percentage of Participants (Aged 2 to 11 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine|Percentage of Participants (Aged 2 to 5 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine|Percentage of Participants (Aged 6 to 11 Years) Seropositive for at Least One, Two, Three or Four Dengue Virus Serotypes Before and After Vaccination With CYD Dengue Vaccine|Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype in Dengue-Immune Participants Before and After Injection With CYD Dengue Vaccine or Placebo|Percentage of Participants Seropositive for Yellow Fever Antibodies Before and Following First Injection With CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Yellow Fever Virus Before and Following First Injection With CYD Dengue Vaccine or Placebo|GMTs of Antibodies Against Each Dengue Virus Serotype Before and Following Injection With CYD Dengue Vaccine or Placebo
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          2 Years to 11 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CYD24|2014-001711-40
  Start Date:                   September 26, 2008
  Primary Completion Date:      February 16, 2010
  Completion Date:              August 16, 2010
  First Posted:                 November 10, 2008
  Results First Posted:         July 29, 2019
  Last Update Posted:           April 5, 2022
  Locations:                    Chulucanas Morropon, Piura, Peru
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00788151

Study 180:
  NCT Number:                   NCT03534245
  Title:                        Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                
  Outcome Measures:             Prevalence of symptomatic and inapparent dengue infection (serotypes 1-4) as detected semiannually via ELISA assay (binary outcome present/absent) over a three-year period in Kampong Speu in children aged 2-9 years old|Prevalence of Aedes aegypti salivary gland homogenate reactivity as detected by ELISA assay (binary outcome present/absent) during wet and dry seasons over a three-year period in Kampong Speu in children aged 2-9 years old|Western blot analysis of sera from participants with strongest ELISA positivity to Ae. aegypti whole salivary gland homogenate compared to Anopheles and Culex to assess cross-reactive immunogenicity to mosquito saliva versus specific Aedes marke...|Positive RT-PCR result for diagnosis of dengue, chikungunya, and Zika viruses (or IgM capture ELISAs for dengue as needed)|Geographic information system with all data components (mosquito catch sites, houses, schools) referenced by latitude and longitude in addition to a series of map layers (point maps, smoothed maps) to evaluate relationships between IgG intensity...|Seroconversion to Ae. aegypti salivary homogenate in relationship to season (wet versus dry) and collected time-dependent variables defined as mean and maximum rainfall, temperature and humidity inaddition to monthly fingerpricks to evaluate ...|Capture a minimum of 25 female Aedes aegypti mosquitoes for transcriptional comparison to LMVR-reared Aedes aegypti mosquitoes
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          2 Years to 9 Years   (Child)
  Phases:                       
  Enrollment:                   775
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    999918100|18-I-N100
  Start Date:                   July 1, 2018
  Primary Completion Date:      January 25, 2022
  Completion Date:              January 25, 2022
  First Posted:                 May 23, 2018
  Results First Posted:         
  Last Update Posted:           December 28, 2022
  Locations:                    Kampong Speu Referral Hospital, Chbar Mon, Kampong Speu, Cambodia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03534245

Study 181:
  NCT Number:                   NCT04839757
  Title:                        Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
  Acronym:                      DengueSEA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue|Vaccination|Seroprevalence|Infectious Disease
  Interventions:                
  Outcome Measures:             Dengue seroprevalence in the study population|Frequency of primary dengue fever|Temporal variation of the risk of dengue infection|Seroprevalence of Zika infection|Assessment of Dengvaxia® vaccine acceptability/characterization of intentions and attitudes
  Sponsor/Collaborators:        University Hospital Center of Martinique|Ecole des Hautes Etudes en Santé Publique|University of Marseille (UVE UMR IRD_190)|University Hospital Center of Guadeloupe|Observatoire Regional de la Sante Provence-Alpes-Côte d'Azur|Unité de Modélisation Marthématique des Maladies Infectieuses UMR 2000, Institut Pasteur|Institut de Recherche en Santé Publique, France
  Gender:                       All
  Age:                          9 Years to 17 Years   (Child)
  Phases:                       
  Enrollment:                   1400
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Cross-Sectional
  Other IDs:                    19_RIPH3_19|2019-A02114-53
  Start Date:                   June 3, 2021
  Primary Completion Date:      December 2022
  Completion Date:              February 2023
  First Posted:                 April 9, 2021
  Results First Posted:         
  Last Update Posted:           March 21, 2022
  Locations:                    Martinique University Hospital Center, Fort-de-france, Martinique
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04839757

Study 182:
  NCT Number:                   NCT01488890
  Title:                        Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Dengue|Dengue Fever|Dengue Hemorrhagic Fever|Yellow Fever
  Interventions:                Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|Biological: Yellow Fever
  Outcome Measures:             Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 3: Group 1 and Group 2|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 and Dose 2: Group 1 and Group 2|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1 In YF Non-Immune Participants: Group 1 and Group 2 (Pooled) and Group 3|Percentage of YF Non-Immune Participants With Seropositivity Against Each Dengue Virus Serotype Following Injection With CYD Dengue Vaccine Dose 1: Group 1 and Group 2 (Pooled) and Group 3|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)|Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Immune Participants)|Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype Following Each Injection With CYD Dengue Vaccine: Group 1, Group 2 and Group 3 (FV Non-Immune Participants)|Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine|Number of Participants Reporting Solicited Systemic Reactions (Fever, Headache, Malaise, Myalgia, Asthenia) Following Any Vaccination With CYD Dengue Vaccine (Administered With or Without Yellow Fever Vaccine) or Yellow Fever Vaccine
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   390
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    CYD51|U1111-1122-1892
  Start Date:                   December 6, 2011
  Primary Completion Date:      September 27, 2013
  Completion Date:              September 27, 2013
  First Posted:                 December 8, 2011
  Results First Posted:         June 14, 2019
  Last Update Posted:           March 24, 2022
  Locations:                    Alabaster, Alabama, United States|Sacramento, California, United States|Jacksonville, Florida, United States|Silver Spring, Maryland, United States|Springfield, Missouri, United States|Las Vegas, Nevada, United States|West Jordan, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01488890

Study 183:
  NCT Number:                   NCT00936429
  Title:                        Study of HBV-001 D1 in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever
  Interventions:                Biological: DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|Biological: Placebo for DEN1-80E
  Outcome Measures:             To determine the safety of the study vaccine formulations in healthy adult subjects by assessing adverse events and laboratory data|To assess the impact of vaccine dose level on immunogenicity determined by the levels of neutralizing antibodies and cell mediated immune responses
  Sponsor/Collaborators:        Hawaii Biotech, Inc.
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   16
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    HBV-001-C-101
  Start Date:                   July 2009
  Primary Completion Date:      July 2010
  Completion Date:              January 2011
  First Posted:                 July 10, 2009
  Results First Posted:         
  Last Update Posted:           February 7, 2011
  Locations:                    Saint Louis University, St. Louis, Missouri, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00936429

Study 184:
  NCT Number:                   NCT02016027
  Title:                        Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
  Acronym:                      CF2013
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Dengue
  Interventions:                Drug: Carica folia
  Outcome Measures:             Increase in platelet count|Increase in Red Blood Cell count
  Sponsor/Collaborators:        Fr Muller Homoeopathic Medical College
  Gender:                       All
  Age:                          18 Years to 25 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    carica 2013|NCD
  Start Date:                   September 2013
  Primary Completion Date:      December 2013
  Completion Date:              December 2013
  First Posted:                 December 19, 2013
  Results First Posted:         
  Last Update Posted:           December 19, 2013
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02016027

Study 185:
  NCT Number:                   NCT02831699
  Title:                        The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
  Acronym:                      Zik01
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Zika Virus Disease (Disorder)|Dengue|Chikungunya
  Interventions:                
  Outcome Measures:             The proportion of subjects that have confirmed Zika, Chikungunya, or Dengue (including co-infections) from the subjects presenting with fever and/or rash in southeastern Mexico.
  Sponsor/Collaborators:        Mexican Emerging Infectious Diseases Clinical Research Network|Secretaria de Salud, Mexico|National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          1 Year and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   600
  Funded Bys:                   Other|NIH
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    Zik01
  Start Date:                   June 21, 2016
  Primary Completion Date:      January 25, 2019
  Completion Date:              January 25, 2019
  First Posted:                 July 13, 2016
  Results First Posted:         
  Last Update Posted:           December 17, 2020
  Locations:                    Hospital General de Tapachula, Tapachula, Chiapas, Mexico|Hospital Regional de Alta Especialidad Ciudad Salud, Chiapas, Mexico|Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Clínica Hospital Dr. Roberto Nettel Flores, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Hospital General de Zona con Medicina Familiar No. 1, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Unidad de Medicina Familiar No. 11, Chiapas, Mexico|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02831699

Study 186:
  NCT Number:                   NCT05611710
  Title:                        Anakinra in Dengue With Hyperinflammation ( AnaDen )
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue|Dengue With Warning Signs|Severe Dengue|Anakinra|Immuno-suppressants|Anti-inflammatory Agents|Macrophage Activated Syndrome|Hyperinflammatory Syndrome|Cytokine Storm
  Interventions:                Drug: Placebo|Drug: Anakinra
  Outcome Measures:             Change in modified Sequential Organ Failure Assessment score (mSOFA core, modified for limited resource settings and dengue) within 4 days|Mortality|Change in modified Sequential Organ Failure Assessment score (mSOFA core, modified for limited resource settings and dengue) at day 7|Number of days treated in Intensive care unit (ICU)|Number of days treated in hospital|Number of participants with Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) per participant|Change in Platelets count|Change in neutrophils count|Change of ALT levels|Change of Ferritin levels|Change of CRP levels|Time to normalization of blood levels|Platelet nadir|Fever clearance time|Duration of viraemia|Area under the curve (AUC) of the serial viral load measurements during hospital stay|Patients' quality of life questionnaire score
  Sponsor/Collaborators:        Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
  Gender:                       All
  Age:                          12 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   160
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    60DX
  Start Date:                   December 31, 2022
  Primary Completion Date:      December 31, 2025
  Completion Date:              December 31, 2027
  First Posted:                 November 10, 2022
  Results First Posted:         
  Last Update Posted:           November 10, 2022
  Locations:                    Hospital for Tropical Diseases, Ho Chi Minh, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05611710

Study 187:
  NCT Number:                   NCT01542632
  Title:                        A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy
  Interventions:                Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Biological: TDV New Formulation|Drug: Placebo|Drug: New Formulation Placebo
  Outcome Measures:             Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported|Number of Participants With at Least 1 Adverse Event Following Either Vaccine Dose|Number of Participants With at Least 1 Adverse Events Related to TDV Following Either Vaccine Dose|Rate of Seroconversion to Each of Four Dengue Serotypes|Percentage of Participants With Serotype-Specific TDV Viral RNA Detected After First and Second Vaccinations|Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   140
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    INV-DEN-104|U1111-1177-8166
  Start Date:                   February 1, 2012
  Primary Completion Date:      January 1, 2014
  Completion Date:              January 10, 2014
  First Posted:                 March 2, 2012
  Results First Posted:         January 9, 2015
  Last Update Posted:           July 18, 2019
  Locations:                    Heart Center of the Rockies, Fort Collins, Colorado, United States|University of Texas Medical Branch, Galveston, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01542632

Study 188:
  NCT Number:                   NCT01868399
  Title:                        Pilot Survey of Dengue Fever in Solomon Islands
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Arbovirus Infections
  Interventions:                
  Outcome Measures:             Dengue fever|Co-infection and interplay of dengue-like pathogens
  Sponsor/Collaborators:        Kaohsiung Medical University Chung-Ho Memorial Hospital|Ministry of Foreign Affairs, Republic of China, TAIWAN|Ministry of Health and Medical Services, Solomon Islands|National Referral Hospital
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   2200
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    KMUH-IRB-20120080
  Start Date:                   March 22, 2013
  Primary Completion Date:      December 31, 2016
  Completion Date:              December 31, 2016
  First Posted:                 June 4, 2013
  Results First Posted:         
  Last Update Posted:           March 7, 2017
  Locations:                    Tropical Medicine center, Kaohsiung city, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01868399

Study 189:
  NCT Number:                   NCT04434846
  Title:                        Sylvatic Transmission and Reservoir Potential of Zika, Dengue, and Chikungunya Viruses of Co-located Humans and Long-tailed Macaques in Thailand and Cambodia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Fever|Zika|Vector-Borne Diseases|Chikungunya
  Interventions:                
  Outcome Measures:             Assessment of seroprevalence via screening ELISA and/or PRNTSO titers for ZIKV, DENV, and CHIKV in Cambodian adults.|Assessment of seroprevalence via screening ELISA and/or PRNTSO titers for ZIKV, DENV, and CHIKV in Cambodian macaques as compared to humans.|Comparative assessment of seroprevalence via PRNTSO titers for ZIKV, DENV, and CHIKV in Cambodian adults and macaques to that of Thai adults and macaques.|Assessment of reactivity to salivary gland homogenate of Aedes aegypti as detected by ELISA or western blot in human and macaque sera.
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       
  Enrollment:                   300
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Cross-Sectional
  Other IDs:                    999920054|20-I-N054
  Start Date:                   February 8, 2021
  Primary Completion Date:      May 7, 2021
  Completion Date:              May 7, 2021
  First Posted:                 June 17, 2020
  Results First Posted:         
  Last Update Posted:           December 16, 2021
  Locations:                    National Malaria Center, Phnom Penh, Cambodia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04434846

Study 190:
  NCT Number:                   NCT04035278
  Title:                        A Phase 1 Safety Study of Dengusiil in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Prevention of Dengue Fever
  Interventions:                Biological: Dengusiil|Biological: Placebo
  Outcome Measures:             Solicited local and systemic reactions|Occurrence, severity, and relatedness to vaccination of unsolicited adverse events|Occurrence, severity, and relatedness to vaccination of serious adverse events|Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings|Proportion of participants with clinically significant physical examination and vital signs findings|Proportion of participants with seroconversion for DENV-1 to 4 virus neutralization antibodies (PRNT50) titer|The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies|Geometric mean titers (GMTs) of DENV-1 to 4 virus neutralization antibodies|GMTs of DENV-1 to 4 virus neutralization antibodies|Proportion of participants with viremia for each of DENV-1 to 4
  Sponsor/Collaborators:        Serum Institute of India Pvt. Ltd.|PPD Australia Pty Ltd
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   60
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    Dengusiil-01
  Start Date:                   December 17, 2019
  Primary Completion Date:      June 11, 2021
  Completion Date:              June 11, 2021
  First Posted:                 July 29, 2019
  Results First Posted:         
  Last Update Posted:           August 17, 2022
  Locations:                    CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04035278

Study 191:
  NCT Number:                   NCT04377451
  Title:                        Metformin in Dengue With Obesity
  Acronym:                      MeDO
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue|Viral Infection|Metformin|Anti-inflammatory Agents|Obesity|Overweight
  Interventions:                Drug: Metformin
  Outcome Measures:             Number of adverse events|Fever clearance time|Platelet nadir|Percentage increase in hematocrit from baseline|Percentage change in endothelial and lipid-inflammatory parameters|Changes in virological parameters|Changes in number of immune cells
  Sponsor/Collaborators:        Oxford University Clinical Research Unit, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
  Gender:                       All
  Age:                          10 Years to 30 Years   (Child, Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   120
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    56DX
  Start Date:                   July 27, 2020
  Primary Completion Date:      December 1, 2023
  Completion Date:              December 1, 2024
  First Posted:                 May 6, 2020
  Results First Posted:         
  Last Update Posted:           July 1, 2022
  Locations:                    Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04377451

Study 192:
  NCT Number:                   NCT03831503
  Title:                        A Study of INO-A002 in Healthy Dengue Virus-naive Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Healthy Volunteers
  Interventions:                Biological: INO-A002|Device: CELLECTRA® 2000|Device: Dengue Fever Antibodies (IgG)
  Outcome Measures:             Evaluate the safety of escalating doses of INO-A002 with Hylenex® administered IM followed by electroporation with the CELLECTRA® 2000 device in healthy adult volunteers.|Evaluate the tolerability of escalating doses of INO-A002 with Hylenex® administered IM followed by electroporation with the CELLECTRA® 2000 device in healthy adult volunteers.|Determine the maximum serum concentration (Cmax) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation.|Determine the minimum serum concentration (Cmin) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation.|Determine the Area Under the Curve (AUC0-t) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation
  Sponsor/Collaborators:        University of Pennsylvania|Inovio Pharmaceuticals
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    832135
  Start Date:                   February 7, 2019
  Primary Completion Date:      October 3, 2022
  Completion Date:              October 3, 2022
  First Posted:                 February 5, 2019
  Results First Posted:         
  Last Update Posted:           November 8, 2022
  Locations:                    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03831503

Study 193:
  NCT Number:                   NCT02887482
  Title:                        GLS-5700 in Dengue Virus Seropositive Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Healthy|Zika
  Interventions:                Biological: GLS-5700|Biological: Placebo
  Outcome Measures:             Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody titers to Zika envelope|Neutralizing antibody response against Zika virus|T cell response|Mean change from baseline for safety measures and adverse events
  Sponsor/Collaborators:        GeneOne Life Science, Inc.|Inovio Pharmaceuticals
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   160
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    Zika-002
  Start Date:                   August 2016
  Primary Completion Date:      October 2017
  Completion Date:              June 2018
  First Posted:                 September 2, 2016
  Results First Posted:         
  Last Update Posted:           January 20, 2022
  Locations:                    Clinical Research of Puerto Rico, San Juan, Puerto Rico|Fundacion De Investigation, San Juan, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02887482

Study 194:
  NCT Number:                   NCT01226173
  Title:                        Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Mass Screening
  Interventions:                Device: Bio-Rad Platelia Dengue NS1 Ag test
  Outcome Measures:             Number of blood donors with repeatedly reactive Platelia Dengue NS1 Ag test results.|Number of blood donors with PCR and/or TMA confirmed positive dengue test results.
  Sponsor/Collaborators:        Bio-Rad Laboratories|American National Red Cross|Centers for Disease Control and Prevention
  Gender:                       All
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   182353
  Funded Bys:                   Industry|Other|U.S. Fed
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Prospective
  Other IDs:                    ARC IRB Protocol # 2009-037|1RC2HL101632-01
  Start Date:                   March 2010
  Primary Completion Date:      August 2012
  Completion Date:              August 2012
  First Posted:                 October 22, 2010
  Results First Posted:         
  Last Update Posted:           September 24, 2012
  Locations:                    Community Blood Centers of Florida, Inc., Lauderhill, Florida, United States|American Red Cross, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01226173

Study 195:
  NCT Number:                   NCT01511250
  Title:                        Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy
  Interventions:                Biological: TDV|Biological: Placebo
  Outcome Measures:             Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination Dose by Severity|Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (In Clinic Assessment) Following Either Vaccination Dose by Severity|Number of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination Dose by Severity|Number of Participants With Any Solicited AE Following Either Vaccination Dose|Number of Participants With at Least One Unsolicited AE Following Either Vaccination Dose by Severity|Seropositivity Rate to Each of the Four Dengue Serotypes at Day 120|Part I: Number of Participants Positive for Vaccine Viremia for Each of Four Vaccine Strain Serotypes After the Each Vaccination|Part I: Duration of Vaccine Viremia|Part I: Titers of Vaccine Viremia|Seropositivity Rate to Each of the Four Dengue Serotypes|Seroconversion Rate to Each of the Four Dengue Serotypes|Geometric Mean Neutralizing Antibody Titers (GMTs) of All Four Dengue Serotypes|Geometric Mean Fold Rise (GMFR) of Dengue Neutralizing Antibody Titers for Each of the 4 Dengue Serotypes|Number of Participants With Confirmed Dengue Fever
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Months to 45 Years   (Child, Adult)
  Phases:                       Phase 2
  Enrollment:                   360
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    INV-DEN-203
  Start Date:                   November 16, 2011
  Primary Completion Date:      April 1, 2016
  Completion Date:              April 15, 2016
  First Posted:                 January 18, 2012
  Results First Posted:         March 27, 2018
  Last Update Posted:           July 18, 2019
  Locations:                    Program For The Study and Control of Tropical Diseases, Medellin, Colombia|Ponce School of Medicine, CAIMED Center, Ponce, Puerto Rico|University of Puerto Rico School of Medicine, San Juan, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|National University Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Faculty of Tropical Medicine, Mahidol University, Bangkok, Krung Thep Maha Nakhon, Thailand|Phramongkutklao Hospital, Bangkok, Krung Thep Maha Nakhon, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01511250

Study 196:
  NCT Number:                   NCT04480736
  Title:                        A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
  Acronym:                      
  Status:                       Suspended
  Study Results:                No Results Available
  Conditions:                   Healthy
  Interventions:                Drug: Placebo|Drug: JNJ-64281802 High dose|Drug: JNJ-64281802 Medium dose|Drug: JNJ-64281802 Low dose|Drug: JNJ-64281802 Dosing Regimen X|Drug: JNJ-64281802 Dosing Regimen Y|Drug: JNJ-64281802 Dosing Regimen Z
  Outcome Measures:             Area Under the DENV-1 RNA VL-concentration time Curve (VL AUC) from Immediately before Inoculation (Baseline on Day 1) until Day 29|Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability|Number of Participants with Clinically Significant Abnormalities in Physical Examination|Number of Participants with Clinically Significant Abnormalities in Vital Signs|Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)|Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters|Number of Participants with DENV Infection Associated AEs|Area Under the log10-transformed DENV 1 RNA VL Concentration-time Curves from Immediately before Inoculation (Baseline on Day 1) until Day 29|Peak of Detectable DENV-1 RNA|Duration of Detectable DENV-1 RNA|Time to First Onset of Detectable DENV-1 RNA|Number of Participants with Detectable DENV-1 RNA|Area Under the Viremia Curves from Immediately before Inoculation (Baseline on Day 1) until Day 29|Area Under the log10-transformed Viremia Curves|Peak of Detectable Viremia Level|Duration of Detectable Viremia|Time to First Onset of Detectable Viremia|Number of Participants with Detectable Viremia|Maximum Observed Analyte Concentration (Cmax) of JNJ-64281802|Minimum Observed Analyte Concentration (Cmin) of JNJ-64281802|Trough Plasma Analyte Concentration (Ctrough) of JNJ-64281802|Average Analyte Concentration (Cavg) of JNJ-64281802|Time to Reach Maximum Observed Plasma Analyte Concentration (Tmax) of JNJ-64281802|Fluctuation Index (FI) of JNJ-64281802|Area Under the Curve from Time Zero to End of Dosing Interval (AUCtau)|Number of Participants with Anti DENV-1 Total IgM and IgG Antibody Titers|Time to First Onset of Anti-DENV-1 Total IgM and IgG Antibody Titers
  Sponsor/Collaborators:        Janssen Research & Development, LLC
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   54
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
  Other IDs:                    CR108700|64281802DNG2001
  Start Date:                   July 28, 2020
  Primary Completion Date:      January 31, 2024
  Completion Date:              April 8, 2024
  First Posted:                 July 21, 2020
  Results First Posted:         
  Last Update Posted:           April 4, 2022
  Locations:                    SUNY Upstate Medical University, Syracuse, New York, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04480736

Study 197:
  NCT Number:                   NCT02948829
  Title:                        Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy Volunteers
  Interventions:                Biological: TDV
  Outcome Measures:             Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination|Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination|Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination|Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination|Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination Post Second Vaccination Assessed by Country|Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination Post Second Vaccination, by Dengue Baseline Seropositivity Status|Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, by Country|Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1 Month Post First; Pre-second Vaccination; 1 and 6 Months Post Second Vaccination, by Dengue Baseline Seropositivity Status|Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age|Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age|Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Proteins at 1 Month Post First, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination|Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins,1 Month Post First, Pre Second Vaccination;1 and 6 Months Post Second Vaccination, by Country|Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Proteins at 1 Month Post First, Pre Second Vaccination,1 and 6 Months Post Second Vaccination, by Dengue Baseline Seropositivity Status|Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years|Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years|Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years|Percentage of Participants Experiencing Unsolicited Adverse Events (AE)|Percentage of Participants With Medically Attended AEs (MAAEs)|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Virologically Confirmed Dengue
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          4 Years to 16 Years   (Child)
  Phases:                       Phase 2
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    DEN-313|U1111-1184-1893
  Start Date:                   April 3, 2017
  Primary Completion Date:      October 16, 2017
  Completion Date:              December 14, 2020
  First Posted:                 October 28, 2016
  Results First Posted:         April 26, 2021
  Last Update Posted:           July 25, 2022
  Locations:                    CEVAXIN, Panama, Panama|Research Institute for Tropical Medicine, Muntinlupa, Philippines
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02948829/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02948829/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02948829

Study 198:
  NCT Number:                   NCT02747927
  Title:                        Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
  Acronym:                      TIDES
  Status:                       Active, not recruiting
  Study Results:                Has Results
  Conditions:                   Healthy Volunteers
  Interventions:                Drug: Placebo|Biological: Tetravalent Dengue Vaccine (TDV)
  Outcome Measures:             Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype|VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Each Dengue Serotype|VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seronegative at Baseline|VE of Two Doses of TDV in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype in Participants Dengue Seropositive at Baseline|VE of Two Doses of TDV in Preventing Hospitalization Due to Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype|VE of Two Doses of TDV in Preventing Virologically-Confirmed Severe Dengue Fever Induced by Any Dengue Serotype|Percentage of Participants With Solicited Local Injection Site Adverse Events (AEs) by Severity in the Safety Subset|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity in the Safety Subset|Severity of Solicited Systemic Adverse Events (AEs) in the Safety Subset|Percentage of Participants With Any Unsolicited Adverse Events (AEs) in the Safety Subset|Percentage of Participants With Serious Adverse Events (SAEs) During Parts 1 and 2|Percentage of Participants With Fatal SAEs and SAEs Related to Study Drug During the First and Second Half of Part 3|Percentage of Participants With a Seropositive Response for Each of the Four Dengue Serotypes in the Immunogenicity Subset|Percentage of Participants With a Seropositive Response for Multiple Dengue Serotypes in the Immunogenicity Subset|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four Dengue Serotypes in the Immunogenicity Subset
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          4 Years to 16 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   20099
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-301|U1111-1166-8401|PHRR150522-001010|2018-003979-34
  Start Date:                   September 7, 2016
  Primary Completion Date:      July 11, 2018
  Completion Date:              March 21, 2024
  First Posted:                 April 22, 2016
  Results First Posted:         August 18, 2021
  Last Update Posted:           August 1, 2022
  Locations:                    Associacao Obras Sociais Irma Dulce Hospital Santo Antonio, Salvador, Bahia, Brazil|Universidade Federal Do Espirito Santo Hospital Universitario Cassiano Antonio de Moraes HUCAM, Vitoria, Espirito Santo, Brazil|Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil|Centro de Estudos e Pesquisa em Molestias Infecciosas LTDA (CPCLIN), Cidade Alta, Natal - RN, Brazil|Centro de Atencion e Investigacion Medica S.A - CAIMED - Aguazul - PPDS-PV, Aguazul, Casanare, Colombia|Centro de Atencion e Investigacion Medica S.A - CAIMED - Yopal - PPDS-PV, Yopal, Casanare, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED - Acacias - PPDS-PV, Acacias, Meta, Colombia|Centro de Estudios em Infectologia Pediatrica SAS (CEIP S.A.S), Cali, San Fernando, Colombia|Hospital Maternidad Nuestra Senora de Altagracia, Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic|Caimed Dominicana S.A.S - PPDS-PV, Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic|Universidad Nacional Autonoma de Nicaragua, Leon, Nicaragua|Centro De Vacunacion Internacional, S.A. (Cevaxin), Ciudad de Panama, Panama|Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede 24 de Diciembre, Panama, Panama|Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede Plaza Carolina, Panama, Panama|Centro De Vacunacion Internacional, S.A.(Cevaxin) - La Chorrera, Panama, Panama|Dela Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines|Philippines-AFRIMS Virology Research Unit, Cebu City, Cebu, Philippines|University of the Philippine Manila, Ermita, Philippines|Las Pinas Health Center A, Las Pinas, Philippines|Las Pinas Health Center D, Las Pinas, Philippines|Research Institute for Tropical Medicine, Muntinlupa, Philippines|Lady Ridgeway Hospital for Children, Colombo, Sri Lanka|Colombo South Teaching Hospital, Dehiwala, Sri Lanka|Negombo General Hospital, Negombo, Sri Lanka|Colombo North Teaching Hospital, Ragama, Sri Lanka|The Hospital for Tropical Diseases, Bangkok, Krung Thep Maha Nakhon, Thailand|Phramongkutklao Hospital, Bangkok, Krung Thep Maha Nakhon, Thailand|Srinagarind Hospital, Khon Kaen, Thailand
  Study Documents:              "Study Protocol: Redacted Protocol Part 1", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_000.pdf|"Study Protocol: Redacted Protocol Part 2", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_001.pdf|"Study Protocol: Redacted Protocol Part 3", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/Prot_002.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02747927/SAP_003.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02747927

Study 199:
  NCT Number:                   NCT03525119
  Title:                        Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy Volunteers
  Interventions:                Biological: TDV|Biological: HAV Vaccine|Biological: TDV Placebo|Biological: HAV Vaccine Placebo
  Outcome Measures:             Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30|Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 30 and Day 120 in Participants HAV/DENV-naive at Baseline|Percentage of Participants HAV/DENV-naive at Baseline Who Are Seropositive for Each of the 4 Dengue Serotypes at Day 30 and Day 120|Geometric Mean Concentrations (GMC) of Anti-HAV Antibodies at Day 30 in Participants HAV/DENV-naive at Baseline|Percentage of Participants With Solicited (Local Injection) Site Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination|Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With Medically Attended AEs (MAAEs)
  Sponsor/Collaborators:        Takeda
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   900
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    DEN-314|2017-001071-23|U1111-1192-7761|18/NW/0008
  Start Date:                   May 16, 2018
  Primary Completion Date:      October 3, 2018
  Completion Date:              July 9, 2019
  First Posted:                 May 15, 2018
  Results First Posted:         July 13, 2020
  Last Update Posted:           August 19, 2022
  Locations:                    Synexus - Midlands, Edgbaston, Birmingham, United Kingdom|Synexus - Lancashire, Chorley, Lancashire, United Kingdom|Synexus - Merseyside, Waterloo, Liverpool, United Kingdom|Royal Hallamshire Hospital, Sheffield, Yorkshire, United Kingdom|Synexus - Wales, Cardiff, United Kingdom|Synexus - Scotland, Glasgow, United Kingdom|North East Clinical Research Centre, Hexham General Hospital, Hexham, United Kingdom|Synexus - Manchester, Manchester, United Kingdom|Synexus - Thames Valley, Reading, United Kingdom|North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees, Stockton-on-Tees, United Kingdom
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03525119

Study 200:
  NCT Number:                   NCT02305732
  Title:                        A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
  Acronym:                      TRUE
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Chikungunya Virus|Dengue Virus
  Interventions:                Biological: INTERCEPT Platelets
  Outcome Measures:             The Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets.|The Proportion of Patients With a Confirmed Case of Transfusion-transmitted Chikungunya Virus or Dengue Infection|The Proportion of Patients With Any Transfusion Reactions|The Proportion of Patients With Any Unrelated Adverse Event|The Proportion of Transfused INTERCEPT Platelet Components Associated With Any Transfusion Reactions and/or Unrelated Adverse Event
  Sponsor/Collaborators:        Cerus Corporation|American National Red Cross
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   90
  Funded Bys:                   Industry|Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    CLI 00108
  Start Date:                   March 2015
  Primary Completion Date:      May 2016
  Completion Date:              May 2016
  First Posted:                 December 3, 2014
  Results First Posted:         October 30, 2018
  Last Update Posted:           October 30, 2018
  Locations:                    Hospital General Menonita de Aibonito, Aibonito, Puerto Rico|Hospital General Menonita de Caguas, Caguas, Puerto Rico|Hospital General Menonita de Cayey, Cayey, Puerto Rico|Center Hospital Manati, Manati, Puerto Rico|Hospital San Lucas Ponce, Ponce, Puerto Rico|Hospital La Concepcion San German, San German, Puerto Rico|Centro Cardiovascular de Puerto Rico and the Caribbean, San Juan, Puerto Rico|Veteran Administration, San Juan, Puerto Rico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02305732

Study 201:
  NCT Number:                   NCT00938379
  Title:                        Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Malaria|Dengue|Japanese Encephalitis
  Interventions:                Drug: 20% deet insect repellent|Drug: placebo control
  Outcome Measures:             reduction in malaria incidence|Reduction in Japanese Encephalitis and / or Dengue infections
  Sponsor/Collaborators:        London School of Hygiene and Tropical Medicine|Population Services International
  Gender:                       All
  Age:                          5 Years to 70 Years   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   5000
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    NHLAO1
  Start Date:                   July 2009
  Primary Completion Date:      December 2010
  Completion Date:              June 2011
  First Posted:                 July 13, 2009
  Results First Posted:         
  Last Update Posted:           July 14, 2009
  Locations:                    Rural villages in Attepu and Sekong Provinces, Laos PDR, Pakse, Attepu, Lao People's Democratic Republic
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00938379

Study 202:
  NCT Number:                   NCT04486638
  Title:                        Dengvaxia US Pregnancy Registry
  Acronym:                      DNG00044
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Dengue Virus Infection
  Interventions:                Biological: Dengue Tetravalent Vaccine, Live
  Outcome Measures:             Percentage of pregnant women with maternal adverse events|Pecentage of women with obstetrical adverse events|Percentage of participants with adverse pregnancy outcome|Percentage of offsprings with neonatal adverse events|Percentage of offsprings with infant adverse events
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   500
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    DNG00044
  Start Date:                   July 31, 2022
  Primary Completion Date:      November 2026
  Completion Date:              November 2026
  First Posted:                 July 24, 2020
  Results First Posted:         
  Last Update Posted:           June 21, 2022
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04486638

Study 203:
  NCT Number:                   NCT04170140
  Title:                        Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update
  Acronym:                      DNG00042
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue Virus Infection
  Interventions:                Other: No intervention
  Outcome Measures:             Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materials|Healthcare professionals' knowledge of Dengvaxia product information
  Sponsor/Collaborators:        Sanofi Pasteur, a Sanofi Company|Sanofi
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   300
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Cross-Sectional
  Other IDs:                    DNG00042|U1111-1233-9599
  Start Date:                   January 7, 2020
  Primary Completion Date:      March 5, 2020
  Completion Date:              March 5, 2020
  First Posted:                 November 20, 2019
  Results First Posted:         
  Last Update Posted:           April 25, 2022
  Locations:                    Real World Evidence Solutions IQVIA, La Defense, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04170140

Study 204:
  NCT Number:                   NCT01973855
  Title:                        Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Viral Haemorrhagic Fever|Dengue Fever
  Interventions:                Drug: Western Medicine|Drug: TCM and Western Medicine
  Outcome Measures:             Mortality|Safety outcome
  Sponsor/Collaborators:        Guangzhou 8th People's Hospital
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    2012ZX10004301-003
  Start Date:                   January 2012
  Primary Completion Date:      March 2015
  Completion Date:              December 2015
  First Posted:                 November 1, 2013
  Results First Posted:         
  Last Update Posted:           November 1, 2013
  Locations:                    Xi 'an eighth people's hospital, XiAn, Shanxi, China
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01973855

Study 205:
  NCT Number:                   NCT02059122
  Title:                        Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Infectious Diseases
  Interventions:                
  Outcome Measures:             number of subjects with positive result
  Sponsor/Collaborators:        InBios International, Inc.
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   911
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Other
  Other IDs:                    DSC0202/0093
  Start Date:                   April 2011
  Primary Completion Date:      April 2018
  Completion Date:              April 2018
  First Posted:                 February 11, 2014
  Results First Posted:         
  Last Update Posted:           May 15, 2018
  Locations:                    Universidad Nacional de Misiones (UNaM), Posadas, Argentina|Leptospira Laboratory, Bridgetown, Barbados|Universidad de Antioquia, Medellin, Colombia|Ruhuna University, Galle, Sri Lanka|AFRIMS, Bangkok, Thailand
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02059122

Study 206:
  NCT Number:                   NCT04350905
  Title:                        Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Vector Borne Diseases
  Interventions:                Other: Mosquito Feeding
  Outcome Measures:             Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin|Measurement of Changes in the Adaptive Immune Response and Cellular Recruitment in the Skin of Bitten Versus Unbitten Skin After Sixth and Final Feeding in Each Vector Group.|Flow Cytometry Analysis of PBMCs Collected Day 0 (Baseline) and Days 2 and 14 After Feeding for Saliva-specific T-cells
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   42
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    999920053|20-I-N053
  Start Date:                   October 27, 2020
  Primary Completion Date:      April 9, 2021
  Completion Date:              April 9, 2021
  First Posted:                 April 17, 2020
  Results First Posted:         April 12, 2022
  Last Update Posted:           April 12, 2022
  Locations:                    Kampong Speu Referral Hoispital, Chbar Mon, Cambodia
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04350905/Prot_SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT04350905

Study 207:
  NCT Number:                   NCT01099852
  Title:                        Cohort of Patients Infected by an Arbovirus
  Acronym:                      CARBO
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Fever|Dengue|Chikungunya|Zika Virus
  Interventions:                Other: biological sample collection|Other: Quality of life Questionnaire EuroQol®|Other: Health Assessment Questionnaire - MDHAQ and RAPID3|Other: Neuropathic Pain Questionnaire (DN4)
  Outcome Measures:             Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.|Specific complications: Onset of hemorrhagic fever (dengue) Onset of encephalitis or neurological disorders (West Nile virus, Japanese encephalitis, Zika virus) Onset of chronic form (Chikungunya)
  Sponsor/Collaborators:        University Hospital Center of Martinique|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane
  Gender:                       All
  Age:                          8 Days and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   1377
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    09/B/08
  Start Date:                   June 2010
  Primary Completion Date:      July 2021
  Completion Date:              July 2021
  First Posted:                 April 8, 2010
  Results First Posted:         
  Last Update Posted:           February 2, 2021
  Locations:                    Hôpital Saint André, Bordeaux, France|Hôpital La Pitié Salpêtrière, Paris, France|Hôpital Bichat-Claude Bernard, Paris, France|CH André Rosemond, Cayenne, French Guiana|CHU de Pointe à Pitre/Abymes, Pointe à Pitre, Guadeloupe|Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique|CHU de la Réunion, Saint-Denis, Réunion|Centre Hospitalier Gabriel Martin, Saint-Paul, Réunion
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01099852

Study 208:
  NCT Number:                   NCT03631719
  Title:                        Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
  Acronym:                      WMP-COL
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Dengue|Chikungunya Virus Infection|Zika Virus Infection
  Interventions:                Biological: Wolbachia-carrying Ae.aegypti mosquitoes
  Outcome Measures:             Dengue cases notified to surveillance system|Virologically-confirmed dengue|IgM test positive for dengue|Severe dengue cases|Zika cases notified to surveillance system|Chikungunya cases notified to surveillance system|Spatial analysis|Virologically-confirmed chikungunya infection|Virologically-confirmed Zika infection
  Sponsor/Collaborators:        Universidad de Antioquia|Monash University|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Wellcome Trust
  Gender:                       All
  Age:                          3 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   834
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Prospective
  Other IDs:                    PEC004_18|PECET-002
  Start Date:                   October 25, 2017
  Primary Completion Date:      December 31, 2021
  Completion Date:              December 31, 2021
  First Posted:                 August 15, 2018
  Results First Posted:         
  Last Update Posted:           April 8, 2022
  Locations:                    Universidad de Antioquia, Medellín, Antioquia, Colombia
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03631719/SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03631719

Study 209:
  NCT Number:                   NCT02794181
  Title:                        Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Zika Virus|Dengue Virus|Chikungunya Virus Infections
  Interventions:                
  Outcome Measures:             Prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among travel-deferred adult blood donors in the study population.|Prevalence of ZIKV infection (RNApositives) among adult blood donors with a history of potential sexual exposure to ZIKV infection, in the study population.|24-week Natural History of ZIKV, DENV and CHIKV (RNA-positives).
  Sponsor/Collaborators:        National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   34
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    160124|16-CC-0124
  Start Date:                   June 8, 2016
  Primary Completion Date:      March 14, 2019
  Completion Date:              March 14, 2019
  First Posted:                 June 9, 2016
  Results First Posted:         
  Last Update Posted:           March 18, 2019
  Locations:                    National Institutes of Health Clinical Center, Bethesda, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02794181

Study 210:
  NCT Number:                   NCT03206541
  Title:                        Neurologic Manifestations of the Arbovirus Infection in Colombia
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Encephalitis|Myelitis|Guillain-Barre Syndrome|Cranial Nerve Palsies|Meningitis|Zika Virus Infection|Dengue (Virus); Fever, Sandfly|Chikungunya Fever
  Interventions:                
  Outcome Measures:             Neurological outcomes in arbovirus infections|Viral genotype|Immune response
  Sponsor/Collaborators:        Johns Hopkins University|Universidad del Valle, Colombia|ZikaPLAN
  Gender:                       All
  Age:                          8 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   570
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Prospective
  Other IDs:                    IRB00093149
  Start Date:                   January 1, 2016
  Primary Completion Date:      December 31, 2019
  Completion Date:              December 31, 2019
  First Posted:                 July 2, 2017
  Results First Posted:         
  Last Update Posted:           February 20, 2020
  Locations:                    Clinica Leon XIII, Medellín, Antioquia, Colombia|Neuroclinica, Medellín, Antioquia, Colombia|Clinica La Misericordia Internacional, Barranquilla, Atlantico, Colombia|Clinica Medilaser, Neiva, Huila, Colombia|Hospital Universitario de Neiva, Neiva, Huila, Colombia|Hospital Universitario de Narino, Pasto, Narino, Colombia|Hospital Universitario Erasmo Meoz, Cúcuta, Norte De Santander, Colombia|Hospital Universitario del Valle, Cali, Valle Del Cauca, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03206541

Study 211:
  NCT Number:                   NCT04273217
  Title:                        A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy Volunteers
  Interventions:                Drug: AV-1|Drug: Placebo
  Outcome Measures:             Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Physical Examination Abnormalities Reported as TEAEs|Number of Participants With Vital Sign Abnormalities Reported as TEAEs|Number of Participants With 12-lead Electrocardiogram (ECG) Abnormalities Reported as TEAEs|Number of Participants With TEAEs|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants by Severity of AEs|Area Under the Serum Concentration-time Curve (AUC) From Time 0 Extrapolated to Infinity (AUC0-infinity) of AV-1|AUC From Time 0 to 48 Hours Postdose (AUC0-48) of AV-1|AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)|Maximum Observed Serum Concentration (Cmax) of AV-1|Time to Reach Cmax (Tmax) of AV-1|Apparent Terminal Half-life (t1/2) of AV-1|Total Serum Clearance (CL) of AV-1|Volume of Distribution During the Terminal Phase (Vz) of AV-1|Number of Participants With Detectable Anti-AV-1 Antibody
  Sponsor/Collaborators:        AbViro LLC|National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 55 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   42
  Funded Bys:                   Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science
  Other IDs:                    AV1-PPD-0005|DMID 18-0016|HHSN272201600028C
  Start Date:                   February 4, 2020
  Primary Completion Date:      July 8, 2021
  Completion Date:              July 8, 2021
  First Posted:                 February 18, 2020
  Results First Posted:         October 31, 2022
  Last Update Posted:           October 31, 2022
  Locations:                    PPD Austin Clinic, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04273217/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04273217/SAP_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT04273217

Study 212:
  NCT Number:                   NCT00118924
  Title:                        Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Tick-Borne Encephalitis
  Interventions:                Biological: LGT(TP21)/DEN4|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse effects, graded by intensity and severity through active and passive surveillance|Immunogenicity of vaccine against anti-Langat neutralizing antibody|Recovery of virus from the blood of a vaccinee or seroconversion|Immunogenicity of the LGT(TP21)/DEN4 vaccine against other TBE viruses|Durability of antibody responses to Langat and other TBE viruses
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 182|H.22.03.09.26.B2
  Start Date:                   July 2005
  Primary Completion Date:      July 2007
  Completion Date:              July 2007
  First Posted:                 July 12, 2005
  Results First Posted:         
  Last Update Posted:           January 21, 2008
  Locations:                    Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00118924

Study 213:
  NCT Number:                   NCT00537147
  Title:                        Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   West Nile Fever
  Interventions:                Biological: WN/DEN4delta30 vaccine|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse events, as classified by both intensity and severity through active and passive surveillance|Immunogenicity, determined by anti-WN/DEN4 neutralizing antibody titer|Assess the frequency, quantity, and duration of viremia after each dose of vaccine by dose cohort (10^4 or 10^5 PFU)|Determine the number of vaccinees infected with WN/DEN4delta30 in each dose cohort (10^4 or 10^5 PFU)|Compare the infectivity rates, safety, and immunogenicity between dose 1 and dose 2 within a cohort and between cohorts
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   26
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 242|WIRB Protocol Number 20071891
  Start Date:                   March 2008
  Primary Completion Date:      June 2009
  Completion Date:              June 2009
  First Posted:                 September 28, 2007
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Center for Immunization Research, Johns Hopkins School of Public Health (DC Location), Washington, District of Columbia, United States|Center for Immunization Research, Johns Hopkins School of Public Health (MD Location), Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00537147

Study 214:
  NCT Number:                   NCT00094718
  Title:                        Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   West Nile Fever Encephalitis
  Interventions:                Biological: WN/DEN4-3'delta30|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse effects, graded by severity, for each dose|Immunogenicity of vaccine against WN virus|To assess the durability of the antibody response|To assess the frequency, quantity, and duration of viremia in each dose cohort studied|To assess the immunogenicity of the WN/DEN4-3'delta30 vaccine against WN wild-type virus|To compare the T cell medicated immune response against West Nile virus of those volunteers infected with the WN/DEN4-3'delta30 vaccine virus with that of uninfected volunteers and placebo recipients|To evaluate the immunopathological mechanism of vaccine-associated rash in those volunteers who are willing to undergo skin biopsy
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|Johns Hopkins Bloomberg School of Public Health
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   56
  Funded Bys:                   NIH|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  Other IDs:                    CIR 206|H.22.04.10.06.A1
  Start Date:                   February 2005
  Primary Completion Date:      April 2005
  Completion Date:              April 2005
  First Posted:                 October 22, 2004
  Results First Posted:         
  Last Update Posted:           January 3, 2013
  Locations:                    Johns Hopkins School of Public Health, Baltimore, Maryland, United States|Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00094718

Study 215:
  NCT Number:                   NCT03553277
  Title:                        Spatial Repellents for Arbovirus Control
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Arbovirus Infections
  Interventions:                Other: transfluthrin|Other: placebo
  Outcome Measures:             Incidence of Aedes-borne virus (ABV) infection.|Clinically apparent laboratory confirmed cases of Aedes-borne virus (ABV) disease.|Adult female Aedes aegypti indoor abundance.|Adult female Aedes aegypti blood fed abundance.|Adult female Aedes aegypti parity rate.|Perception of product efficacy.
  Sponsor/Collaborators:        University of Notre Dame|University of California, Davis
  Gender:                       All
  Age:                          2 Years and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   18240
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other
  Other IDs:                    18-01-4370
  Start Date:                   June 2015
  Primary Completion Date:      November 2018
  Completion Date:              March 2019
  First Posted:                 June 12, 2018
  Results First Posted:         
  Last Update Posted:           March 5, 2021
  Locations:                    University of California, Davis, Iquitos, Peru
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03553277

Study 216:
  NCT Number:                   NCT03989895
  Title:                        Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma
  Acronym:                      
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Advanced Melanoma
  Interventions:                Biological: Dengue Virus-1 #45AZ5 (PV-001-DV)
  Outcome Measures:             Incidence and severity of Treatment-Emergent Adverse Events of PV-001-DV|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)
  Sponsor/Collaborators:        PrimeVax Immuno-Oncology Inc.|Walter Reed Army Institute of Research (WRAIR)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   10
  Funded Bys:                   Industry|U.S. Fed
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    PV001-001 (Arm 2)
  Start Date:                   April 1, 2023
  Primary Completion Date:      September 30, 2023
  Completion Date:              December 31, 2023
  First Posted:                 June 18, 2019
  Results First Posted:         
  Last Update Posted:           August 8, 2022
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03989895

Study 217:
  NCT Number:                   NCT02107677
  Title:                        Specificity Study of Diagnostic for Early Detection of Dengue Infection
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Infectious Diseases
  Interventions:                
  Outcome Measures:             number of subjects with negative result
  Sponsor/Collaborators:        InBios International, Inc.
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   300
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Retrospective
  Other IDs:                    DSC0094
  Start Date:                   August 2012
  Primary Completion Date:      August 2014
  Completion Date:              August 2014
  First Posted:                 April 8, 2014
  Results First Posted:         
  Last Update Posted:           August 18, 2017
  Locations:                    State of Florida Dept. of Health Bureau of Laboratories Virology, Jacksonville, Florida, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02107677

Study 218:
  NCT Number:                   NCT02741882
  Title:                        Zika and Microcephaly: Case-control Study
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Microcephaly
  Interventions:                Other: Questionary
  Outcome Measures:             Zika virus infection clinical outcomes during pregnancy|zika virus serology|Chikungunya virus serology|Dengue virus serology
  Sponsor/Collaborators:        Laboratório Sabin
  Gender:                       Female
  Age:                          16 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   110
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Retrospective
  Other IDs:                    Zika and microcephaly
  Start Date:                   February 2016
  Primary Completion Date:      August 2016
  Completion Date:              February 2017
  First Posted:                 April 18, 2016
  Results First Posted:         
  Last Update Posted:           February 23, 2017
  Locations:                    Sabin laboratory, Brasilia, Distrito Federal, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02741882

Study 219:
  NCT Number:                   NCT02174341
  Title:                        The Pilot Study of Chikungunya Virus Infections in Southern Taiwan
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chikungunya Fever
  Interventions:                
  Outcome Measures:             For persons with suspected dengue fever, Chikungunya disease-related testing conducted to clarify the clinical dengue and Chikungunya disease of judgment
  Sponsor/Collaborators:        Kaohsiung Medical University Chung-Ho Memorial Hospital
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   28
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Control|Time Perspective: Other
  Other IDs:                    KMUH-IRB-20110428
  Start Date:                   April 2012
  Primary Completion Date:      July 2018
  Completion Date:              July 2018
  First Posted:                 June 25, 2014
  Results First Posted:         
  Last Update Posted:           March 1, 2019
  Locations:                    Kaoshing Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02174341

Study 220:
  NCT Number:                   NCT02809443
  Title:                        GLS-5700 in Healthy Volunteers
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Healthy
  Interventions:                Biological: GLS-5700
  Outcome Measures:             Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody titers to Zika envelope|Neutralizing antibody response against Zika virus|T cell response
  Sponsor/Collaborators:        GeneOne Life Science, Inc.|Inovio Pharmaceuticals
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   40
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    Zika-001
  Start Date:                   July 2016
  Primary Completion Date:      November 2017
  Completion Date:              December 2017
  First Posted:                 June 22, 2016
  Results First Posted:         
  Last Update Posted:           January 20, 2022
  Locations:                    Miami Research Associate, Miami, Florida, United States|University of Pennslyvania, Philadelphia, Pennsylvania, United States|CHU de Québec -Université Laval hopital CHUL Centre de Recherche en infectiologie, Quebec, Canada
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02809443

Study 221:
  NCT Number:                   NCT04478656
  Title:                        Safety and Immunogenicity of BBV121
  Acronym:                      Zika
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Zika Virus Infection
  Interventions:                Biological: BBV121
  Outcome Measures:             Occurrence of adverse events and Serious Adverse events|Geometric mean titre estimated by 50% plaque reduction neutralization test and four-fold seroconversion|Geometric mean titre estimated by 50% plaque reduction neutralization test
  Sponsor/Collaborators:        Bharat Biotech International Limited
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    BBIL/ZIKV/I/2016
  Start Date:                   June 3, 2017
  Primary Completion Date:      November 15, 2017
  Completion Date:              November 15, 2018
  First Posted:                 July 21, 2020
  Results First Posted:         
  Last Update Posted:           October 22, 2020
  Locations:                    Bharat Biotech International Ltd, Hyderabad, Telangana, India
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04478656

Study 222:
  NCT Number:                   NCT02186626
  Title:                        Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   West Nile Virus
  Interventions:                Biological: WN/DEN4Δ30 Vaccine|Biological: Placebo
  Outcome Measures:             Frequency of vaccine-related adverse events (AEs)|Measurement of anti-WNV neutralizing antibody
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          50 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    CIR 290|WIRB/20140078
  Start Date:                   February 2014
  Primary Completion Date:      July 2016
  Completion Date:              July 2016
  First Posted:                 July 10, 2014
  Results First Posted:         
  Last Update Posted:           February 1, 2017
  Locations:                    Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|Vaccine Testing Center, University of Vermont College of Medicine (UVM), Burlington, Vermont, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02186626

Study 223:
  NCT Number:                   NCT01765426
  Title:                        Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Healthy Volunteers
  Interventions:                Biological: TDV|Drug: Placebo
  Outcome Measures:             Percentage of Participants With Local (Injection Site) Adverse Events (AEs) After Either Vaccine Dose by Maximum Severity as Assessed by the Clinical Staff|Percentage of Participants With Unsolicited Adverse Events (AE) by Maximum Severity|Percentage of Participants With Solicited Systemic AEs as Reported by the Participant Using a Memory Aid 14 Days After Either Vaccine Dose by Maximum Severity|Percentage of Participants With Solicited Local AEs as Reported by the Participant Using a Memory Aid 14 Days After Either Vaccine Dose by Maximum Severity|Percentage of Participants With Unsolicited Vaccine-Related AEs Within 28 Days After Either Vaccine Dose by Maximum Severity|Percentage of Participants With Abnormal Laboratory Values Reported as Adverse Events (AEs)|Seroconversion Rates (SCR) for Each of the Four Dengue Serotypes After First Injection|Seroconversion Rates (SCR) for Each of the Four Dengue Serotypes After Second Injection|Percentage of Participants With Unsolicited Vaccine-Related SAEs|Geometric Mean Titers of Neutralizing Antibody Titers Against Each of the Four Dengue Serotypes|Seroconversion Rates (SCR) for Each of the Four Dengue Serotypes at Days 90 and 270|Percentage of Participants With Serotype-Specific DENVax RNA Detected Due to Each of the Four Dengue Vaccine Components After Each Vaccination
  Sponsor/Collaborators:        Takeda|National Institutes of Health (NIH)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   67
  Funded Bys:                   Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  Other IDs:                    11-0049|U1111-1178-6503
  Start Date:                   February 15, 2013
  Primary Completion Date:      June 26, 2014
  Completion Date:              June 26, 2014
  First Posted:                 January 10, 2013
  Results First Posted:         January 5, 2017
  Last Update Posted:           July 18, 2019
  Locations:                    University of Texas Medical Branch, Galveston, Texas, United States|Group Health Research Institute, Seattle, Washington, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01765426

Study 224:
  NCT Number:                   NCT04615364
  Title:                        Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
  Acronym:                      DENWOLUTION
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Arbovirus Infections|Dengue|Zika|Chikungunya
  Interventions:                
  Outcome Measures:             arbovirus genome sequencing|genetic evolution of arbovirus strains|measurement of the impact of Wolbachia on the virus genetic evolution|measurement of the ability of these viruses to replicate in the presence of Wolbachia
  Sponsor/Collaborators:        Institut Pasteur|Institut Pasteur de Nouvelle-Calédonie|Centre Hospitalier Territorial de Nouvelle-Calédonie
  Gender:                       All
  Age:                          2 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   600
  Funded Bys:                   Industry|Other
  Study Type:                   Observational
  Study Designs:                
  Other IDs:                    2019-022
  Start Date:                   July 17, 2020
  Primary Completion Date:      July 17, 2025
  Completion Date:              July 17, 2025
  First Posted:                 November 4, 2020
  Results First Posted:         
  Last Update Posted:           October 7, 2022
  Locations:                    Centre Hospitalier Territorial, Dumbéa Sur Mer, Nouvelle-Calédonie, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04615364

Study 225:
  NCT Number:                   NCT04343521
  Title:                        Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
  Acronym:                      
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Aedes-borne Diseases|Dengue|Chikungunya|Zika
  Interventions:                Biological: Targeted Indoor Residual Spraying (TIRS)
  Outcome Measures:             Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the core 3x3 city blocks of each cluster.|Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses cases in annual surveillance samples|Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV)|Ae. aegypti indoor entomological index adult presence/abundance|Ae. aegypti indoor entomological index female presence/abundance|Ae. aegypti indoor entomological index bloodfed female presence/abundance. Number of bloodfed females per house. The higher the value, the works the outcome.|Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the entire cluster.
  Sponsor/Collaborators:        Emory University|National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          2 Years to 15 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   4702
  Funded Bys:                   Other|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    IRB00108666|1U01AI148069-01
  Start Date:                   November 3, 2020
  Primary Completion Date:      December 1, 2024
  Completion Date:              December 31, 2024
  First Posted:                 April 13, 2020
  Results First Posted:         
  Last Update Posted:           February 9, 2022
  Locations:                    Universidad Autonoma de Yucatan, Merida, Yucatan, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04343521

Study 226:
  NCT Number:                   NCT04619823
  Title:                        Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
  Acronym:                      VIRIMA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Arbovirus Infections|Zika|Dengue|Chikungunya
  Interventions:                Other: Blood sample collection
  Outcome Measures:             Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals.|Molecular characterization of arborviruses strains included in the blood of patients and which may be diffused by mosquitoes carrying Wolbachia or not during deported blood meals|Molecular characterization of arborviruses strains contained in mosquitoes present in patients' homes
  Sponsor/Collaborators:        Institut Pasteur|Institut Pasteur de Nouvelle-Calédonie|Centre Hospitalier Territorial de Nouvelle-Calédonie
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   250
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    2019-062
  Start Date:                   February 15, 2021
  Primary Completion Date:      February 15, 2026
  Completion Date:              February 15, 2026
  First Posted:                 November 6, 2020
  Results First Posted:         
  Last Update Posted:           October 7, 2022
  Locations:                    Centre Hospitalier Territorial de Nouvelle-Calédonie, Dumbéa Sur Mer, New Caledonia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04619823

Study 227:
  NCT Number:                   NCT05218304
  Title:                        Baromètre Santé Adulte 2021-2022
  Acronym:                      
  Status:                       Suspended
  Study Results:                No Results Available
  Conditions:                   Diabetes|Hypercholesterolemia|Renal Failure|Dengue Fever|Zika|Chikungunya|Ross River|Malaria|SARS-CoV Infection|Chronic Disease
  Interventions:                Biological: Blood sample
  Outcome Measures:             To know the prevalence of the main risk factors chronic diseases (obesity, diabetes, high blood pressure, high cholesterol and kidney failure) in the adult population of New Caledonia aged 18 to 64 using the WHO STEPS survey method.|Health behaviors of the target population using the first step of the WHO STEPS survey method.|To calculate the cardiovascular risk of the New Caledonian population using the SCORE projet|Seroprevalence of infectious diseases
  Sponsor/Collaborators:        Agence Sanitaire et Sociale de Nouvelle Calédonie|Institut Pasteur|Pacific Community|World Health Organization|Institut de la Statitique et des Etudes Economiques Nouvelle Calédonie
  Gender:                       All
  Age:                          18 Years to 64 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   5471
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other
  Other IDs:                    2021-A01260-41
  Start Date:                   July 26, 2021
  Primary Completion Date:      April 30, 2022
  Completion Date:              May 30, 2022
  First Posted:                 February 1, 2022
  Results First Posted:         
  Last Update Posted:           February 1, 2022
  Locations:                    Agence Sanitaire et Sociale Nouvelle Calédonie, Nouméa, New Caledonia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05218304

Study 228:
  NCT Number:                   NCT03641339
  Title:                        Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Zika|Dengue|Malaria|Chikungunya|Leishmaniasis
  Interventions:                Other: One vector feeding|Other: Four vector feeding
  Outcome Measures:             Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups|Participants With Local Skin Adaptive Immune Response After Multiple Exposures Over Time to Bites of Each of the Three Vector Groups
  Sponsor/Collaborators:        National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          18 Years to 64 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   95
  Funded Bys:                   NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    180139|18-I-0139
  Start Date:                   September 5, 2018
  Primary Completion Date:      May 20, 2020
  Completion Date:              May 20, 2020
  First Posted:                 August 22, 2018
  Results First Posted:         December 8, 2021
  Last Update Posted:           December 8, 2021
  Locations:                    National Institutes of Health Clinical Center, Bethesda, Maryland, United States
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03641339/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03641339/ICF_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03641339

Study 229:
  NCT Number:                   NCT04235361
  Title:                        Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
  Acronym:                      MobEboDRC
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Ebola Virus Disease|Malaria|Typhoid Fever|Dengue Fever|Chikungunya Fever|Yellow Fever
  Interventions:                Diagnostic Test: Differential RPA tests
  Outcome Measures:             Recombinase polymerase amplifictaion test result
  Sponsor/Collaborators:        University of Stirling|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|Institut Pasteur de Dakar|University of Göttingen|Centre de Recheche du Centre Hospitalier Université Laval
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   500
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    992770|RIA2018EF-2089
  Start Date:                   January 15, 2021
  Primary Completion Date:      June 30, 2021
  Completion Date:              July 30, 2021
  First Posted:                 January 21, 2020
  Results First Posted:         
  Last Update Posted:           November 10, 2020
  Locations:                    Québec City-Université Laval Hospital Research Centre's CRI Infectious Disease Research Centre, Québec, Canada|National Institute for Biomedical Research (NIBR) Democratic Republic of the Congo, Kinshasa, Congo, The Democratic Republic of the|University of Göttingen, Göttingen, Germany|Institute Pasteur de Dakar, Senegal, Dakar, Senegal
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04235361

Study 230:
  NCT Number:                   NCT05050825
  Title:                        Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Malaria|Dengue|Influenza -Like Illness|Diarrhea|Pneumonia|Acute Febrile Illness
  Interventions:                Other: Patient clinical management based on the CDSA strategy
  Outcome Measures:             Non-inferiority of the CDSA strategy when compared to routine practice in terms of clinical status assessed at Day 7|Superiority of the CDSA strategy when compared to routine practice in terms of antibiotic prescription at Day 0|Antibiotic prescription rate during 7 days of follow-up in the intervention arm compared to the control arm|Diagnostic performance of the dengue rapid diagnostic test (RDT)|Identification of risk factors associated with viral and bacterial infections
  Sponsor/Collaborators:        Foundation for Innovative New Diagnostics, Switzerland|Institut Pasteur de Dakar|Ministry of Health, Senegal
  Gender:                       All
  Age:                          6 Months to 15 Years   (Child)
  Phases:                       Not Applicable
  Enrollment:                   470
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    FE007
  Start Date:                   May 3, 2021
  Primary Completion Date:      November 30, 2021
  Completion Date:              December 15, 2021
  First Posted:                 September 21, 2021
  Results First Posted:         
  Last Update Posted:           October 27, 2021
  Locations:                    PS Ndiaye-Fatick, Fatick, Senegal|PS Kedougou-Dalaba, Kedougou, Senegal|PS Mbour-Toucouleur, Mbour, Senegal|PS Pont-Tambacounda, Tambacounda, Senegal
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05050825

Study 231:
  NCT Number:                   NCT05153018
  Title:                        Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
  Acronym:                      PIANO
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Arbovirus Disease|Zika|Dengue|Ross River|Chikungunya|COVID-19
  Interventions:                Other: Blood collection
  Outcome Measures:             Determination of the seroprevalence of dengue, Zika, chikungunya, Ross River and Covid-19 in Vanuatu.
  Sponsor/Collaborators:        Institut Pasteur|Ministry of Health of Vanuatu|Vanuatu National Hospital
  Gender:                       All
  Age:                          6 Years and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   1200
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    2020-100
  Start Date:                   October 17, 2022
  Primary Completion Date:      April 1, 2023
  Completion Date:              April 1, 2023
  First Posted:                 December 10, 2021
  Results First Posted:         
  Last Update Posted:           November 14, 2022
  Locations:                    Blood centers, hospitals, health facilities, Luganville, Vanuatu|Schools, Luganville, Vanuatu|Blood centers, hospitals, health facilities, Port-Vila, Vanuatu|Schools, Port-Vila, Vanuatu
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05153018

Study 232:
  NCT Number:                   NCT04672577
  Title:                        Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
  Acronym:                      ITIT
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Travel-Related Illness|Malaria|Dengue|Chikungunya|Zika|SARS-CoV Infection|MERS|Influenza|Diarrhea
  Interventions:                Other: Observational study
  Outcome Measures:             incidence of travel-related infectious diseases|long-term sequelae of arboviral infections and malaria|change in epidemiology of travel-related infectious diseases
  Sponsor/Collaborators:        Patricia Schlagenhauf|ETH Zurich|Swiss Tropical & Public Health Institute|University Hospital, Geneva|Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|University of Zurich
  Gender:                       All
  Age:                          18 Years to 90 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   10000
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    ITIT
  Start Date:                   January 30, 2021
  Primary Completion Date:      December 31, 2024
  Completion Date:              December 31, 2025
  First Posted:                 December 17, 2020
  Results First Posted:         
  Last Update Posted:           December 17, 2020
  Locations:                    Epidemiology, Biostatistics and Prevention Institute at the University of Zurich, Zürich, Switzerland
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04672577

Study 233:
  NCT Number:                   NCT03204409
  Title:                        ZIKAlliance Natural History Study
  Acronym:                      ZIKAllianceNH
  Status:                       Withdrawn
  Study Results:                No Results Available
  Conditions:                   Zika Virus|Zika Virus Infection
  Interventions:                
  Outcome Measures:             ZIKA Virus Infection|DENGUE Virus Infection|Chikungunya Virus Infection
  Sponsor/Collaborators:        University of Heidelberg Medical Center|University of Sao Paulo
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   0
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    734548NH (EC   H2020   RIA)
  Start Date:                   April 1, 2018
  Primary Completion Date:      September 30, 2021
  Completion Date:              September 30, 2021
  First Posted:                 July 2, 2017
  Results First Posted:         
  Last Update Posted:           May 18, 2022
  Locations:                    University of Sao Paulo, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03204409

Study 234:
  NCT Number:                   NCT03078894
  Title:                        A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Tropical Disease
  Interventions:                Diagnostic Test: Zika|Diagnostic Test: Chikagunya|Diagnostic Test: Dengue
  Outcome Measures:             The number of contaminated water bodies|Proportion of population with Zika, Dengue or Chikagunya infections
  Sponsor/Collaborators:        BioRed LLC
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   100
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    CUIRBTL231
  Start Date:                   March 17, 2017
  Primary Completion Date:      May 1, 2017
  Completion Date:              May 1, 2017
  First Posted:                 March 14, 2017
  Results First Posted:         
  Last Update Posted:           March 31, 2017
  Locations:                    BioRed, Patapo, Lambayeque, Peru|BioRed, Pucala, Lambayeque, Peru|BioRed, Tuman, Lambayeque, Peru|BioRed, Pomalca, Peru
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03078894

Study 235:
  NCT Number:                   NCT03188731
  Title:                        ZIKAlliance Pregnant Women Cohort
  Acronym:                      ZIKAlliancePW
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Zika Virus|Pregnancy Related
  Interventions:                
  Outcome Measures:             Congenital Abnormalities
  Sponsor/Collaborators:        University of Heidelberg Medical Center|European Union|ZIKAlliance|Oswaldo Cruz Foundation|University of Sao Paulo|London School of Hygiene and Tropical Medicine|Federal University of Bahia|Universidade Federal de Goias|University Medical Center Groningen|University of Carabobo|Universidad Industrial de Santander|Sosecali Hospital, Guyaquil|Instituto de Medicina Tropical "Pedro Kourí (IPK), Cuba|Mexican National Institute of Public Health|Instituto Mexicano del Seguro Social|Institut National de la Santé Et de la Recherche Médicale, France|Erasmus Medical Center
  Gender:                       Female
  Age:                          16 Years to 45 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   3852
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    734548PW (EC   H2020   RIA)
  Start Date:                   May 24, 2017
  Primary Completion Date:      September 30, 2021
  Completion Date:              September 30, 2021
  First Posted:                 June 15, 2017
  Results First Posted:         
  Last Update Posted:           May 24, 2022
  Locations:                    Sosecali Ltd. (SOSE), Guaqui, Bolivia|INSERM, Santa Cruz, Bolivia|Federal University of Bahia (UFB), Bahia, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Federal University of Goias, Goiás, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, São Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-à-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), Mérida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03188731

Study 236:
  NCT Number:                   NCT05452447
  Title:                        Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
  Acronym:                      AEGIS ABV
  Status:                       Not yet recruiting
  Study Results:                No Results Available
  Conditions:                   Arbovirus Infections
  Interventions:                Device: Transfluthrin|Device: Placebo
  Outcome Measures:             Incidence of Aedes-borne virus (ABV) infection in the 'longitudinal cohort'.|Clinically apparent cases of Aedes-borne virus (ABV) disease.|Adult female Aedes aegypti indoor abundance.|Adult female Aedes aegypti blood fed rate.|Diversion of Aedes aegypti mosquitoes into untreated houses.|Overall incidence of Aedes-borne virus (ABV) infection.
  Sponsor/Collaborators:        University of Notre Dame|SC Johnson, A Family Company|fhiClinical|Ministry of Health, Sri Lanka|University of Sri Jayewardenepura, Sri Lanka|University of Washington|RemediumOne
  Gender:                       All
  Age:                          6 Months and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   14430
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  Other IDs:                    21-05-6629
  Start Date:                   August 2022
  Primary Completion Date:      July 2024
  Completion Date:              October 2024
  First Posted:                 July 11, 2022
  Results First Posted:         
  Last Update Posted:           July 11, 2022
  Locations:                    Epidemiology Unit, Ministry of Health, Colombo, West, Sri Lanka|Clinical Trials Unit, Ragama, West, Sri Lanka
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05452447

Study 237:
  NCT Number:                   NCT02696291
  Title:                        Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
  Acronym:                      
  Status:                       Terminated
  Study Results:                Has Results
  Conditions:                   Viral Infection
  Interventions:                Drug: UV-4B 30 mg oral solution|Drug: UV-4B 75 mg oral solution|Drug: UV-4B 150 mg oral solution|Drug: UV-4B X mg (dose to be determined) oral solution|Drug: UV-4B Y mg (dose to be determined) oral solution|Drug: Placebo
  Outcome Measures:             Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group|Number of Subjects Reporting Serious Adverse Events (SAEs) by Group|Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group|Number of Subjects With Outlying Vital Sign Results by Group|Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group|Maximum Plasma Concentration (Cmax)|Time of Maximum Plasma Concentration (Tmax)|Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)]|Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)]|Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)]|Apparent Systemic Clearance (CL/F) at Steady State|Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses|Apparent Terminal Half Life (t1/2)|Accumulation Ratio (AR)
  Sponsor/Collaborators:        Emergent BioSolutions|National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   7
  Funded Bys:                   Industry|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    DMID 15-0062|HHSN272201100030C|8311-270
  Start Date:                   May 27, 2016
  Primary Completion Date:      March 2, 2017
  Completion Date:              March 2, 2017
  First Posted:                 March 2, 2016
  Results First Posted:         March 16, 2018
  Last Update Posted:           March 11, 2020
  Locations:                    Clinical Research Unit, Dallas, Texas, United States|Clinical Research Unit, Madison, Wisconsin, United States
  Study Documents:              "Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02696291/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02696291/Prot_001.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02696291

Study 238:
  NCT Number:                   NCT02061358
  Title:                        Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
  Acronym:                      UV
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Viral Infection
  Interventions:                Drug: UV-4B 3 mg|Drug: UV-4B 10 mg|Drug: UV-4B 30 mg|Drug: UV-4B 90 mg|Drug: UV-4B 180 mg|Drug: UV-4B 360 mg|Drug: UV-4B 720 mg|Drug: UV-4B 1000 mg|Drug: Placebo
  Outcome Measures:             Subjects With Treatment-emergent Adverse Event (TEAEs) by Treatment Group|Subjects With Serious Adverse Event (SAEs) by Treatment Group|Number of Subjects With Vital Sign Values of Toxicity Grade 1 or Higher Postdose by Treatment Group (Safety Population)|Number of Subjects With Electrocardiogram Outlier Values Postdose by Treatment Group|Number of Subjects With Clinical Laboratory Test Results of Toxicity Grade 1 or Higher at Day 9 by Treatment Group|Cmax by Treatment Group: UV-4|Tmax by Treatment Group: UV-4|AUC(0-last) by Treatment Group: UV-4|AUC(0-inf) by Treatment Group: UV-4|CL/F by Treatment Group: UV-4|Vz/F by Treatment Group: UV-4|t(1/2) by Treatment Group: UV-4|Interval and Cumulative Amount (mg) of UV-4 Excreted in Urine, Ae, by Treatment Group|Interval and Cumulative Percent of UV-4 Excreted in Urine, fe, by Treatment Group|CLr by Treatment Group: UV-4
  Sponsor/Collaborators:        Emergent BioSolutions|Quintiles, Inc.|Unither Virology
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   64
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    DMID 13-0001|KQA71264|UV-DEN-0001
  Start Date:                   July 2014
  Primary Completion Date:      July 2015
  Completion Date:              September 2015
  First Posted:                 February 12, 2014
  Results First Posted:         September 1, 2016
  Last Update Posted:           August 23, 2022
  Locations:                    Quintiles, Inc, Overland Park, Kansas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02061358

Study 239:
  NCT Number:                   NCT05400824
  Title:                        Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Infectious Disease|Cardiovascular Diseases|General Population|Metabolic Disease
  Interventions:                Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection
  Outcome Measures:             Prevalence of cardiometabolic diseases|Prevalence of infectious diseases
  Sponsor/Collaborators:        Institut National de la Santé Et de la Recherche Médicale, France
  Gender:                       All
  Age:                          18 Years to 67 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   2000
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    C19-68|2020A0209435
  Start Date:                   May 1, 2022
  Primary Completion Date:      May 2024
  Completion Date:              May 2024
  First Posted:                 June 2, 2022
  Results First Posted:         
  Last Update Posted:           July 5, 2022
  Locations:                    Centre Hospitalier Universitaire de La Réunion, La Réunion, Saint-Pierre, France
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05400824

